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Abstract
 
! Engrailed-2 (EN2) is a transcription factor involved in development, where it 
is has multiple functions and is expressed in a caudal-to-rostral gradient in the 
midbrain. Its mRNA and protein expression are absent from most adult cells, but are 
switched back on in cancer cells. Although transcription factors are usually located 
in the nucleus, a number of previous reports have indicated that EN2 protein could 
be in the cell membrane and on the cell surface on tumour samples, from where 
some at least might be released, as EN2 has been found in the urine of prostate 
cancer patients - a more readily obtainable clinical sample than tumour biopsies. 
! In this study EN2 protein is definitively shown to be on the membrane of 
prostate cancer cells and in the tumour microenvironment. The commercial anti-EN2 
antibody was found to be non-specific and we therefore used a tagged version of 
EN2 to study its cellular distribution and behaviour. This revealed different modes of 
EN2 protein transport and secretory mechanisms in different cancer cell lines. Live 
cell imaging further revealed the generation of secretory vesicles from PC3 cells, 
which are derived from metastatic prostate cancer, but not WPMY-1 cells that are 
derived from normal prostate fibroblasts. The findings further suggest that EN2 
protein switches roles during tumour progression, from a transcriptional regulator to 
a regulator of protein translation in localised regions of the cytoplasm. The latter 
mechanism is especially significant as EN2 cellular localisation becomes 
dysregulated in cancer, becoming widely cytoplasmic and available for packaging 
into luminal vesicles. The findings also indicate that the translation factor EIF4E is a 
potential binding partner of EN2, in prostate cancer.
! The study findings also indicate that a monoclonal antibody-drug conjugate 
targeting EN2 may not be the most effective method of targeting EN2-expressing 
cells. A blocking peptide or antibody would be more appropriate to prevent its 
secretion and transfer, both of which have been shown to be possible mechanisms 
of tumour progression. Alternatively, because less EN2 is secreted (and hence more 
is retained) in prostate cancer cell lines with low metastatic potential, such as 
LnCaP, T cells could be employed to target early-stage prostate cancer. 
! To conclude, cancer cells have seemingly retained the ability to tightly 
regulate the expression of EN2 protein in a spatial and temporal manner, unlike 
3  
normal adult cells. EN2 is secreted in large vesicles by cells from more advanced 
prostate tumours and thus monoclonal antibodies may not be the most effective 
approach to therapy.
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1. Introduction
!
! The chapter is arranged as follows. First, the thesis question is stated and the 
literature and theoretical framework on which the thesis was formed is presented. 
The motivation for the work to be carried out and the methodological approach are 
justified. The thesis aims, objectives and hypotheses are listed. Lastly, the overall 
structure of the individual chapters are outlined. 
1.1 Thesis question
‣ Is Engrailed-2 (EN2) a suitable prostate cancer target for an antibody 
drug-conjugate? 
1.2 Scope of research
! EN2 is a developmental protein required for brain development, principally 
patterning the brain (for more detail see Section 2.3.1), and is subsequently 
downregulated. It is then re-expressed in cancer and thus can be used as a means 
of differentiating between the normal healthy tissue and tumour. However, its unique 
ability to be secreted and internalised means that it is able to be detected in bio-
fluid, such as urine, and in tissue away from the tumour (expanded upon in Section 
2.3.4). Aside from being used as a biomarker, if EN2 resides stably on the 
membrane of cancer cells only, it can also be used as a target for monoclonal 
antibody therapy (see Section 2.2.2). 
! EN2 could be involved in initiating tumorigenesis. In 2005 Martin et al. 
identified En2 as an oncogene in breast cancer (Martin et al. 2005). In addition to 
showing the overexpression of EN2 at mRNA and protein levels, they also suggest 
that EN2 was necessary for the loss of contact inhibition and an increased 
proliferation rate in breast cancer cell lines. EN2 forced expression was able to 
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generate adenocarcinomas after 14 weeks and with PBX co-expression there was 
accelerated development of adenocarcinomas. 
! It is possible that the expression of any potential binding partner of EN2 could 
also be regulated by EN2 in a similar feedback mechanism to PAX2. In 2008, Bose 
et al. looked at PAX2 as a potential downstream effector due to its vital role in 
prostate cancer cell survival (Bose et al. 2008). They concluded that PAX2 may be 
an activating transcription factor for En2 and proposed that there was a feedback 
mechanism in which EN2 then affects its own expression by regulating PAX2‘s 
expression and so on. 
! In 2011 Morgan et al showed that EN2 was a potential diagnostic biomarker 
for prostate cancer. Secreted EN2 was detected by an antibody-based test (ELISA) 
in the urine of prostate cancer patients with better accuracy than PSA (R. Morgan et 
al. 2011). Subsequently, EN2 was also found to be a protein biomarker in non-
muscle invasive bladder cancer. High grade tumours had progressively less EN2 
expression but, conversely, urinary EN2 detection was sensitive to increasing 
tumour grades. 
! More recently, there have been several reports of EN2 down regulation as a 
marker of poor prognosis for renal cancer, whilst higher amounts of EN2 protein was 
found in adjacent normal tissue (Lai et al. 2014) (Lai et al. 2016). Furthermore, Lai et 
al showed that forced En2 expression (in vitro) slowed proliferation, increased 
apoptosis and reduced the invasive ability of the cancer cells.
1.3 Study rationale 
! The research into EN2 in cancer has been sporadic and has given 
contradicting results. EN2 has been reported to be both an oncogene and tumour 
suppressor and the size of EN2 has been reported at different sizes with no 
explanation (see Section 2.3.3).
! The lack of knowledge in the function of EN2, compared to other 
homeoproteins, during fetal development and especially cancer has left a 
considerable gap in the research and hindered its application in the clinic. The 
structure of the homeodomain (depicted in Section 2.3.2, Figure 2.13), located 
within EN2 (and other homeoproteins), responsible for DNA binding, has been 
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studied extensively and found to be responsible for secretion. Penetratin, a cell-
penetrating peptide that drives internalisation, has been largely studied for its 
potential to cargo molecules in and out of the cell (Dupont et al. 2015). However, a 
recent study shows that the whole homeodomain is fundamental to the transfer 
process, in and out of the cell (Carlier et al. 2013). Despite these advances, 
downstream effectors of EN2 and their physiological (and pathological) effects are 
still largely unknown. Nevertheless, EN2’s unique property of intercellular transfer 
makes it an attractive biomarker and target. 
! The specificity of the widely used PSA biomarker for prostate cancer is sub-
standard and often results in unnecessary biopsies and over-treatment. PSA 
remains as a tool in the clinic for two reasons firstly, there is sufficient knowledge in 
the literature to guide its application in the clinic and secondly, there is no better 
biomarker available (for prostate cancer) to replace it, see Section 2.1.4 for further 
details. 
! EN2 could replace PSA or supplement PSA (in making a panel of biomarkers) 
to improve the diagnosis of prostate cancer, and has yet to be explored as a 
therapeutic target - this study was designed to explore these possibilities. 
1.4 Methodological approach
! The chosen therapy to investigate was an antibody-drug conjugate (ADC) 
against EN2. An antibody-drug conjugate is a type of targeted therapy, which falls 
under personalised medicine as it relies on the cell surface profile of the individuals 
cancer (as further described in Section 2.1.6.1). A good example of a successful 
treatment using this approach is Herceptin and its target, HER2, in breast cancer 
therapy (also mentioned in Section 2.2.3.1). An ADC has a low satisfaction criteria: 
EN2 must be accessible via the circulation and preferably reside on or tether the cell 
surface of cancer cells. In this way the drug (attached to the antibody) can be easily 
administered - injected into the bloodstream - and is targeted to the cancer cells, not 
the surrounding normal cells; this should lessen unwanted side effects in the clinic.  
! As this is, to my knowledge, the first time EN2 has been investigated in the 
context of a therapeutic target, the most logical type of investigation was an in vitro 
one. In vitro experiments are a cost-effective approach when investigating under an 
26  
exploratory nature; a necessity in this case as very little is known about EN2 and its 
role in cancer. In order to model prostate cancer in vitro, the following cell lines were 
used: high grade (PC3) and low grade (LnCaP) prostate cancer cell lines and 
WPMY-1 normal cells that have been immortalised for laboratory use. For more 
information regarding their origin see Chapter 3. 
! Antibodies are commonly raised against a protein of interest and the 
antibodies produced are either monoclonal or polyclonal. Monoclonal antibodies all 
bind to the same peptide of a protein, this can be extremely limiting when dealing 
with an unstable protein which can, for example, drastically change its structure 
depending on its environment. Polyclonal antibodies bind to different peptides of a 
protein and thus, allow for a general overview of protein expression as it is not 
restricted to one peptide. Generally speaking antibodies are robust, inexpensive and 
amenable but they do require validation - polyclonal antibodies, especially, can bind 
to non-specific proteins (further expanded upon in Section 2.2.4). The validation 
experiments carried out in this study are:
• protein overexpression - where we’d expect the antibody to detect 
higher levels of protein  
• protein knockdown - where we’d expect the antibody to detect lower 
levels of protein  
• No primary antibody controls - this is to show if and to what extent the 
secondary antibody, which is raised against the primary antibody and 
provides the quantifiable marker, is binding non-specifically and falsely  
increasing the signal detected 
! The other part of an antibody, beside from its antigen binding properties, is 
the effector. The effector can also be engineered to a) indirectly kill the tumour by 
eliciting an internal immune response or b) directly kill the tumour by attaching a 
drug. For the latter - the chosen approach in this study - the whole structure has to 
be taken up by the cell otherwise the drug is overly exposed on the outside and is 
likely to cause harm to the surrounding healthy tissue in the clinic. Thus, it is 
imperative that the chosen antibody is shown in vitro to be internalised preferentially 
by the cancer cell and not ‘normal’ healthy cells. 
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1.5 Thesis aims, objectives and hypotheses 
!
! The overarching aims of this study were to validate and explore EN2 as a 
cancer specific cell surface protein target and increase our understanding of the role 
and behaviour of EN2 in cancer. 
! The overarching hypotheses of the thesis was that a) there would be a 
significant level of EN2 on the cell surface of prostate cancer cells relative to 
‘healthy’ cells (in vitro), and b) EN2 localisation to the cytoplasm is promoted as 
prostate tumour grade increases due to its potential translational role on the cell 
surface of cancer cells.
! In order to achieve this, the following objectives (1-5) were formulated:
1. determine EN2‘s expression and localisation within cancer cells
2. further define EN2’s secretion and internalisation mechanisms 
3. identify a suitable EN2 antibody for development into an antibody-drug 
conjugate 
4. carry out preliminary in vitro experiments on the candidate antibody-drug 
conjugate to direct the next set of experiments
5. further investigate EN2’s cell autonomous and cell non-autonomous role
1.6 Thesis structure
	 The thesis is organised as follows:
‣ Chapter 2 collates the relevant literature in order to provide the 
necessary background knowledge to follow the thesis. It outlines the 
current state of prostate cancer management and highlights the gaps in 
the area of EN2 research, particularly in cancer. It also reviews prostate 
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cancer biomarkers and the potential role of EN2 in this respect. It also 
provides the underlying evidence required to formulate the objectives and 
hypotheses in Section 1.5. 
‣ Chapter 3 firstly outlines the general materials and methods used and 
then the specific and more novel methodology created for each of the 
three results sections that follow.  
‣ Chapter 4 is one of three self-contained results section and provides only 
the required background knowledge for the chapter, and a specific subset 
of objectives and hypotheses. It addresses the expression of EN2 in 
prostate cancer and seeks to validate it further as a biomarker before 
exploring its potential as a therapeutic target. Therefore, this Chapter 
addresses Objective 1 (detailed in Section 1.5).
‣ Chapter 5 is the second results section that further assesses EN2 on the 
cell surface of prostate cancer cells. It also explores the secretory and 
internalisation mechanism of EN2. The candidate antibody for developing 
an antibody-drug conjugate against EN2 is further investigated in vitro. 
This Chapter has dealt with Objectives 1 - 4. 
‣ Chapter 6 is the third and final results chapter which aims to further 
define the cell autonomous and non-autonomous functions of EN2; the 
Chapter focuses on Objective 5.
‣ Chapter 7 concludes the thesis by drawing together the achievements 
from all three results chapters, and addresses future research aims.
! This chapter has provided a guide and breakdown of the thesis. The next 
chapter will expand on this to provide the background knowledge and further 
highlight the gap in the literature. 
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Chapter 2: Literature review
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2. Literature Review
	 The review outlines the characteristics of prostate cancer and its demography in 
the UK, and highlights the lack of biomarkers for early stage screening and for 
distinguishing indolent from aggressive prostate tumours. Thus, prognosis varies 
widely as does the subsequent treatment administered. For EN2 as a potential 
biomarker and therapeutic target, there is a significant gap in the basic etiology 
concerning EN2 and cancer and EN2’s secretory and internalisation mechanisms.
2.1 Prostate Cancer 
! The prostate is an exocrine gland of the male reproductive system, which can 
be found below the bladder, surrounding the urethra. It is about the size of a walnut 
and produces the milky-white fluid for semen. Its growth heavily relies on the 
androgenic hormone: testosterone (Aumüller 1983). Prostate cancer is the most 
common cancer in men and the second most common cause of cancer-related 
deaths in men in the UK (Cancer Research UK). Though most prostate cancer 
cases remain indolent, men who go on to progress to have an aggressive form have 
very few treatment options available to them and survival is poor. 
2.1.1 Incidence and survival 
! The estimated prostate cancer incidence world-wide, in 2012, was more than 
1.1 million (World Health Organisation), of which 417,000 were European (Office for 
National Statistics). In 2013, in the UK alone, prostate cancer was the most common 
cancer in men with over 40,000 cases registered (Cancer Research UK). The 
following year, there were 11,287 prostate cancer deaths in the UK (Office for 
National Statistics); accounting for 13% of all cancer deaths in males that year in the 
UK (Office for National Statistics). 
! Below Figure 2.1 highlights the percentage of men surviving prostate cancer 
even after ten years, falling to approximately 84% only.
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Figure 2.1. Net Survival up to Ten Years after Diagnosis, Adults (Aged 15-99), England and 
Wales. Prostate Cancer 2010-2011 (Cancer Research UK).
! The high survival percentage depicted in Figure 2.1 is due to the earlier 
detection of prostate tumours after the widespread use of transurethral resection of 
the prostate (TURP) and the diagnostic prostate specific antigen (PSA) blood test 
(Potosky et al. 1990) (Levy et al. 1993). This however, is accompanied by higher 
incidence. Figure 2.2, which highlights the number of new cases (per year) by age, 
it is clear that men aged over 50 years routinely undergo PSA testing and TURP 
when prostate cancer is suspected. However, 25% of the 40,000 diagnosed in 2013 
would have presented with metastases, for which the 5-year survival rate is only 
30% compared to 84% in Figure 2.1; only 10% will survive for at least 10 years 
(Office for National Statistics).
32  
Figure 2.2. The average number of new cases per year, between 2011-2013, and age-specific 
incidence rates per 100,000 male population in the UK. Taken from Cancer Research UK.
! There are several reasons for the increasing number of cases, including an 
aging population, but the predominant reason is the unspecific nature of the PSA 
test. The PSA test has directly resulted in frequent over-diagnosis and over-
treatment (Cary & Cooperberg 2013). Studies have been carried out to further 
determine whether it actually reduces mortality when there is a) an increase in 
incidence (Figure 2.2) and b) an increase in both the over-diagnoses and over-
treatment of prostate cancer happening at the same time (further discussed in 
Section 2.1.4.1). The unnecessary tests and subsequent treatments can affect a 
patient’s quality of life and are not reflected in the national statistics (Figure 2.1 and 
2.2). The general lack of clinical biomarkers and testing means that the usual next 
step (after measuring serum PSA) is to biopsy the patient’s tumour - a much more 
invasive test that can cause long-term damage (see Section 2.1.4.2 for further 
details). Equally, no good biomarker exists to distinguish (early-on especially) the 
subpopulation that will progress to have a more aggressive disease subtype.
!
2.1.3 Characteristic features 
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! Only a limited number of common mutations and chromosomal alterations 
have been identified between prostate cancers that could potentially be used as 
biomarkers - forming the basis of a diagnostic test or be used as a therapeutic 
target. Prostate cancer, compared to other solid cancers, have: a) high 
heterogeneity, which means that the genetic mutations within the tumour itself are 
highly varied, and b) high multifocality - the cancer originates at multiple locations, 
each going on to consist of different mutational landscapes and inevitably forming a 
number of tumours within a prostate. Androgens, as biomarkers, are an exception - 
they play a wide and considerable role in promoting the progression of prostate 
cancer - but their use as a therapeutic target in androgen therapy has been 
exhausted. Furthermore, androgen therapy is redundant for those tumours that are 
or become androgen-independent (also known as hormone-resistant); and due to 
hormone deprivation therapy, most tumours eventually switch to become androgen-
independent, for which the therapeutic options are few.  
 
2.1.3.1 Pathophysiology 
! Research that aims to understand the fundamental aetiology of the disease 
such as the key pathways involved in the progression of cells down the tumorigenic 
path, are key to producing effective and reliable clinical biomarkers and targets for 
therapy. Unfortunately, the pathways are numerous in prostate cancer and the 
information cannot be translated in a sufficiently useful manner in the clinic, further 
details are provided below. 
! Prostate cancer can be broken down into three categories depending on its 
spatial relationship with the prostate gland: localised, where the cancer remains 
confined within the prostate and has not spread elsewhere in the body; locally 
advanced, cancer that has started to extend out of the prostate or has spread to the 
area just outside the prostate but is not yet metastatic; and metastatic cancer, like 
most other solid tumours, can spread to distant areas such as the brain. Prostate 
cancer tends to metastasise to the bone (Rucci & Angelucci 2014) (Jin et al. 2011); 
this is the most frequent cause of death in metastatic prostate cancer patients and, 
as such, the 5-year survival drops significantly to 31% (Figure 2.1) (Jin et al. 2011). 
Figure 2.3 below outlines a more common pathogenesis pathway of prostate 
cancer. Examples of mutational events that have been shown to be significant at 
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those stages are highlighted in red (the molecular mechanisms will be further 
discussed in Sections 2.1.3.2 and 2.1.3.3).
Figure 2.3. The pathogenesis of prostate cancer. A flow-diagram following the development and 
progression of prostate cancer (adapted from (Shen & Abate-Shen 2010)). Highlighted in red are 
events shown to be important at those steps and the genes associated.
 
! As stated above, prostate cancer is difficult to manage because of its highly 
heterogeneous nature (Schoenborn et al. 2013). In order to further explain this 
characteristic, it is important to have a clear image of the different types of cells the 
prostate tissue is made up of - and the type of cells that the cancer can originate 
from - as depicted below:
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Figure 2.4. Structure of the prostate tissue. A schematic diagram that highlights the different cell 
types that make up the prostate. There are three types of epithelial cells: basal, luminal and 
neuroendocrine cells. Taken from Prostate Cancer UK.
! When determining the origin of prostate cancer, there are some patterns or 
commonalities to the type of cell the cancer initiates; research has uncovered that 
these cells are namely basal and/or luminal cells - the cancer originating cells are 
also known as ‘cells-of-origin’. Basal and luminal cells in the prostate are two major 
epithelial cell types that strongly depend on androgen receptor (AR) signaling. 
The neuroendocrine cells, which are rare and interspersed through the prostate, act 
on the surrounding cells to stimulate growth (Terry & H. Beltran 2014). 
Neuroendocrine cells do not express androgen receptors and research that show 
neuroendocrine differentiation (NED) in prostate cancer have suggested this as a 
mechanism of resistance to androgen therapy (J. Huang et al. 2007; Parimi et al. 
2014). It is important to distinguish cells-of-origin from cancer stem cells (CSCs), 
CSCs are largely seen as those that sustain and regenerate or replenish tumours 
and not cells from which the cancer initiates from (Rycaj & Tang 2015). Research 
that explores the mechanisms of tumour initiation have revealed a more detailed 
picture, such as the one below (Figure 2.5). 
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Figure 2.5. Cells-of-origin in prostate cancer. a) During development stem cells commit to 
generate basal and luminal cells. b) Both the basal and luminal cells may serve as the cell of origin 
for (primary and metastatic) prostate cancer (Xin 2013). 
 ! Figure 2.5 depicts the common cell types involved at broad stages of 
tumourigenesis: initiation, progression, and metastasis. The research shows that the 
basal cells and luminal cells are independently self-sustained. Furthermore, a basal-
luminal transition plays a significant role to the cancer cells - during tumour 
progression - that originate from basal cells; basal cells are seemingly more 
resistant to oncogenic signals and this infers a characteristic of stem-like plasticity 
(Xin 2013). In addition to this, prostate cancer tends to progress to form multiple 
tumours (multifocal prostate cancer) and this is problematic because each has its 
own cells-of-origin and tumourigenic pathways. There is currently investigations into 
how best to identify the index lesion (or the driving lesion), which is supposedly the 
best representative of the overall behaviour of the disease. Currently, the larger 
lesion is taken as the index lesion and tumour grading (Section 2.1.4.3) is typically 
based on the index lesion alone (Walz et al. 2011).
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! The resulting intratumour and intertumour (within the prostate and between 
patients) heterogeneity makes it difficult to: a) develop robust biomarkers that are 
successful and cost-effective in the clinic; b) to interpret these in a useful manner 
and c) predict how the disease will progress (i.e. the prognosis) (Wei et al. 2017). 
Thus, without sufficient studies that further delineate and categorise these markers - 
to certain traits such as responsive to a type of treatment or indicative of metastasis 
- it is difficult for the markers to be informative and aid in clinical decision-making. As 
an alternative approach to standard diagnosis that is based on its spatial localisation 
alone (please see Section 2.1.4 for current clinic diagnostic practices including the 
Gleason grading system), tumours could be further sub-typed according to the 
pattern of molecular markers or mutational events they harbour and patients 
assigned treatment on an individual basis (for more details see Section 2.1.6), 
however this could be argued to be less cost-effective. 
2.1.3.2 Molecular basis of initiation and progression 
  
! Section 2.1.3.1 highlighted the highly varied nature of prostate cancer 
between patients particularly at the genetic level, compared to other cancers (Spahn 
et al. 2015). 
! Figure 2.2 shows that one of the early, more common events is the loss of 
chromosomal regions at 8p that leads to the loss of NKX3.1 (homeobox gene). This 
loss has been further shown to be restricted to cells within the prostate (and is not 
found in metastases) (Abate-Shen et al. 2008). Subsequently, the cancer commonly 
progresses with the loss of chromosome 10q and this most likely results in the loss 
of PTEN, a lipid phosphatase that inhibits PI3K/Akt signaling. This signaling pathway 
plays a key role in cell survival, proliferation and differentiation (P. Liu et al. 2009) 
and is the focus of current targeted therapy (Section 2.1.6.1).
! Prostate tumours can be either androgen dependent (also known as 
androgen-sensitive) or androgen-independent (also known as castrate-resistant). 
The acquisition of castrate-resistance is defined as disease progression that is 
difficult to treat. After initial ADT response, resistant cells arise and ADT eventually 
fails; castrate-resistant tumours then develop in these patients with a much more 
aggressive phenotype discussed further in Section 2.1.3.3. Androgens (usually a 
steroid hormone such as testosterone) work by binding to androgen receptors 
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(ARs); these then translocate to the nucleus where they bind to androgen 
responsive elements and affect the expression of downstream effectors such as 
PSA (Richter et al. 2007). The AR has been found to be amplified, mutated and 
have several splice variants, post-translational modifications, aberrant transcriptional 
activity. Furthermore, associated factors or binding partners have been found to be 
dysregulated - all towards the same goal of progressing tumour growth (Karantanos 
et al. 2013). Androgen sensitive tumours can be targeted via androgen depletion 
and androgen receptor inhibition (Section 2.1.5.2.2) and thus are easier to treat as 
this is not an option for castrate-resistant tumours. 
! ! In addition, by identifying the molecular mutations that drive individual 
tumours it is possible to distinguish between indolent tumours (early-stage, 
androgen-sensitive) and aggressive tumours (late-stage, castrate-resistant). From 
this, a signature profile can be created for each tumour type. However, this is difficult 
when the tumour is highly heterogeneic by nature with so much variation between 
individual tumours and within the cells of the tumour itself. A recent study has 
focused on further defining the mechanisms that underlie indolent prostate tumours 
and a prominent marker here is the TMPRSS2-ERG fusion (Irshad et al. 2014) 
(Shen & Abate-Shen 2010). The role of this fusion remains undefined but recent 
evidence suggests that it functions in invasion (Hägglöf et al. 2014). The TMPRSS2-
ERG fusion is actually the most common event throughout all cancers as it can be 
found in up to 70% of prostate tumours and is seemingly exclusive to prostate 
tumours (L. Huang et al. 2011). This means that it has the potential to be a highly 
specific prostate cancer biomarker (Sanguedolce et al. 2016). 
! Despite this, prostate cancer generally has high heterogeneity and individual 
management (that includes early PSA screening and monitoring) would be more 
cost-effective (Section 2.1.4.1). A collaborative molecular screening platform could 
be a possibility, suggested by Spahn et al, in which patients with specific genotypes 
are quickly included in a sub-group biomarker driven clinical trial (Spahn et al. 
2015). 
2.1.3.3 Molecular basis of metastases and beyond
!
! The features of invasion and metastasis are well-defined in tumour biology 
and these are (in this order): angiogenesis; migration; invasion; intravasation; 
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circulation, and extravasation of tumor cells and further angiogenesis and 
colonization at the new site (Hanahan & Weinberg 2011).
! The acquisition of androgen-independence plays a huge part in the 
progression of prostate cancer, switching to a much more mobile and aggressive 
form that is usually fundamental to metastasis (Arnold & Isaacs 2002). Besides 
androgens, another key molecule in the castrate-resistant transition is interleukin-6 
(IL-6). IL-6 is a glycoprotein that has been shown (when overexpressed) to activate 
AR-mediated gene expression and therefore increase PSA mRNA levels (Lin et al. 
2001) and induce the growth of neuroendocrine and neuroendocrine-like cells 
(Deeble et al. 2001). These cells can secrete a cocktail of growth stimulating factors 
and are associated with drug resistance (Hu et al. 2015). This neuroendocrine 
phenotype is a result of transdifferentiation, which typically occurs at advanced 
stages (beyond castration-resistance) and is therefore usually present in the 
metastatic sites rather than the primary site. Thus, these tumours are not treated 
with ADT, but with platinum-based chemotherapy (Aparicio et al. 2013), and 
consequently treatment options are even fewer at this stage. It was recently shown 
that there is bias towards neuronal features during transdifferentiation, as opposed 
to endocrine features (Grigore et al. 2015). Unfortunately, the neuronal phenotype is 
associated with higher proliferation rates and thus, a poor prognosis (Grigore et al. 
2015).
! Alternatively, ADT therapy produces a selective pressure towards androgen 
independence and instead drives alternative pathways that need to be further 
defined and characterised, in order to provide more appropriate targets for therapy 
(Karantanos et al. 2013; Karantanos et al. 2015). Even though AR - to some degree 
- stays active, these alternative pathways drive the tumours regrowth (such as the 
neuroendocrine differentiation just described) but other more common pathways 
become dominant, for example: C-MYC overexpression; PI3K/AKT/mammalian 
target of rapamycin (mTOR) pathway and survival pathways such as RAS/MAPK 
pathway (Karantanos et al. 2013). Thus, once a tumour becomes independent of 
androgen, it become harder to treat as the treatment options available are currently 
limited. 
2.1.3.4 Risk factors  
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! Although risk factors, such as smoking, exposure to UV and family history, 
sometimes indicate the likelihood of individuals developing cancer, prostate cancer 
is not significantly linked to such risk factors; instead it is strongly related to 
endogenous risk factors such as age and ethnicity (Cancer Research UK). 
! Men aged 65 and over are at higher risk of getting prostate cancer (Cancer 
Research UK). The same is true for African-American men compared to white men, 
and amongst the former the disease tends to progress at an earlier age and be 
more aggressive (Shenoy et al. 2016). There is a clear association between a 
history of prostate cancer in the family and the risk to that individual of developing 
the disease. Furthermore, the closer the relatedness, the greater number of family 
members affected and the earlier the onset (Madersbacher et al. 2011). Therefore, 
prostate cancer risk is linked to genetic markers such as the (BRCA2) mutation that 
has a role in DNA repair; a man is at higher risk of developing prostate cancer if he 
has then BRCA2 mutation (Cavanagh & Rogers 2015). !
! Discrepancies in copy number variations (CNVs) has recently come to the 
forefront of cancer research; it has been shown that there is greater diversity in the 
number of gene copies amongst the human population than previously thought 
(Zarrei et al. 2015). These have been studied in hereditary and familial prostate 
cancer especially (Shlien et al. 2008). Similarly, single nucleotide polymorphisms 
(SNPs), which describes a single nucleotide change within a significant proportion of 
the population (Erichsen & Chanock 2004). SNPs have been strongly associated 
with prostate cancer and are already under investigation for use as clinical 
biomarkers (Williams et al. 2014; Van den Broeck et al. 2014). Both CNVs and 
SNPs could be useful indicators of risk.
! For hormones, insulin-like growth factor 1 (IGF-1) has been implicated as a 
cause of prostate cancer (Borugian et al. 2008);(Chokkalingam et al. 2001). For 
androgens (such as testosterone), which play a vital role in prostate tumour 
progression, there is surprisingly limited evidence to show that higher levels of 
androgen increases an individuals prostate cancer risk (Michaud et al. 2015). In 
addition, there is no compelling evidence that prostatitis (infection or inflammation of 
the prostate) is linked to prostate cancer (Roberts et al. 2004). 
2.1.4 Clinical screening, diagnosis and staging
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! It is widely accepted that the earlier the tumour can be detected and treated, 
the better the survival outcome (Singal et al. 2014) (Pande et al. 2013). A national 
screening programme aims to detect cancer early when symptoms are not 
necessarily present. This could be, for example, screening the population for a 
genetic biomarker. In addition, the more information obtained at diagnosis, the 
easier it is to make clinical decisions regarding treatment. 
! Staging is a hierarchical system against which all prostate cancers are 
described; this ensures standardisation, allows changes to be easily adopted and 
more information to be obtained. Tumour biopsies are then further assessed by the 
Gleason grading system, which provides more information regarding the behaviour 
of the cells that is reflected by the architecture of the tissue. Further details about 
the ways in which prostate cancer is currently managed, specifically in the UK, can 
be found in the following subsections. 
2.1.4.1 National screening programme 
!
 ! There are currently no prostate cancer screening systems in the UK as there 
are no suitable biomarkers or non-invasive tests. Though, men aged 50 and over 
can request a PSA test (Hodgson et al. 2012). PSA has been tried as a screening 
tool and the results are inconclusive as to its suitability as a number of studies have 
indicated that it is not specific and produces a number of false-positive results (Nna 
2013). Thus, if PSA were to be used as a screening tool with a larger population it 
would result in more over-diagnosis and over-treatment. Several studies have 
shown that PSA screening actually reduces prostate cancer deaths. However, 
whether PSA screening is beneficial, when taking into consideration the amount of 
over-treatment and thus harm caused, is still to be determined (Nna 2013). One of 
the more established and successful screening programmes is the mammogram for 
women in their 40s, although is it non-invasive it is difficult to standardise and, 
similar to prostate cancer, breast cancer is often over-diagnosed (Brennan & 
Houssami 2016).
! The big problem in prostate cancer management is distinguishing the slow-
growing indolent tumours from aggressive ones at an early stage in the process. 
Many men with prostate cancer actually live a long time without being treated at all 
because no symptoms are apparent and in some cases the cancer is never 
diagnosed and only discovered at autopsy (K. J. L. Bell et al. 2015). Therefore, the 
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early detection of aggressive tumours can allow more radical treatment early whilst 
slow-growing ones can be monitored, treated much later or not treated at all. In 
addition, some believe that hormone therapy (even when a patient is asymptomatic) 
works better when used as early as possible and studies have shown this to be true 
after radical prostatectomy (Moul et al. 2008). 
! In summary, an effective screening programme requires a reliable marker or 
panel of markers (see section 2.1.4.1), and further work is needed to identify these. 
More recent advances in this area include discovery of the urinary biomarkers 
prostate cancer antigen (PCA3) mRNA and EN2, EN2 is further discussed in 
Section 2.3. The PCA3 gene expresses a non-coding RNA that is restricted to 
human prostate tissue; overexpression of the PCA3 mRNA in prostate cancer cells 
has led to the development of a PCA3 mRNA urinary test (Schmid et al. 2015). 
2.1.4.2 Route to diagnosis 
! There are a number of ways men can be diagnosed with prostate cancer and 
these are highlighted in Figure 2.6 below. 
Figure 2.6. Percentage of Cases by Route to Diagnosis, Males Aged 15-99, England. Prostate 
cancer 2012-2013. Taken from Cancer Research UK.
! The initial indicators, for example, are urinary symptoms such as passing 
urine more often and erection problems (Jefferies et al. 2016). The primary test is a 
digital rectal examination (DRE). However, even with an experienced examiner, this 
43  
will only have fair reproducibility and these are likely to be diagnosed as advanced 
stages (Borley & Feneley 2008). The advantage of carrying out a DRE is that it can 
detect non-PSA-secreting tumours that might be missed, shown to be possible in 
Figure 2.6. 
! The PSA test is a relatively cheap and minimally invasive blood test that can 
be monitored continuously over time. PSA is a serine protease that is produced by 
the prostate gland to turn semen liquid. Only during prostate cancer are unusual 
(though still minute) amounts of PSA detected in the serum (blood) (Stamey et al. 
1987). PSA is also commonly used as a monitoring tool, further discussed in 
Section 2.1.5. 
! There are numerous ways in which PSA has been tested as a diagnostic and 
monitoring tool. These include the quantification of PSA as free, complexed to 
serum proteins and a ratio of the two with age-specific delineation or biopsy 
(Sharma et al. 2016). Active surveillance, for example, heavily relies on PSA 
measurements that are then used to calculate PSA kinetics such as PSA velocity 
and doubling time (Vickers & Brewster 2012). Unfortunately, best practice and 
standardisation of these individual PSA tests has been difficult. The limitations of 
PSA are that PSA levels can rise due to factors such as prostate infection and 
hypertrophy, which means it is not specific to prostate tumours (Nadler et al. 1995). 
Furthermore, the PSA test cannot be a standalone diagnostic test. PSA is 
unspecific, and further tests must be carried out such as a DRE, Transrectal 
ultrasound (TRUS) and occasionally magnetic resonance imaging (MRI). In addition, 
PSA levels cannot distinguish between indolent and aggressive tumours. Despite 
this, continued improvements on the PSA test management are being explore. For 
example, the PRIAS (Prostate Cancer Research International: Active Surveillance), 
which is an online protocol, is aimed towards helping to standardise the PSA 
interpretation for men with early stage prostate cancer during active surveillance 
(Punnen et al. 2015). For more information about current and potential prostate 
cancer biomarkers see Section 2.2.2. 
! There is a need for additional prognostic biomarkers at the diagnostic stage 
to supplement PSA and provide more information regarding the disease state before 
advancing to biopsy. Despite this, PSA is currently used as a diagnostic and 
monitoring tool (see Section 2.1.5). Unfortunately, there are no better clinical 
biomarkers available to further delineate the disease state. Thus, the clinician must 
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make a decision to whether to go ahead with a biopsy or not currently based on the 
PSA test, risk factors and perhaps other (less-invasive) tests such as an MRI. 
! A biopsy is necessary to reconfirm the PSA findings - only 30% of those that 
test “positive” for PSA will actually go on to have a “positive” biopsy (Troyer et al. 
2004). A TRUS-guided biopsy is carried out that takes 10 to 12 cores of prostatic 
tissue () to help account for the high heterogeneity and multifocality that are 
associated with prostate cancer (Boutros et al. 2015); both of which make accurate 
staging, diagnosis and prognosis difficult. Furthermore, biopsies are unpleasant and 
can cause complications such as infection (Efesoy et al. 2013). Ideally, there could 
be biomarkers that slot in here to help decipher whether a biopsy is actually 
required; currently under investigation are further detailed in Section 2.2.1.1. 
!
2.1.4.3 Histological staging and the Gleason grading system 
! TMN staging is used world-wide and separately assesses the tumour (T), 
lymph node involvement (N) and secondary metastases (M). The stages define the 
size of the tumour and how far it has grown (Borley & Feneley 2008). The T stage is 
split into four (T1-T4) where T1 tumours are too small to see on the scan, T2 
tumours are completely localised within the prostate (T1 and T2 are classed as 
localised tumours), T3 tumours have broken through the prostate covering but have 
not spread into other organs, whereas T4 tumours have invaded neighboring organs 
(T3 and T4 are classed as locally advanced prostate cancer) (Borley & Feneley 
2008). T2 and T3 are further sub-categorised according to the extent of tissue 
coverage.  
! The Gleason grading system is based on morphology using haematoxylin 
and eosin (H&E) staining of the tumour (under a microscope) (Humphrey 2004). 
This allows the assessment of the extent of cell differentiation relative to normal 
cells. Cancer cells tend to be poorly differentiated as they become less specialised 
and more proliferative and thus unpredictable or out of control. More than one 
biopsy sample is taken in order to take into account the heterogeneity within the 
tumour itself (Section 2.1.3.1), multiple sections are assessed from each sample 
and the two most common grades are added together. Grades 1 and 2 are normal 
prostate cells and 3-5 are cancer cells, increasing in abnormality (Humphrey 2004). 
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2.1.5 Clinical management 
! Guidelines (provided by NICE) or recommendations are closely followed by 
clinicians to treat their patients and are compiled of evidence-based data, which are 
continually evaluated (https://www.nice.org.uk/guidance). 
2.1.5.1 Assessment
! Men (typically over 65 years), diagnosed with prostate cancer, will be 
managed during their lifetime as the cancer progresses (or does not progress) 
through the following stages: risk at diagnosis, active surveillance, active treatment, 
recurrence, recurrence free, metastatic castrate-resistant prostate cancer, and 
death. 
! The risk is assessed using the PSA result with the inclusion of exogenous 
factors such as weight, as clinical evidence exists linking it to advanced prostate 
cancer (Cao & Ma 2011) and other factors such as prostate size and DRE, as 
described in Section 2.1.3.3, and a decision is made as to whether to carry out a 
biopsy. As mentioned in Section 2.1.4.2, it is at this stage where prognostic markers 
are lacking, prognosis varies widely and so does the treatment. Ideally, there should 
be molecular stratification that could allow for a better prognosis and a tailored 
treatment stream instead of the very general ‘one size fits all’ approach (Sedelaar & 
Schalken 2015), this is known as personalised medicine (see Section 2.1.6 for 
more details). 
! Next, the tumour will then be assigned a stage and a grade. Localised 
prostate cancer are then further assigned to one of the following risk groups: Low 
risk  - less than 10ng/ml PSA, a Gleason score lower than 6 and Stages T1- T2a; 
Intermediate risk - PSA levels are between 10-20 ng/ml, Gleason score of 7 and 
Stage T2b; and High risk - PSA is more than 20 ng/ml, Gleason score between 8-10, 
Stage T2c, T3 or T4 (Borley & Feneley 2008). These classifications help assign 
patients to the most appropriate treatment streams currently available. 
2.1.5.2 Treatment
! Figure 2.7 is a summary of the most common treatments administered for 
different stages of the disease.
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Figure 2.7. Summary of the standard treatment available as the prostate cancer develops. For 
localised and low-risk the patient is monitored closely, at high-risk immediate action is taken to 
remove the prostate with adjuvant radiation or hormone therapy and  if recurrent (due to hormone 
therapy) then hormone therapy is stopped and chemotherapy and targeted therapy are used (taken 
from (J. Zhang et al. 2015)).
! The routine treatments for most localised prostate cancer are active 
surveillance or active monitoring, surgery (such as radical prostatectomy), external 
beam radiotherapy and brachytherapy - depending on the stage at which the cancer 
presents or progresses to. Other treatment options, that are less common, include 
cryotherapy, high intensity focused ultrasound (HIFU) and watchful waiting (see 
Section 2.1.5.2.1 for more details). Targeted therapy are specifically designed drugs 
that target specific molecules that are largely found in or on cancer cells compared 
to normal cells (Fisher et al. 2013; Begley et al. 2008). As more targeted therapy 
comes through the clinical pipeline these will replace current treatment as they tend 
to be more effective and cause less side effects (see Section 2.1.6.1). 
2.1.5.2.1 Localised and locally advanced prostate cancer
! The majority of prostate cancers are slow-growing and asymptomatic and are 
therefore considered low-risk, and these men will normally be offered active 
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surveillance or watchful waiting to closely monitor the tumour (Loeb et al. 2013). 
Active surveillance is favoured, especially for young men, as an alternative to 
therapeutic intervention that could cause long term side effects. This usually 
involves serial PSA tests to monitor and calculate PSA kinetics such as velocity and 
doubling time (Section 2.1.4.2) and repeat biopsies. Alternatively, there is active 
monitoring that involves serial PSA tests only or watchful waiting that relies on a 
change in symptoms and so generally less tests are involved (Hayes et al. 2010) 
(Albertsen 2011). The latter methods avoid unwanted complications or side effects 
from biopsy or therapy, this is also useful for those who are asymptomatic. The 
problem is recognising those few that will go on to produce much more aggressive 
prostate cancer where treatment may be administered too late. Another issue is the 
anxiety of waiting and having no treatment that is often experienced by patients 
(Anderson et al. 2014). 
! For intermediate-risk and high-risk it is usually radical treatment such a 
radical prostatectomy or radiation therapy with adjuvant hormone therapy (Section 
2.1.5.2.2). For high-risk individuals, the following factors must influence the overall 
decision: age, life expectancy and potential damage to their quality of life. A radical 
prostatectomy involves the complete removal of the prostate gland, although there is 
an approximately 30% chance of recurrence within 10 years (Roehl et al. 2004). 
PSA is used to detect this recurrence (see Section 2.1.5.3). Due to the large effects 
on quality of life, such as sexual dysfunction and incontinence (Alivizatos & 
Skolarikos 2005), this is generally an option only for men aged 70 and over.  
! It is possible that the cancer could be missed even though it showed a 
‘normal’ PSA result. Conversely, PSA is can be elevated in asymptomatic patients 
with slow-growing, localised prostate cancer (Hugosson & Carlsson 2014). Thus, in 
the latter case it is the opposite problem and active surveillance or monitoring is a 
better option, preventing unnecessary treatment. 
2.1.5.2.2 Hormone therapy 
!
! Excess androgens provide a growth advantage to cancer cells (Section 
2.1.3.2) and this makes them a good therapeutic target. Hormone therapy or 
androgen-deprivation therapy (ADT) are a relatively simplistic type of targeted 
therapy, more sophisticated ways to target androgens and androgen receptors have 
been developed and are detailed in Section 2.1.6.1. ADT are either agonistic or 
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antagonistic to testosterone, as such they work by different mechanism but lead to 
the same result: to slowly decrease the amount of testosterone available in the 
serum. An agonist works similarly to androgen by binding to the androgen receptor 
and eventually they out-compete the androgens and saturate the androgen 
receptors, however this does cause an initial short surge in testoterone. The most 
common types of agonist are called LHRH agonists or luteinizing hormone releasing 
hormone agonists (Hellerstedt & Pienta 2002). Alternatively, and the option for more 
advanced disease, there are the antagonists that target the receptor directly - 
blocking the androgens from binding to the receptor. The antagonists commonly 
used are known as gonadotrophin releasing hormone antagonists or GnRH (Cook & 
Sheridan 2000). In addition, both LHRH and GnRH can be used as an agonist and 
antagonist (Hellerstedt & Pienta 2002). Thus, most clinicians struggle to understand, 
select and optimise these treatment for individual patients (Harris et al. 2009).
! More research is required to uncover the exact mechanisms by which the 
cancer becomes resistant and thus which pathways to target subsequently. As 
hormone therapy is the most widespread treatment for prostate cancer, even after 
disease recurrence, the disease (as mentioned before, Section 2.1.3.2) almost 
always progresses to hormone-resistant status and the therapy becomes redundant 
(Dutt & A. C. Gao 2009). For advanced and metastatic disease hormone therapy is 
not normally enough but the progression rate varies so extensively that decisions on 
additional treatment are made on a patient-by-patient basis (as quality of life at late-
stages become more pressing). Usually hormone therapy will be used as adjuvant 
therapy to surgery or radiotherapy (Gomella et al. 2010). 
! Controversy surrounds when exactly to administer this treatment, some 
believe that when it is used early on localised or locally advanced stages it could 
improve outcomes (Moul et al. 2008). However, this is only true for those with 
localised cancer that will go on to develop a much more aggressive form and until 
there is a better method of distinguishing this small proportion of patients it is difficult 
to know who to treat aggressively at an early stage.
2.1.5.2.3 Metastatic prostate cancer 
! The main treatment for metastatic or advanced prostate cancer is 
chemotherapy and ADT (see Section 2.1.5.2.2). If the metastatic disease is a result 
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of biochemical relapse after ADT and is hormone-resistant, then Docetaxel - an anti-
mitotic chemotherapy agent that interferes with cell division - is usually administered 
(Yagoda & Petrylak 1993; Lorenzo et al. 2007). After this, treatment options are 
limited and so more chemotherapy is usually administered. 
! Palliative type treatment would usually be made available as soon as 
possible. Similarly, watchful waiting would be appropriate if the patient was elderly 
(70 or older) and had only a short-survival time; therapy would severely and 
unnecessarily affect the patients quality of life. Thus, treatment is often tailored to 
the patients needs at this stage.  
! Unfortunately, it is clear that not many options are available to patients that go 
on to have metastatic disease and thus, more research is desperately needed here. 
Section 2.1.6 outlines some examples of ongoing research that aims to develop 
more targeted and effective therapy for those with more advanced prostate cancer. 
2.1.5.3 Monitoring after treatment 
! In addition to active monitoring and surveillance discussed in Section 
2.1.5.2.1, monitoring is also necessary for two different stages that follow one after 
the other. These are: a) monitoring effectiveness of the treatment and b) monitoring 
cancer recurrence after treatment is complete. The PSA levels are measured to 
monitor the success of radical prostatectomy where any detectable PSA is treated 
as suspicious and a sign of biochemical recurrence (Paller & Antonarakis 2013). No 
other (non-invasive) biomarkers for monitoring are clinically available, though some 
are currently under investigation such as PCA3 (Jamaspishvili et al. 2010). 
2.1.6 Current advances in therapy
! Figure 2.7 shows that the standard medicine for localised tumours today is 
radical prostatectomy - a risky procedure for many of these men who then instead 
choose active surveillance and avoid unwanted side effects, such as sexual 
dysfunction. Thus, a wider range of treatment options are urgently needed at the 
early stages of the disease as this will have a huge impact on the patient’s quality of 
life. In addition, there is a bottleneck at the flow of molecular information coming 
from research, such as high-throughput microarrays, to an effective tool in the clinic 
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- an issue that a more translational approach and push can only solve. For prostate 
cancer, it could be argued that there is a higher demand for personalised medicine 
due to its particularly high heterogeneic nature relative to cancers that originate from 
other areas of the body. The current model in which prostate cancer treatment is 
decided by stratification (using parameters such as PSA and the Gleason score) is 
therefore far too generalised and ineffective (Lazzeri 2015). Encouragingly, there 
have been recent developments in targeted therapy (Section 2.1.6.1), 
immunotherapy (Section 2.1.6.2) and a combination of the two - all of which are 
more personalised than current conventional therapy - and are being tested in 
clinical trials (Table 2.1) and are outlined in more detail below. 
! !
2.1.6.1 Prostate cancer targeted therapy
! Targeted therapies are based on drugs that act on specific molecules found 
largely in cancer cells, for example proteins necessary for continued survival and 
progression, and its high specificity means that toxicity and side effects are minimal. 
Targeted therapy differs from conventional therapy such as chemotherapy, which 
instead acts more generally on rapidly dividing cells and is associated with higher 
levels of toxicity. Several targeted treatments for solid cancers exist in the clinic 
already, such as HER2 (over-expressed in breast cancer cells to enhance its 
growth) with the drug Herceptin, which has been highly successful (Ahmed et al. 
2015). Hormone therapy in prostate cancer is an example of targeted therapy, 
where androgens and androgen receptors are targeted (Wong et al. 2014). There 
are two main types of hormone therapy, ones which work to either: a) block 
androgens (ADT) such as the agonists and antagonists detailed in Section 2.1.5.2.2 
or b) target the androgen receptor with a drug, for example to block its translocation 
to the nucleus and preventing its association with heat shock protein 90 (De Leon et 
al. 2011). Unfortunately, androgen therapies have been exhausted and are not 
always effective, especially when androgen is no longer required for growth by the 
cancer cells (as is the case for hormone-resistant tumours). Thus, new therapeutic 
targets are urgently required to develop new targeted therapies or immunotherapy 
agents (Section 2.1.6.2) against it; the criteria for an ideal target to be used in 
therapy is detailed in Section 2.2.2. Currently in development are targeted therapies 
for advanced and metastatic disease that focus on blocking the PI3K/Akt/mTOR 
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pathway, which is upregulated in 30-50% of prostate cancers (T. M. Morgan et al. 
2009).
!  Molecular analysis such as genomics, transcriptomics, and metabolomics 
have allowed for the stratification of prostate cancer into much more relevant and 
useful subclasses that are associated with distinct patterns of mutations or 
abnormalities (that could be used as biomarkers and/ or targets for targeted 
therapy). High-throughput sequencing can now identify CNVs. 
2.1.6.2 Immunotherapy for prostate cancer 
! Immunotherapy is a relatively new branch of treatment, which harnesses, 
guides and strengthens the immune system through engineering components of the 
immune system such as monoclonal antibodies and T cells. In addition, 
immunotherapy can evoke a whole systemic immune response, with the use of 
cancer vaccines (Noguchi et al. 2016).
! The use of immune cells in a therapeutic context can be active or passive; the 
key difference being the mechanism of action. Active immunotherapy acts to 
stimulate a host immune response, for example through the use of a vaccine, and 
passive immunotherapy enhances an already existing immune response and acts 
immediately. An example of the latter is an antibody-drug conjugate (ADC) carrying 
a toxin; additional examples are depicted in Figure 2.8. 
 
Figure 2.8. Schematic representation of the different mechanism of actions performed by 
monoclonal antibodies to directly kill cancer cells. Antibodies targeting a cell surface antigen on 
tumour cells can directly cause apoptosis to the cancer cell it binds to. The antibodies act by different 
mechanisms and these include being used as a vehicle for a drug or toxin, inhibiting receptors and 
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blocking downstream signaling or alternatively activating receptors that then leads to apoptosis 
(Neves & Kwok 2015).
! These monoclonal antibodies are initially engineered or humanised, which 
means that the mouse Fc (or CH and CL) and Fv (or VH and VL) framework regions 
(see Figure 2.9) of the mouse antibodies are replaced by human germ-line amino 
acids, this minimises its immunogenecity and avoids rejection by the host immune 
system (Gonzales et al. 2005). 
Figure 2.9. Schematic representation of the humanisation of murine monoclonal antibodies.  
The variant unit gives the antibody its specificity to an antigen, if the minimum amount required to still 
recognise and bind that antigen the rest can be changed to be made human. (Carter 2001).
!
! These humanised, chimeric or fully human monoclonal antibodies can then 
be further engineered to increase their anti-tumour activity (A. M. Scott et al. 2012). 
The Fv regions at the top of the antibody provide the specificity that can be modified 
to increase the affinity (strength of binding to one binding site) and valency (number 
of antigen binding sites), which both, in turn, would increase the overall strength of 
binding to the antigen (also known as avidity). Innovative approaches include single 
chain variant fragments (scFv) that have much better and more even tissue 
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penetration and distribution and a shorter serum half life (Ahmad et al. 2012). 
Another example are bispecific antibodies that target two cancer specific antigens 
that have the ability to block two pathways and limit the number of ways in which 
cancer cells can become resistant (Weidle et al. 2014). Knowing which approach is 
best heavily depends on the target antigen. Fortunately, monoclonal antibodies have 
been very successful with over 12 being approved by the FDA for use in the clinic so 
far (A. M. Scott et al. 2012).
! Both targeted therapy and immunotherapy treatment strategies have shown 
to be more potent when used together, most drugs or toxins will induce an immune 
response to some degree anyway. Some examples are shown in Table 2.1. 
! A Phase III clinical trial has just ended, which sought to test the monoclonal 
antibody Ipilimumab (brand name is Yervoy) against metastatic castrate-resistant 
tumours (already in the clinic to treat advanced melanoma) with radiotherapy. The 
monoclonal antibody binds the receptor CTLA-4 on the surface of T cells, essentially 
activating it. This prevents the T cells from switching off and instead keeps them 
active (also known as checkpoint blockade). Unfortunately, the results indicated no 
significant overall survival (OS) difference (Kwon et al. 2014). However, the study 
indicated that it may work with those who had lower disease burden and thus, will be 
tested in early prostate cancer stages instead (Reese et al. 2015). 
! Adoptive cell transfer is a highly personalised form of immunotherapy. Here, T 
cells are taken from the patient (ex vivo), activated and expanded before being 
transferred back to the patient or another recipient (Neves & Kwok 2015). Tumour-
specific T cells can be generated through the use of antigen-presenting cells 
(APCs). APCs, such as dendritic cells, are the cells which present the antigen to the 
T cells bound to the major histocompatibility complex (MHC), those T cells that 
recognise the MHC-antigen complex will go on to mature into CD8+ cytotoxic T cells 
(O'Hagan & Valiante 2003). 
! Sipuleucel-T (Provenge) is a cancer vaccine that is made by isolating 
dendritic cells and stimulating them ex vivo. These ‘primed’ cells (against the 
cancer) are then re-injected back into the patient. This was approved by the FDA but 
subsequently rejected NICE for use by the NHS, due to cost. 
! It is clear that different types of immunotherapy are at different stages, 
especially as so much is still unknown in immunology and good biomarkers (to be 
targeted) are also required. For prostate cancer, the immunotherapies in 
development are intended for patients who have metastatic and hormone-resistant 
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tumours. Key and recent clinical trials, for prostate cancer immunotherapy, are listed 
in Table 2.1.
Drug Mechanism of action Patient group 
and number
Phase Findings Reference
Sipuleucel-T DC-based vaccine, 
primed with PAP and 
GM-CSF
Asymptomatic 
metastatic 
CRPC
512 patients
III Improved OS by 
sipuleucel-T 
compared to 
placebo (25.8 
versus 21.7 
months)
Kantoff et 
al. 2010
Ipilimumab Targets CTLA-4 and 
keeps cytotoxic T 
lymphocytes active 
Metastatic 
CRPC after 
docetaxel
799 patients
III No significant 
difference in OS 
Kwon et 
al. 2014
Prostvac-VF Viral vaccine that 
infects dendritic cells 
and leads to the 
activation of PSA-
specific CD8+ T 
lymphocytes
Metastatic 
CRPC
125 patients
II Improved OS 
compared to 
placebo control 
(25.1 versus 
16.6 months)
Kantoff et 
al. 2010
GVAX with 
docetaxel
Whole tumour cells 
genetically modified to 
secrete granulocyte-
macrophage colony-
stimulating factor
Taxane-naïve 
patients with 
asymptomatic 
CRPC
III Trial terminated Petrylak 
2006
!
Table 2.1. Four key clinical trials in prostate cancer immunotherapy. Immunotherapy is 
becoming the first-line treatment for metastatic castration-resistant prostate cancer (CRPC). 
Sipuleucel and Prostvac-VF are cancer vaccines that have shown improved overall survival (adapted 
from (Noguchi et al. 2016)). 
! Listed in Table 2.1 are just some examples of biomarkers that have been 
tested as a target for therapy and have come through the clinical pipeline, such as 
PAP and CTLA-4. With the emergence of high-throughput data analysis bringing us 
into the ‘-omics’ era (such as the increasing sophistication of genomic microarrays 
and mass spectrometry), there has been a rise in the number of potential 
biomarkers and targets that are currently being investigated. Deciphering how to 
best to streamline the biomarkers path to the clinic and ensure that it is more fruitful 
is still ongoing. For more information see Section 2.2. 
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2.2 Cancer biomarkers
! The definition of a biomarker, according to the National Cancer Institute 
(NCI), is “a biological molecule found in blood, other body fluids, or tissues that is a 
sign of a normal or abnormal process, or of a condition or disease” (NCI). 
Biomarkers are now widely used in the clinic and increasingly relied upon for vital 
clinical decisions. Biomarkers can emerge from a number of places such as 
transcriptional changes or post-translational modifications, which can include one or 
a combination of microRNAs, proteins, and antibodies, and more. Exosomes, other 
extracellular vesicles and circulating tumour cells are another rich source of 
biomarkers. 
! Unfortunately, not enough biomarkers are reaching the clinic. Some of the 
areas that need improvement are basic research and preclinical validation studies, 
both are integral and evolving parts of the biomarker pipeline. The most successful 
and informative biomarkers are proteins that are extracellular and/or located on the 
cell surface - importantly, some cell surface biomarkers are exploited for therapy. 
2.2.1 The biomarker discovery and preclinical pipeline 
! The standard procedure for the clinical integration of biomarkers and 
therapeutic targets often follows a similar pathway involving: discovery (e.g. 
genomics, proteomics), in vitro pre-clinical validation (e.g. 2D cell culture), in vivo 
pre-clinical validation (e.g. mouse models), human clinical trials (phases I-III). If a 
biomarker is successful it then awaits approval by the European Medical Association 
(EMA) or MHRA (in the UK) (Goossens et al. 2015). Each stage is still a working 
process; it has to be adaptable to keep up with increasingly sophisticated 
technology and the size of the data that is being produced. The key issues and 
challenges that have to be considered are summarised in Figure 2.10.
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Figure 2.10. A schematic representation of the biomarker pipeline from discovery through to
clinical implementation. The four stages are outlined to the left and key issues and challenges to 
be considered and improved upon are listed on the right, at each stage (taken from (Goossens et al. 
2015)).
! The pipeline is essentially a funnel where the experimentation becomes more 
sophisticated, expensive and accurate from one stage to the next. Each stage 
requires a model that is balanced between cost-effectiveness and accuracy to test 
either a large number of potential biomarkers (cell lines) or one (human clinical 
trials). Usually, during biomarker validation these tests are specific to a cancer type 
(i.e. prostate, breast or ovarian cancer) and progress within this framework through 
to clinical trials. Through clinical trials a specific subset of patients are tested, such 
as those bearing metastatic castrate-resistant tumours.  
! A major problem of the pipeline is finding an ideal model (that is both cost-
effective and accurate), which becomes exponentially difficult as the cohort to be 
tested becomes larger (Makawita & Diamandis 2010). It is unsurprising then that 
biomarkers fail to make it to the clinic when the validation stages lack rigour. In vitro 
preclinical validation testing commonly involves the use of cell lines but under non-
physiological conditions. In vivo testing usually involves mouse models - the stage 
just before human clinical trials - and are crucial in helping to decide the therapeutic 
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strategy to be adopted, such as the optimal drug dosage. The features of the two 
most common mouse models used are shown in Figure 2.11.
Figure 2.11. The standard mouse models used today in the preclinical stage for biomarkers. 
The two models outlined either side of the cancer patient are the best representative cancer models 
outside of humans to test new therapies, these were chosen due to a balance of cost and accuracy. 
Highlighted in green are the advantages and in red are the disadvantages. On the right, genetically 
engineered mice (GEM) focuses on mimicking the tumour microenvironment, whereas the patient-
derived xenograft (PDX) mice on the left are explanted fragments of tumor tissue that have been 
directly transferred into immuno-suppressed mice that preserve the intratumour genetic diversity 
(taken from (Herter-Sprie et al. 2013)).
!
! The two models in Figure 2.11 fail to truly mimic the tumour 
microenvironment, which usually undergoes a constant and complex interplay with, 
for example, the immune system and human vasculature. The model fails to 
recapture the genetic diversity within a tumour and thus also fails to recapitulate de 
novo human tumour development, which can be responsible for drug resistance. 
Mouse models only represent a snapshot of what occurs in humans (Herter-Sprie et 
al. 2013). !
! The first in vitro phase is still necessary and should be retained; it is cost-
effective when starting with a large cohort of potential biomarkers. This is a growing 
issue in the era of ‘-omics’ technology - such as genomics and proteomics - that 
have become much more cost-effective and widely used and are producing a large 
amount of data at a faster rate. Furthermore, it is especially important considering 
there is less than 100% concordance between mRNA and protein levels (Carter 
2004). The pre-clinical in vitro phase is also a means by which the initial hypothesis 
can be tested and the study design re-evaluated before proceeding. The large 
amount of potential biomarkers fail to be adequately scrutinized and selected for a 
number of reasons such as the lack of rigorous pre-clinical in vitro testing (Makawita 
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& Diamandis 2010). Thus, many ineffectual biomarkers are retained in the pipeline 
and moved into the preclinical stages.	Consequently, very few new cancer 
biomarkers have been implemented into the clinic over the last 20 years (Diamandis 
2012). Ideally, an additional in vitro pre-clinical validation step is required in order to 
shift the focus onto accuracy much earlier on in the pipeline. This could involve the 
use of in vitro 3D cell culture or tumour models that are evolving into cost-effective 
tools (Nyga et al. 2011), further discussed in Section 2.2.4. !
2.2.2 Cancer biomarkers in the clinic 
! Section 2.1 shows how biomarkers are currently integrated into the 
management of prostate cancer, such as helping to decide whether treatment is 
needed and which treatment to administer to patients. Biomarkers can be used in 
the clinic in numerous ways: inherited genetic variation (or disposition) allow the 
clinician to assess the patient’s risk of cancer development in the future; population 
screening tools allow earlier detection of the cancer in order to reduce mortality 
(usually not very invasive, robust and fast); diagnostic tool, in order to confirm 
cancer and provide information on disease state (such as the grade); prognostic 
tool, which provide information about the likely clinical outcome; as a predictor in 
order to aid the clinician in choosing the most appropriate therapy; as a monitor to 
establish how well the current therapy is working or not in order to adjust the therapy  
appropriately and to determine (post-treatment) whether there is disease 
recurrence; or as a pharmacogenomic tool in order to determine suitable dosage 
and assess the risk for adverse effects at that dose.
! Some biomarkers currently used in the clinic are listed in Table 2.2, alongside 
their application/s. 
Biomarker Biomarker 
type
Cancer type Sample 
type
Clinical 
application
Prostate-specific 
antigen (PSA)
Protein Prostate Blood Diagnosis 
Treatment response 
Disease recurrence
Alpha- 
fetoprotein 
(AFP)
Protein Hepatocellular 
carcinoma (HCC)
Germ cell tumours 
(GCT)
Blood Diagnosis
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Biomarker Biomarker 
type
Cancer type Sample 
type
Clinical 
application
ALK Gene 
rearrangement 
Non small cell lung 
cancer (NSCLC)
Tumour Prognosis 
CA-125 Protein Ovarian Blood Treatment response 
Disease recurrence
HER2 Protein Breast Tumour Predictive 
Beta-2-
Microglobulin 
(B2M)
Protein Multiple myeloma 
Chronic 
lymphocytic 
leukemia (CLL)
Some lymphomas 
Blood
Urine
Cerebral 
Spinal fluid 
(CSF)
Prognosis 
Treatment response 
BCR-ABL Gene fusion Chronic myeloid 
leukemia (CML)
Blood
Bone 
Marrow
Disease recurrence
Table 2.2. Cancer biomarkers with current clinical utility.  A list of the more common biomarkers 
used in the clinic today with the cancer type, the type of detection and its specific application (NCI, 
Tumor markers http://www.cancer.gov/cancertopics/factsheet/Detection/tumor-markers). 
! !
! ! The more established, accurate and reliable the biomarkers, the more 
information they will provide to clinicians, which then aids in clinical decision-making. 
Furthermore, patients with prostate caner usually live for a long time and thus, there 
is limited patient history to strengthen the interpretation of predictive biomarkers. In 
addition, none of the currently available biomarkers provide optimal clinical utility 
and often fail to fulfill one or more of the following criteria: time, cost, and patient 
conscious. Commonly, the issues are that these biomarkers are not easily attainable 
(but invasive), do not have adequate sensitivity and specificity, and do not lead to 
patient benefit (Kohn et al. 2007). There is therefore an urgent unmet need for 
clinically robust biomarkers.
2.2.2.1 Extracellular protein biomarkers 
! Extracellular biomarkers, for example proteins found in ascites for ovarian 
cancer or urine for prostate cancer (see Section 2.3.4), are generally easier and 
less invasive to measure. !
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! An example of an extracellular protein biomarker that has successfully 
reached the clinic, despite being limited by a low specificity, is PSA (Section 
2.1.4.2). PSA is measured in the blood and satisfies three out of four of the criteria. 
It has multiple purposes in the clinical management of prostate cancer (Prensner et 
al. 2012). PSA’s utility ranges from a screening tool to an indicator of disease 
recurrence (Table 2.2). There are a number of specific reasons for its widespread 
use in prostate cancer: it is inexpensive and easy to measure; it can be monitored 
over time and therefore tailored to each individual; it is a very good indicator of 
disease progression (Fleming et al. 2006) and there is currently no better biomarker 
to take its place despite the fact that its use is associated with the over-diagnosis of 
prostate cancer (Troyer et al. 2004). It may be impossible to completely replace 
PSA due to its widespread use.
! The PSA test is a good first-line screening test as you can narrow down the 
population to those that are at higher risk. In doing so, it would reduce the number of 
men that are over-treated. However, PSA cannot distinguish between indolent and 
aggressive tumours and it is not a very established prognostic marker (Ballentine 
Carter 2012; Saini 2016). Unfortunately, no other biomarker has successfully 
reached the clinical pipeline that is able to do this. There are a number of 
biomarkers still under investigation that could make up a panel of biomarkers to 
supplement PSA, including PCA3 and TMPRSS2-ERG (Cary & Cooperberg 2013). 
Together, this panel of biomarkers would provide more prognostic information and 
reduce the number of men that are over-diagnosed.
! As a therapeutic target (for monoclonal antibodies) PSA is not ideal because 
it is not located or stable on the cell surface, it is released into circulation (away from 
the tumour) and it provides no growth advantage to the tumour. Examples of cell 
surface biomarkers that could be targeted for therapy are discussed in Section 
2.2.3. !
2.2.3 Cancer Specific Cell Surface Proteins (CSCSPs) 
	 Cancer specific cell surface proteins (CSCSPs) are generally those that are 
located in the plasma membrane, exposed to the tumor micro-environment and 
largely absent from the surface of normal adult tissue.
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! The cell surface location of CSCSPs means that they could be used to direct 
therapies to the cancer cells only and spare normal healthy tissue (that do not 
express the CSCSP on its cell surface). Therapies such as antibody drug-
conjugates, which are made to target the CSCSP and engineered to carry a 
cytotoxic payload that becomes active once the antibody is internalised (Ducry & 
Stump 2010). Another advantage of using cell surface proteins is that major 
histocompatibility complex (MHC) presentation is not needed; peptides are 
constantly being broken down and complexed to the MHC to be presented on the 
cell surface . The advantage is that the MHC pathway allows intracellular proteins to 
become targets for monoclonal antibodies or peptide-based vaccine (Roche & 
Furuta 2015). However, cell surface proteins are generally more accessible on the 
cell surface as they are not complexed to MHC or fragments but the whole, or at 
least a substantial part of the protein. 
! Most of the biomarkers in Table 2.2 are proteins found on the cell surface, 
and these could be candidates for therapy. These candidates can be used solely as 
molecular flags on the cancer cell that do not directly contribute to tumour growth 
itself. These could then be targeted by an ADC, for example. PMSA is a 
transmembrane protein that has been investigated in clinical trials as a therapeutic 
(and imaging) target for prostate cancer because it is highly expressed at all stages 
of the disease, being an integral membrane protein that is not released into the 
circulation and which facilitates the internalisation of bound antibodies (by receptor-
mediated endocytosis) (Bouchelouche et al. 2010). Alternatively, the cell surface 
biomarker is the target itself as it contributes directly to tumour growth and, for 
example, can cause apoptosis by interfering or blocking receptor dimerization or its 
downstream signaling with a peptide (A. M. Scott et al. 2012). Therefore, it is 
important to understand the functional significance of such markers to further 
validate their potential as a therapeutic target and to establish the best therapeutic 
strategy, such as deciding between the approaches just outlined. 
2.2.3.1 Current CSCSPs in the clinic 
	  In Section 2.1.6.2 it was described how monoclonal antibodies, in particular, 
have been very successful in the clinic. The protein targets of these monoclonal 
antibodies and other types of therapy are usually those found on the cell surface of 
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cancer cells.
! There is an unmet need for clinically effective cancer therapies that can be 
tailored for personalised treatment (Section 2.1.6). The most efficient way to identify 
new targets (and biomarkers) is through a proteomic screen of cell surface proteins, 
a practice which tends to be faster, more accurate and informative than preceding 
techniques such as genomic profiling (Workman & Johnston 2005). 
! One of the most important CSCSPs to emerge, HER2, is a cell surface 
growth receptor over-expressed in only 15-20% of invasive breast carcinomas 
(Witton et al. 2003) and is currently the most successful target in breast cancer 
therapy. HER2 is utilised not only as a therapeutic target but also as a prognostic 
and predictive factor in breast cancer (Cooke et al. 2001) and other HER2 positive 
cancers. The success achieved by this antibody-receptor pairing is rare and is due 
to several factors: a) the lack of extensive heterogeneity with one common mutation 
(constitutive activation) that does not affect antibody binding, instead its 
overexpression increases the chances of the antibody finding its target on the 
cancer cell b) HER2 is stable with enough of it on the cell surface at one time and c) 
is fully exposed for antibody binding, which makes it a reliable target for antibody 
therapy. 
2.2.3.2 Functional significance of cell surface proteins
! It is now well established that phenotypic changes to the surface of cancer 
cells contribute to tumourigenesis (Yarden 2001). These changes can be seen 
clearly during invasion and metastasis (Karhemo et al. 2012) where the cell adopts 
a more rounded shape (Yin et al. 2013). Another common deregulation is aberrant 
signaling through the over-expression of a growth factor receptor or ion transporter 
that leads to cellular changes such as sustained cell growth or an increased 
metabolic turnover, respectively, two broad and defining hallmarks of cancer 
(Hanahan & Weinberg 2011). Therefore, the cell surface localisation of these 
proteins serves a functional role in maintaining normal physiological activity.
 ! CSCSPs can be classified to the following functional taxonomies: nuclear 
receptors; growth factor receptors; G protein coupled receptors; ion channels and 
transporters; cell-adhesion molecules; proteases; stem cell-like markers, and others 
(Figure 2.12). From this, we can summarise the foremost changes that arise on the 
cell surface of cancer cells: loss of signaling feedback between the cell surface and 
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nucleus; increased solute transfer of essential nutrients; loss of cell polarity and cell-
cell adhesion; acquisition of migratory and invasive properties with fibroblast-like 
shape (epithelial-mesenchymal transition), and  increased cell surface proteolytic 
activity (metastatic properties). 
Growth factor 
receptors
Nuclear 
Receptors 
Stem cell-
like 
markers
Other
Proteases Ion channels 
and 
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Figure 2.12. A spider diagram stratifying CSCSPs into functional and phenotypic groups. The 
functional groups are coloured green, and these are further sub-grouped into the labeled blue and 
pink boxes. The CSCSPs that are being investigated within the subgroups are named in purple 
boxes. These include cell proliferation and survival. A number of these are candidate therapeutic 
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targets.  
! Figure 2.12 summarises the vast amount of cancer specific proteomic data 
available in the literature and highlights potential functional therapeutic targets. 
Despite this potential, only a small number of CSCSPs are used effectively in 
therapy (Brooks & Brooks 2012). The low success rate at clinical trials could be due 
to the following: heterogeneic populations that exist between tumours and within the 
cells of the tumour, (Meacham & Morrison 2013) such as cancer stem cells; a lack of 
robust clinical validation before entering clinical trials, as previously mentioned in 
Section 2.2.2 and a lack of understanding of the function of the markers that would 
help create the most effective treatment strategy. 
2.2.4 Limitations of current techniques and approaches
	
! Cell surface biomarkers that have been approved for clinical use are comprised 
of aberrantly expressed proteins, such as those in Figure 2.12. The proteome rather 
than the genome more accurately portrays the disease state and progression, as 
proteins directly mediate signaling. Unfortunately, the early promise of this approach 
was dampened and not many of these biomarkers have made it to the clinic over the 
past 20 years (Diamandis 2014). There has been difficulty in establishing the level of 
change that is functionally significant for a) therapeutic targeting with minimal toxicity 
b) identifying the subset of patients who are most likely to benefit from treatment and 
c) diagnosis and prognosis. Currently the over-expression of a protein receptor on 
the cell surface is assessed on the basis of a differential change between a cancer 
cell and its normal counterpart; for example, a tumor with a HER2 
immunohistochemistry (IHC) score of 3+ is generally classified as a high HER2 
expressing tumor (Gustavson et al. 2009). 
! To rely on the cell surface phenotype (as described in Section 2.2.3.2) as a 
diagnostic tool alone would be to assume that it accurately represents the 
complexity that exists inside the cell; this is not the case and especially true for 
prostate cancer that is highly heterogeneic. The cell surface phenotype is one way 
of uncovering part of this hidden heterogeneity and should be integrated into a panel 
of markers. The panel of markers for now could include genomic profiling (Lorico & 
Rappa 2011) and easy to attain extracellular protein in biofluid, as described in 
Section 2.2.2.1. 
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! Inter-tumour heterogeneity is a problem for the development of robust 
biomarkers and targeted therapy, and intra-tumour heterogeneity is just as 
problematic for personalised medicine. Personalised medicine could help solve the 
first issue and for the second there is now technology such as next-generation 
sequencing. Next-generation sequencing is able to simultaneously sequence whole 
genomes and proteins at the single cell level, which then allows the detection of 
mutation clusters within the tumour (Gawad et al. 2016).!
! Antibodies are typically used to measure this level of change but are not 
accurate or reliable enough to be solely used as a tool for measurement, especially 
without appropriate controls and chances of cross-reactivity. Most commercially 
bought antibodies can be polyclonal or monoclonal, monoclonal antibodies are 
generally more expensive. A polyclonal antibody is produced by a number of B 
lymphocytes and consist of a mixed population of antibodies that recognise the 
same antigen but not necessarily the same epitope. Or, in the case of monoclonal 
antibodies, they are produced by a single B lymphocyte clone and so recognise the 
same epitope on the same antigen. Both these types are susceptible to cross-
reactivity as they recognise a small component of an antigen and the chances of 
recognising a similar epitope on another antigen is relatively high (Lipman et al. 
2005). 
! Furthermore, when working with biofluid samples such as blood and urine there 
is often a low signal-to-noise ratio that makes it more difficult to detect a single 
marker. However, monoclonal antibodies are more cost-effective and have the 
potential (through antibody engineering) to have a high affinity and avidity against 
the target protein and potentially be used as an antibody-drug conjugate instead 
(Section 2.1.6.2).
2.3 Engrailed-2 (EN2)
! EN2 is a member of the homeobox-containing transcription factor family and 
is essential for the normal development and organisation of the nervous system. It is 
largely down-regulated after embryonic development and its expression is restricted 
to the purkinje cells in the cerebellum. However, its expression is upregulated again 
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in several different types of cancer and, thus far, EN2 has been detected by 
antibody assays in cancer cell lines, malignant tissue and urine samples.  
! EN2 has the ability to regulate gene transcription and protein translation, as 
well as participate in an extracellular signaling pathway. The protein is unusual for a 
transcription factor as it can be secreted from cells and taken up by other cells. This 
secretion results in the presence of EN2 in the urine of patients with prostate cancer, 
which in turn, has great potential as a biomarker. EN2 is currently being investigated 
as a biomarker in prostate, bladder, kidney and ovarian cancers. However, the 
potential therapeutic role of EN2 has yet to be explored and the role it plays in 
cancer remains unclear.
2.3.1 Homeoboxes 
! The homeobox genes are a superfamily of regulatory genes that all contain a 
signature homeobox domain. They were initially discovered by observing homeotic 
mutations in Drosophila that caused embryonic segments to be switched, indicating 
that they have a role in providing positional information (Lawrence et al. 1983). 
! Homeobox genes are found in all multicellular organisms and the homeobox 
sequence is highly conserved (Santini et al. 2003). The homeobox is encoded by a 
183 base pair DNA segment that encodes a 61 amino acid (aa) homeodomain 
(McGrath, Michael, et al. 2013). In humans 235 functional homeobox genes (those 
that will translate to proteins) and 65 pseudogenes (structurally similar genes that do 
not translate to proteins) have been identified (Holland et al. 2007). Homeobox 
genes often occur in clusters on chromosomes and on this basis are broadly 
grouped into clustered and non-clustered genes. These are further grouped into 
subfamilies such as HOX, PAX and the Engrailed gene families, though the 
groupings are inconsistent (Holland et al. 2007).
! The National Human Genome Research Institute has been collating the 
homeobox superfamily data online (found at https://research.nhgri.nih.gov/
homeodomain) such as the number of DNA binding sequences, protein coding 
genes and organisms, known protein-protein interactions, and the number of 
proteins implicated in disease. This is an extensive resource that will help to create 
a bigger picture of the role of homeobox genes in cancer, which is currently highly 
varied and limited. 
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2.3.1.1 Homeobox gene expression and function 
! The homeogenes encode proteins that primarily act as nuclear transcription 
factors, known as homeoproteins (used hereafter). Homeoproteins are conserved 
both structurally and functionally through evolution (Akam 1989). They play a 
fundamental role in vertebrate develpment (Manak & M. P. Scott 1994), including the 
formation of limbs and organs along the anterior-posterior axis (Addison & Wilkinson 
2016). Homeoproteins have multiple functions although they often regulate cell 
characteristics such as shape, size, cell movement, proliferation and differentiation 
(Stettler & Moya 2014). The majority of homeoproteins continue to be expressed in 
the adult, although their function in this context is less well understood. 
! The homeodomain enables the homeoproteins to bind to specific DNA 
sequences in the regulatory regions of target genes, resulting in transcriptional 
activation or repression (McGinnis & Krumlauf 1992). EN2-DNA binding specificity is 
increased through interactions with specific cofactors (Chan et al. 1997). An 
example of three homeoproteins that often interact during development are HOX, 
MEIS and PREP. Mutations that deregulate these interactions have been reported to 
be associated with disease (Section 2.3.1.3), an example is HOXA9 and its co-
factors MEIS1, MEIS2, and PBX1 that promotes prostate tumour progression (J. L. 
Chen et al. 2012). The combination of cofactors for each homeoprotein is not strict, 
such that HOX proteins can act alone or with other homeoproteins and both MEIS 
and PREP can act as cofactors to other homeoproteins (Moens & Selleri 2006). 
! The majority of homeoproteins have different functions depending on its 
localisation and level of expression such as EN2 and OTX2 (Prochiantz & Di Nardo 
2015). EN2 is initially expressed in the midbrain-hindbrain boundary an is largely 
switched off after embryonic development. However, EN2 continues to be present at 
low levels in adult cerebellum but its expression become restricted to cells such as 
purkinje neurons and granule cells (Table 4) (Choi et al. 2011). EN2 most likely 
shifts from a transcriptional role in the nucleus to a translational role as its moves 
into the cytoplasm and outside the cell (see Section 2.3.2.1 for more details). Both 
OXT2 and EN2 homeoproteins are seemingly required by the adult nervous system 
for the continued survival of mesencephalic dopaminergic (mDA) neurons (Joshi, 
Torero Ibad, et al. 2011) in a non-autonomous manner (expanded upon in Section 
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2.3.2.1). A further role of transferred OTX2 has been identified in the visual cortex 
where it was found to regulate cortical plasticity (Sugiyama et al. 2009). 
2.3.1.2 Homeoproteins and disease 
! Homeoproteins have been linked to many genetic and developmental 
diseases due to their vital role in development. For example HOXA13 and hand-
foot-genital syndrome (Goodman et al. 2000; Goodman 2002). Many cancers exhibit 
expression or alteration in homeobox genes (Spatazza et al. 2013). Normal 
development and cancer progression have a lot in common; both processes involve 
shifts between cell proliferation and differentiation and therefore the deregulation of 
homeogenes found in many cancer types is unsurprising (Nunes et al. 2003).
!  HOX proteins have been extensively investigated in cancer. Fortunately, 
HOX expression and functions in development are well-characterised. Their role in 
development has been identified as fundamental to normal limb and organ 
development along the posterior-anterior axis, blood vessel formation and prostate 
gland development (Moens & Selleri 2006). HOX protein expression remains in the 
adult where they, for example, regulate normal hematopoietic differentiation (Magli 
et al. 1991). Consequently, Hox gene deregulation are often found in leukemia (Rice 
& Licht 2007).  EN2 has been linked to autism (expanded upon in Section 2.3.2) 
and prostate cancer (detailed in Section 2.3.3).
!
2.3.2 The biology of EN2
!
! EN2, like most other homeoproteins, is multifunctional and the defined functions 
have largely been discovered through its distinctive protein domains, highlighted in 
Figure 2.13 and its expression pattern during different developmental stages (Table 
2.3). A key mechanism of action by homeoproteins is tight spatio-temporal 
expression that define boundaries during development, such as a caudal-to-rostral 
gradient in the developing tectum that can act as axon guidance cues for 
topographic map formation in the vertebrate visual system. This tight spatio-
temporal expression of homeoproteins likely explains how EN2 was able to rescue 
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the EN1 mutant phenotype (Hanks et al. 1995) and compensate for the depletion of 
PAX2/5 (Koenig et al. 2010). Therefore, it is possible that EN2 is able to carry out 
many of the functions identified in other homeoproteins and homeoproteins 
identified in other species. The C-terminal homeodomain of EN2, known as EH4 
(EN homology region 4), is a highly conserved 61aa sequence (as described in 
Section 2.3.1.1) (Logan et al. 1992), which adopts an alpha helical protein fold 
allowing EN2 to bind to A/T-rich DNA sequences (Laughon & M. P. Scott 1984). 
Upstream of the homeodomain are PBX interacting domains, another family of 
homeodomain transcription factors, that confer DNA binding specificity to EN2 
(Peltenburg & Murre 1996), represented in Figure 2.13 below. 
Figure 2.13. Schematic representation of EN2 protein structure with known functional 
domains.  Engrailed proteins have a secretion and an internalisation motif (Penetratin), located 
within the homeodomain, and a PBX binding domain at its C-terminal region. At the N-terminal region 
a binding site for elf4E and a phosphorylation site were identified. Modified from (R. Morgan 2006).
! EN2 has the ability to carry out all three major functions assigned to 
homeoproteins, thus far, which are the following: regulating gene transcription and 
protein translation, as well as participating in an extracellular signaling pathway. EN2 
has been reported to predominantly act as a transcriptional repressor (Choi et al. 
2011). In order to do so EN2 uses two distinct mechanisms: a) EH1 confers direct 
transcriptional repression b) EH1 and EH5 recruit the non-DNA binding co-
repressor, Groucho (Tolkunova et al. 1998), please see Figure 2.13 for reference. 
The translational regulation by EN2 in the cytoplasm may involve eIF4E (Nédélec et 
al. 2004) (Choi et al. 2011). The eukaryotic translation initiation factor (eIF4E) 
70  
binding domain can be found at the N-terminal (Figure 2.13). A previous study, in 
adult mice, found a significant amount of Emx2 and eIF4E in high-density fractions 
outside the nucleus, enriched in vesicles, where RNase treatment failed to 
dissociate the two proteins; in order to locally control protein translation. This study 
also confirmed EN2 and OTX2 direct binding to eIF4E, in fact, there are 
approximately 200 homeodomains that contain eIF4E binding sites, which could 
dysregulate eIF4E activity (Topisirovic et al. 2005). EN2‘s association with vesicles 
has been reported in a number of studies; Section 2.3.2.1 focuses on EN2’s ability 
to be translocated out of the nucleus, out of cells and internalised by other cells. The 
phoshophorylation site, also found at the N-terminal, could be involved in regulating 
DNA binding as this was found to be the case in Drosophila (Bourbon et al. 1995). 
!
Table 2.3. List of EN2 expression patterns and functions at different developmental stages in 
mice. Taken from Choi et al. 2011.
! At early developmental stages the EN genes (EN1 and EN2) participate in 
neural development, determining the midbrain/hindbrain (MH) border and continue 
to be expressed at high levels in the alar (dorsal) cells of this region. Interestingly, 
when these alar (dorsal) cells were transplanted to other areas they then promoted 
EN expression in new neighbouring cells (Martinez et al. 1991). In addition, 
fibroblast growth factor 8 (FGF8) was identified as a transcriptional target of the EN 
genes; it is a secreted peptide that was found to induce the expression of EN genes 
(Gemel et al. 1999; A. Liu & Joyner 2001). Subsequently, neuronal subtypes arise 
from the MH region such as the mesencephalic dopaminergic (mesDA) neurons and 
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these have been shown to require EN expression for their continued survival (Simon 
et al. 2001; Albéri et al. 2004). EN is also involved in retinal-tectal mapping such as 
axonal guidance, it does so by two mechansims: a) outside the cell where it is 
expressed in a caudal-to-rostral gradient and generally enhances the sensitivity of 
the cells to the action of other growth factors, such as EphrinA whereby EN2 
promotes its transcription (Logan et al. 1996) and b) directly by being internalised by 
axons and modifiying local protein synthesis (Brunet et al. 2005; Wizenmann et al. 
2009; Nédélec et al. 2004), further discussed in Section 2.3.2.1.
! There has been considerably more interest in other members of this 
superfamily, such as the HOX genes (Section 2.3.1.2), with respect to their 
developmental (Izpisúa-Belmonte et al. 1991) or etiological role (Boncinelli 1997). 
There are three main reasons for this: (i) EN2 expression and regulation have been 
difficult to understand both during development and in adult cells because of their 
complex and diverse nature (ii) EN2 has low and extremely restricted expression in 
the adult with unclear function, and (iii) its developmental function, mode of action 
and localisation are yet to be fully characterised, leaving an incomplete EN2 
expression profile and difficulty in establishing its role in disease, such as cancer 
(expanded upon in Section 2.3.3). The only known sites of normal adult EN2 
expression are in the nervous system, particularly the Purkinje neurones (Sillitoe et 
al. 2008), and in the tubular epithelial cells of the kidney (Lai et al. 2014; Guan et al. 
2014). 
! Due to EN2s role in the continued survival of mesDA neurons, EN2 was 
investigated in individuals with young-onset Parkinson’s disease and a SNP was 
found in EN2‘s promoter region (Rissling et al. 2009). EN2 has also been linked to 
autism; EN2 is found at the Chromosomal region 7q36.3, which is an autism 
susceptibility locus. Subsequent investigations into EN2’s elevated expression in 
autism revealed no de novo mutational event but strong indications of single 
nucleotide polymorphism (P. Yang et al. 2010) and/or an epigenetic change (James 
et al. 2013). 
2.3.2.1 EN2’s localisation and translocation properties 
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! Although homeoproteins primarily reside in the nucleus and act as 
transcriptional regulators they do have the ability to translocate outside the nucleus. 
A conserved nuclear export sequence (NES) has been identified as the mechanism 
by which EN2 guides axons during retinal-tectal mapping (Stettler et al. 2012). The 
NES is an 11aa sequence that exists within the homeodomain and is essential to the 
intercellular transfer of EN2 (Maizel et al. 1999). Furthermore, the NES and lack of a 
classical secretory sequence suggests that EN2 has to initially translocate out of the 
nucleus and into the cytoplasm before being secreted out of the cell (Arnoys & J. L. 
Wang 2007).
! The homeodomain consists of three helices that make a helix-turn-helix 
structure, and the third helix is required for translocation (Derossi et al. 1994). 
Therefore, due to conservation of homeodomain between homeoproteins, it is likely 
that this property is universal amongst all homeoproteins. The third helix of the 
Antennapedia homeodomain has been further exploited as a means to transfer 
molecules across membranes and between cells, these peptides are collectively 
known as cell penetrating peptides (Dupont et al. 2015).
! The exact mechanism by which these proteins are secreted and internalised 
is yet to be fully characterised. The conventional route would normally involve 
receptor-mediated exocytosis and endocytosis (Baines & B. Zhang 2007). However, 
homeoprotein intercellular transfer occurs both at 37℃ and 4℃ degrees (Chatelin 
et al. 1996). Thus, the mechanism is likely to be receptor independent and an 
unknown or ‘unconventional’ pathway that has yet to be discovered. Cofactors and 
post-translational modification could play an important role in EN2’s localisation; 
EN2 has a number of phosphorylation sites and more recent advances revealed that 
phosphorylation by CK2 - that targets a serine rich site on the C-terminal end of the 
En protein - prevents EN2’s intercellular transfer (Maizel et al. 2002). 
! Due to the ability to be transferred between cells, homeoproteins are likely to 
have distinct cell autonomous roles and non-autonomous roles (Joshi, Torero Ibad, 
et al. 2011; Prin et al. 2014; Rampon et al. 2015; Albéri et al. 2004). Interestingly, 
EN2 may have a role in cell-cell communication due to its ability to be secreted 
(Joliot et al. 1998) and internalized by other cells (Cosgaya et al. 1998; Rampon et 
al. 2015). The mechanism by which it does this has been investigated and 
concluded that it occurs through an unconventional route that is shared by other 
members of the homoebox family; further investigation into the mechanism is 
needed. However, Brunet et al showed that internalised EN2 was able to trigger 
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rapid phosphorylation of proteins involved in translation initiation and thus, trigger 
local protein synthesis (Brunet et al. 2005). Furthermore, EN2‘s ability to control the 
responses of both nasal and temporal growth cones occurred through its 
accumulation inside these cones within minutes, which would suggest a change to 
protein synthesis in such as short time, was stopped both when EN2 could not be 
internalised and when protein synthesis was blocked (in the recipient cells) (Brunet 
et al. 2005). An example of a protein involved in translation initiation is EIF4E that 
has also been shown to bind to EN2 and other homeoproteins (Nédélec et al. 2004), 
also mentioned in Section 2.3.2. EN2 has been shown to create extracellular 
caudal-to-rostral gradients (in the developing mid-brain) outside of the cell and be 
internalised to act directly on protein synthesis (Brunet et al. 2005), as discussed in 
Section 2.3.2; PBX is internalised by neighbouring cells to control brain patterning 
(Rampon et al. 2015) and OTX2 intercellular transfer regulates the plasticity of 
postnatal neurons in the visual cortex (Rebsam & Mason 2008). Other 
homeoproteins have also been detected outside of the cell and shown to be able to 
translocate between cells, such as VAX1 (Kim et al. 2014). 
2.3.3 EN2 in cancer
! EN2 is down-regulated after embryonic development with the exception of 
brain tissue where it is confined to Purkinje cells (Albéri et al. 2004). The differential 
expression of EN2 in cancer and a normal adult cells indicated a possible role for 
EN2 in tumorigenesis; much less progress has been made with the latter. EN2 was 
put forward as a candidate oncogene by Martin et al showed that aberrant EN2 
expression in breast cancer (Martin et al. 2005), with ectopic expression of EN2 in 
ductal carcinoma and breast cancer cell lines and no detectable EN2 expression in 
normal tissue and cell lines. They showed that ectopic EN2 expression readily 
transforms mammary epithelial cells and enhances metastatic adenocarcinoma that 
involved a reduction in cell cycling time, a loss of cell to cell contact and a failure to 
differentiate in response to lactogenic hormones, and that siRNA knockdown of EN2 
inhibits human breast cancer cell proliferation. SAGE libraries comprised of human 
brain glioblastoma, colon and ovarian carcinomas also revealed EN2 expression 
(Martin et al. 2005). Furthermore, there was no evidence of gene rearrangement or 
amplification. The study provided a rationale for further exploration of EN2 in 
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targeted therapy as it is expressed in only a subset of breast cancers and toxicity 
was likely to be minimal as there was no EN2 expression in normal breast epithelial 
cells. However, the lack of a large cohort of ductal carcinomas makes it difficult to 
draw a definitive conclusion. EN2 expression was subsequently investigated in 
prostate cancer (Bose et al. 2008), with findings similar to those made in breast 
cancer (Martin et al. 2005). The study showed that the knockdown of EN2 in cell 
lines resulted in a decrease in PAX-2 expression, which lead to a decrease in cell 
proliferation. Further studies have been carried out in various cancer types that 
show elevated EN2 expression and these are summarised in Table 2.4 below. 
EN2 involvement in 
cancer
Cancer type Technique Reference
Promotes malignant 
characteristics
Breast (mouse) Forced overexpression Martin et al. 2005
Required for cancer cell 
proliferation
Breast 
Prostate 
RNAi knockdown 
RNAi knockdown 
Martin et al. 2005
Bose et al. 2008
Overexpression Breast
Prostate
Ovary
Bladder
RT-qPCR
IHC
RT-qPCR
IHC
RT-qPCR
IHC
RT-qPCR
IHC
Martin et al. 2005
Bose et al. 2008 
Morgan et al. 2011
Michael et al. 2011
Morgan et al. 2013
Secretion in urine Prostate
Bladder
ELISA
ELISA
Morgan et al. 2011
Pandha et al. 2012
Morgan et al. 2013
Hypermethylation Lung
Follicular lymphoma
Methylated-CpG island 
recovery
 
Methylation-specific 
PCR
Rauch et al. 2007
Bennett et al. 2009
Table 2.4. A summary of the current evidence linking EN2 gene and protein expression to 
cancer development. Adapted from (McGrath et al. 2013).
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! Immunohistochemistry (IHC) staining revealed the presence of EN2 in the 
cytoplasm and the membrane, exclusively in prostate cancer tissue and not normal 
prostatic epithelium (R. Morgan et al. 2011; R. Morgan et al. 2013; Killick et al. 
2013). There was no detection of EN2 in the nucleus in prostate cancer tissue. 
Interestingly, high levels of EN2 were detected in ductal structures of tumours, which 
created ‘blebs’ in prostatic acini and ducts and provided further evidence and insight 
into EN2’s secretory properties. Morgan et al went on to describe a single EN2 
ELISA test that detected EN2 in the urine of biopsy-proven prostate cancer patients, 
without a prior DRE test, see Section 2.3.3.1 for more details. 
! More recent investigations in renal cancer have shown a higher level of EN2 
expression in the stroma surrounding the tumor than in the tumor itself (Lai et al. 
2014). EN2 is best characterised as a transcriptional repressor during development 
(Choi et al. 2011), the activity of which is again located at the C-terminus (Figure 
2.13). If EN2 was identified as a transcriptional repressor in cancer, it could suggest 
that EN2 is switched on as a consequence of tumorigenesis and not as a precursor. 
Unfortunately with no obvious pattern of expression it has been difficult to assign a 
definitive role to EN2 in cancer, which is likely to be multifunctional. 
!  An EN1 study demonstrated, for the first time in 2011, increased EN1 protein 
expression in adenoid cystic carcinoma after identifying significant hypermethylation 
at EN1’s transcriptional start site (D. Bell et al. 2011). A more recent EN1 study 
showed the exclusive overexpression of EN1 in the breast cancer subtype: basal-
like breast tumours. It was found to act as a pro-survival factor when short hairpin 
RNA (shRNA)-mediated knockdown of EN1 led to immediate cell death to breast 
cancer cells; overexpression of EN1 resulted in the increased resistance to drugs. 
The study went on to target EN1 with blocking peptides that mediated a strong 
apoptotic response in breast cancer cells and increased their sensitivity to drugs 
with no toxicity to normal cells (A. S. Beltran et al. 2014). The hypermethylation of 
En genes has also been demonstrated in lung cancer (Rauch et al. 2007), colorectal 
cancer (Mayor et al. 2009), astrocytomas (Wu et al. 2010) and prostate cancer 
(Devaney et al. 2011). The significance of the hypermethylation is not known but 
they could be useful DNA methylation markers for early diagnosis of cancer (further 
discussed in Section 2.3.3.1). 
2.3.3.1 EN2 as a clinical biomarker
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! There have been very limited investigations in the use of homeoproteins as 
diagnostic and prognostic biomarkers, and those that exist are mainly investigating 
HOX proteins (Barba-de la Rosa et al. 2012; Javed & Langley 2013; R. Morgan & 
El-Tanani 2016). However, EN2’s presence in the urine of prostate cancer patients 
make it an attractive, non-invasive target and recent publications have continued to 
show EN2’s potential as a clinical biomarker (R. Morgan et al. 2013; McGrath, 
McGrath, et al. 2013). 
! Morgan et al in 2011investigated EN2 as a diagnostic biomarker in prostate 
cancer (R. Morgan et al. 2011). In this study EN2 protein was shown to be secreted 
in the urine by prostate cancer cells, and enzyme-linked immunosorbent assay 
(ELISA) measurements of urinary EN2 in cancer patients and aged-matched 
controls revealed that this marker had a 66% sensitivity and 88.2% specificity (R. 
Morgan et al. 2011). Another study in 2012 showed that pre-treatment urinary EN2 
levels were positively correlated with prostate tumor volume of men who 
subsequently underwent a radical prostatectomy (Pandha et al. 2012). 
Consequently, EN2 is being investigated in other urothelial cancers. An almost 
equivalent study was carried out recently in bladder cancer where EN2 was 
detected in the urine at slightly reduced levels compared to patients with prostate 
cancer (R. Morgan et al. 2013). Additionally, a weak correlation has been found 
between tumour grade and the level of EN2 expression (R. Morgan et al. 2013). 
! Studies that show the secretion and internalisation of EN2, together with the 
sequence of the EN2 homeodomain, suggest that some EN2 could be localised to 
the cell membrane (Joliot et al. 1997; Joliot et al. 1998; Maizel et al. 1999; Brunet et 
al. 2005; R. Morgan et al. 2011). In 1997 Joliot’s team demonstrated the association 
of EN2 with membrane fractions or caveolae-like structures (Joliot et al. 1997). In 
addition, EN2 was identified in the basal membrane of prostatic tissue by IHC 
analyses (R. Morgan et al. 2011). Intriguingly, there has been controversy 
surrounding a reliable, commercial anti-EN2 antibody for its detection in western 
blots and IHC (Guan et al. 2014). The goat anti-EN2 antibody, used in this project, 
was confirmed by Guan et al to detect EN2. The study also suggests that a ‘non-
EN2’ protein is detected by other commercial EN2 antibodies. Additionally, EN1 
shares 90% homology with EN2 and it is a possibility that some commercial 
antibodies could pick up this protein and, coincidentally, these commercial 
antibodies to EN1 also pick up the presence of a unspecific band of the same size. 
Thus far, no study has tried to identify this protein. 
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! EN2 expression has already been investigated in epithelial cancers such as 
prostate, ovarian, bladder, breast, and kidney though knowledge regarding its role in 
cancer remains limited. EN2 could potentially be a useful biomarker for identifying 
the switch from indolent to aggressive phenotype when EN2 measurement in the 
urine is no longer correlative with the tumour volume. In the long term, this could 
help reduce the number of men that are over-diagnosed and over-treated. 
2.3.3.2 EN2 as a therapeutic target
! EN2 has yet to be investigated as a target for therapy. A recent publication 
provides further rationale for the use of EN2 as a therapeutic target by 
demonstrating its immunogenicity. The study showed that the number of EN2 auto-
antibodies in prostate cancer patient sera were significantly higher compared to 
healthy controls (Annels et al. 2014).
! EN2’s secretory and internalisation mechanisms are unconventional and 
undefined, though it is likely to be receptor independent (Section 2.3.2) without a 
classical secretion signal sequence (Joliot et al. 1998). EN2’s association with 
vesicles (Joliot et al. 1997; Maizel et al. 2002; R. Morgan et al. 2011) may prevent 
EN2 from being highly accessible to an antibody. However, a study using micelles to 
mimic the membrane environment sought to characterize the conformational 
transition of the full-length homedomain using circular dichroism (Carlier et al. 2013). 
Carlier et al concluded that EN2, placed in a lipid environment, loses its overall 3D 
shape but keeps its helical secondary structures of the homoedomain intact. 
Consequently, this conformation allows previously buried hydrophobic amino acids, 
such as Trp-48 (Le Roux et al. 1993), to become available to insert into the 
membrane. They also suggest that the initial electrostatic interactions with the 
membrane may be enough to trigger a conformational change and enable Trp-48 to 
insert into the membrane. !Consequently, there is a possibility that EN2 is tethered 
onto the cell membrane for a prolonged period of time. This window could be 
enough to use EN2 to directly internalise an antibody such as an antibody-drug 
conjugate (Section 2.1.6.2). 
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2.4 Summary 
! The literature acknowledges that there is a problem in the biomarker pipeline: 
large numbers of potential biomarkers from genomic or proteomic analysis that do 
not equally translate to large amounts of biomarkers in the clinic. For prostate 
cancer biomarkers that initially show promise, they do not significantly fair better 
than PSA to warrant a change in practice and so PSA remains. It is possible to 
create a panel of biomarkers with PSA and EN2, which would make the information 
gained early on in the process more informative; this could lead to more appropriate 
treatment being administered. 
! There is a growing body of evidence for the role of EN2 in prostate cancer as a 
clinical biomarker and perhaps a therapeutic target. EN2 is a homeobox-containing 
transcription factor secreted specifically by prostate cancers into urine that is 
detectable by an ELISA assay. The functional significance of the overexpression of 
EN2 in cancer, and especially in prostate cancer, is not known. Thus, this study aims 
to evaluate EN2’s gene expression, protein expression and localisation in prostate 
cancer; and its translocation between cells. These experiments will be carried out in 
vitro in a handful of prostate cancer cell lines that range from low to high metastatic 
potential (or aggressiveness). In addition, this study will seek to confirm its presence 
on the cell surface of cancer cells; and further investigate its accessibility and 
stability on the cell surface, in order to provide further rationale towards its use as a 
therapeutic target. EN2’s role in cancer is further evaluated by looking at the cellular 
responses as a result of EN2 messenger RNA (mRNA) silencing and over-
expression. Ultimately, if EN2 protein is confirmed to be stable on the cell surface 
and shown to have functional significance (such as being a vital component to 
tumour progression), it would provide information on how best to design the 
therapeutic antibody against EN2. 
! The next chapter outlines the specific materials and methodology utilised and 
designed for this study to address the specific objectives, restated below from 
Section 1.5:
1. determine EN2‘s expression and localisation within cancer cells.
! !
2. further define EN2’s secretion and internalisation mechanisms. 
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3. identify a suitable EN2 antibody for development into an antibody-drug 
conjugate. 
4. carry out preliminary in vitro experiments on the candidate antibody-drug 
conjugate to direct the next set of experiments.
5. further investigate EN2’s cell autonomous and cell non-autonomous role
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Chapter 3: Materials and 
Methods
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3. Materials and Methods
! All materials and methodology are described in the order of experimentation 
displayed in the results section from Chapter 4 to Chapter 6. 
3.1 Tissue culture 
3.1.1 Culture media
! All culture media used for the in vitro cell line experiments carried out in this 
study are listed below in Table 3.1 as well as the supplier.   
Medium Supplier
DMEM Sigma-Aldrich, UK
MEM Sigma-Aldrich, UK
RPMI-1640 Sigma-Aldrich, UK
F-12K ATCC, USA
IMDM Sigma-Aldrich, UK
HBSS (Hanks Balanced Salt Solution) Sigma-Aldrich, UK
Opti-MEM I Reduced Serum Sigma-Aldrich, UK
FluoroBriteTM DMEM Life Technologies, UK 
Table 3.1.  A list of the culture media required for all cell lines and their source.
3.1.2 Cell lines
! All cell lines (Table 3.2) were purchased from the American Type Culture 
Collection (ATCC, USA); except for the Fibroblasts, which were obtained from the 
University of Birmingham and Peripheral blood mononuclear cells (PBMCs) that 
were isolated from blood samples obtained from healthy donors on the premises 
(see Section 3.1.3).
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Cell line Tissue type Origin Source Reference
HL-60 Human AML
Peripheral blood
ATCC, USA Gallagher et al. 
1979
SK-MEL-5 Human Malignant melanoma
Skin, metastatic axillary 
node
ATCC, USA Fogh et al. 1977
PC3 Human prostate 
adenocarcinoma 
Grade IV, 
adenocarcinoma
Prostate, metastatic site: 
bone
ATCC, USA Kaighn et al. 1979
Du145 Human prostate 
carcinoma
Prostate; derived from 
metastatic site: brain
ATCC, USA Stone et al. 1978
LnCaP Human prostate 
carcinoma
Prostate; derived from 
metastatic site: left 
supraclavicular 
ATCC, USA Gibas et al. 1984
WPMY-1 Human normal 
prostate stroma/
fibroblasts 
- ATCC, USA (Bello et al. 1997)
T47D Human
ductal carcinoma
Mammary gland; derived 
from metastatic site: 
pleural effusion
ATCC, USA Judge & 
Chatterton 1983
NIH/3T3 Mouse embryo 
fibroblast
- ATCC, USA Jainchill et al. 
1969
Dermal 
Fibroblasts
Human adult skin 
(epidermis) 
- - -
Table 3.2. A summary of all cell lines used in this study, including their source and derivation. 
! All cell lines that were purchased prior to the start of the study have a valid 
authentication certification. Other cell lines, including the clones that were created 
as part of the study, were sent for reauthentication using short tandem repeat (STR) 
profiling against the original STR profile (LGC, USA). All cell lines that were sent 
were confirmed to be an exact match. 
! The atmospheric conditions and working cell culture media required to 
maintain each cell line in cell culture are listed in Table 3.3, with the exception of the 
stable clones that were also maintained under selection pressure using an 
appropriate antibiotic. 
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Cell line Media and supplements Atmospheric  
conditions
HL-60 IMDM + 20% FBS +1% P/S 5% CO2, 37℃
SK-MEL-5 MEM + 10% FBS + 1% glu + 1% P/S + 1% 
sodium pyruvate (Invitrogen, UK)
5% CO2, 37℃
PC3 F-12K + 10% FBS + 1% P/S 5% CO2, 37℃
Du145 DMEM + 10% FBS + 1% glu + 1% P/S 5% CO2, 37℃
LnCaP RPMI-1640 + 10% FBS + 1% glu + 1% P/S 5% CO2, 37℃
WPMY-1 DMEM + 10% FBS + 1% glu + 1% P/S 10% CO2, 37℃
NIH/3T3 DMEM + 10% FBS + 1% glu + 1% P/S 5% CO2, 37℃
Dermal Fibroblasts DMEM + 10% FBS + 1% glu + 1% P/S 5% CO2, 37℃
Table 3.3. A list of recommended media, supplements and environmental conditions for 
optimal growth for each cell line. Working media for in vitro cell culture usually contain the 
following additional supplements: Fetal bovine serum (FBS) (Life Technologies, UK), Penicillin and 
Streptomycin (P/S) (Sigma, UK) and glutamine (glu) (Sigma, UK). 
! All cell lines are adherent lines except HL-60, which are a suspension cell 
line. Cells were generally kept at 5% CO2 and at 37℃, only WPMY-1 required 10% 
CO2  (Table 3.3). All tissue culture work was performed in a sterile class II biosafety 
cabinet (Kendro, UK); these were cleaned and maintained on a regular basis. The 
working media was prepared in 500ml bottles and supplements added (outlined in 
Table 3.3) in sterile conditions and this was kept at 4℃. Penicillin-Streptomycin (P/
S) were used to prevent bacterial contamination, due to the combined gram-positive 
and gram-negative bacteria action. In addition, mycoplasma testing was carried out 
regularly using a MycoAlert™ Mycoplasma Detection Kit (Lonza, UK).  
3.1.3 Isolation of PBMCs from healthy donors
! A venesection of 10ml or 20ml of blood was taken from a healthy volunteer 
and collected in ‘green top’ heparin blood tubes (BD Vacutainer System, UK). These 
were diluted in HBSS and carefully layered on top of 15ml Ficoll-Paque (Invitrogen, 
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UK). This was spun at 690g for 25 minutes at room temperature after which, the 
‘cloudy’ ring at the interface was carefully collected. This was topped up with HBSS 
to 50 ml and spun at 690g for 10 minutes. The supernatant was discarded and the 
pellet was resuspended in 20ml red blood cell lysis buffer (Pierce, UK) for 10 
minutes before pelleting (690g, 10 minutes). The final pellet were carefully 
resuspended in 1ml PBS to be counted. 
3.1.4 Passaging adherent cells 
!
! All cells were cultured in appropriate media specified in the suppliers 
instructions (found on the ATCC website). Cells were generally grown in T-75 (75 
cm3 ) flasks. If cells were less than 60% confluent, half of the culture medium was 
removed and fresh medium added. If cells were more than 60% confluent (usually 3 
days after previous passage) then they were harvested by removing the culture 
medium, washing cells with 10ml HBSS and subsequently 10ml (10X) trypsin 
ethylenediaminetetraacetic (0.5% trypsin, 0.2% EDTA), leaving the residual trypsin-
EDTA on the cells. After a few minutes 10 ml culture medium was used to neutralize 
the trypsin, and cells were collected and centrifuged at 1500rpm for 3 minutes. 
Supernatant was decanted and the pellet was re-suspended in 1-10ml complete 
culture medium for either a 1:2 to 1:8 cell split depending on the experiment to be 
set up shortly after. The cell suspension was transferred to a new flask, which was 
subsequently topped up with complete culture medium. Cells were then incubated 
according to the conditions stated in Table 3.3. 
3.1.5 Passaging suspension cells 
! A percentage of the culture media was simply removed, discarded and fresh 
culture media replaced what was taken. 
3.1.6 Cell viability count
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! Cell viability was assessed by trypan blue (Sigma, UK) exclusion. Cell 
suspension was diluted 1:10 with trypan blue. 10µL of the mixture was loaded onto 
the grid of a Neubauer haemocytometer counting chamber. Trypan blue is 
membrane impermeable and so cells that had taken up trypan blue, observed by 
light microscopy, were considered non-viable. Once all four grids had been counted, 
the following calculation was then carried out:
‣! Mean number of cells per quadrant × dilution factor × 104 = number of 
! cells/mL
3.1.7 Cell cryopreservation and storage 
! Cells were harvested by centrifugation at 1500rpm for 3 minutes and 
resuspended in culture media to 1x106 cells/ml supplemented with 5% dimethyl 
sulfoxide (DMSO) (Sigma, UK). 1 ml aliquots were distributed into sterile cryovials 
Nunc® CryoTubes®), placed into Mr. FrostyTM freezing containers 
(ThermoScientific, UK) and frozen at - 80℃ overnight, to allow a steady decline in 
temperature, before being transferred to liquid nitrogen storage tanks.
3.1.8 Cell recovery from cryopreservation 
!
! Cryovials were removed from liquid nitrogen, kept on ice and quickly thawed 
in a water bath at 37℃. After approximately 2 minutes, the 1ml cell solution was 
pipetted into a to universal tube (pre-filled with 9ml of warm culture media) and 
centrifuged at 1500rpm for 3 minutes. The supernatant was discanted to remove 
traces of DMSO and the cell pellet was resuspended in approximately 6mL cell 
culture media and transferred to a T-25 flask and incubated at 37°C. The media was 
changed to fresh media the next day once cells had adhered. 
!
3.1.9 General cell seeding densities for downstream applications 
! Table 3.4 provides the optimal culturing conditions for each cell line when 
carrying out an experiment using different sized culture-ware.  
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Culture-ware cells/ ml Total volume Applications
96-well plate 1x104 200µl MTS assay 
Cloning 
siRNA
pH-Ab internalisation 
24-well plate 1x104 500µl Cloning
8-chambered slide 1x104 500µl ICC
35mm glass-
bottom dish
4x105 1.5ml Live cell imaging/ time-lapse 
microscopy
6-well plate 4x105 1.5ml RNA extraction
Western blot lysates
Lipid plasmid transfections
Cloning 
Table 3.4. A list of culture-ware used in this study and the optimal seeding densities, volume 
and their common applications. 
 
3.2 Total RNA extraction  
! Total RNA was extracted using the RNeasy Plus Micro Kit (Qiagen, UK). Cells 
were washed with HBSS and trypsinised before being counted. Cell pellets were 
fully resuspended and lysed using a suitable volume of RLT plus β-mercaptoethanol 
buffer recommended by Qiagen. For homogenization lysates were pipetted directly 
into a QIAshredder spin column (Qiagen, UK) placed in a 2ml collection tube and 
centrifuged for 2 minutes at 13,000rpm. Lysates were then treated according to 
manufacturer’s instructions. In summary, lysates were first passed through a gDNA 
eliminator spin column in order to remove genomic DNA. Ethanol was then added to 
ensure enable RNA to bind to the silica membrane of the RNAeasy spin column, 
which was then washed a number of times. The RNA was then eluted from the 
membranes with 14µL RNase-free water. The RNA concentration (ng/µl) was 
measured as well as the ratio of absorbances at 260nm and 280nm using a 
NanoDrop® ND-1000 Spectrophotometer (Labtech International, UK). A 260/280 
ratio less than 1.7 was discarded as the sample was likely to be contaminated with 
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proteins, for example. Samples were immediately stored at - 80℃ or used 
immediately for cDNA synthesis (Section 3.3)
3.3 Complementary DNA (cDNA) synthesis from total RNA 
! A two-step cDNA Synthesis Reaction using nanoScript Reverse Transcription 
kit (Primer design Ltd, UK) was performed. First, the annealing step, samples were 
made up to equal concentrations with RNAse/DNAse free water in a total of 9µL. 
1µL of Oligo(dT) primers was added to each RNA sample. The RNA template-primer 
solution was denatured by heating to 65℃ for five minutes and immediately placed 
on ice to cool. Second, the extension step, a master mix was made up for all 
samples, which was made up of the following: 5µL of nanoScript2 4X reaction 
buffer; 1µL dNTP mix (10mM); 3µL RNase/DNAse free water and 1µL nanoScript 2 
enzyme. Subsequently, 10µL of the master mix was added to each sample on ice to 
make a total of 20µL reaction volume. These were transferred to a preheated PCR 
thermal cycler (Applied Biosystems, UK) and incubated at 42℃ for 20 minutes, the 
reaction was terminated by incubating at 75℃ for 10 minutes. Assuming the cDNA 
synthesis was 100% efficient the cDNA synthesised was equal to the amount of 
RNA initially added to the reaction; this was then diluted to 5ng/µL accordingly. The 
cDNA were stored as at -20℃ or used immediately for RT-qPCR.
!
3.4 Real time-quantitative polymerase chain reaction (RT-qPCR)  
! RT-qPCR reaction was carried out using a Stratagene Mx3005P qPCR 
system (Agilent Technologies, USA) and SYBR Green fluorescence to quantify the 
amount of target cDNA in the sample. The MxPro software (Agilent Technologies, 
USA) measured the cycle threshold (Ct) for each sample, which is the number of 
PCR cycles required to amplify the target cDNA past the background level 
(reference dye) and up to a fixed concentration of amplicon (threshold). The amount 
of SYBR green fluorescence captured is equal to the amount of cDNA as it only 
emits light when bound to double stranded DNA. Therefore, Ct values are inversely 
proportional to the amount of target cDNA in the sample. House keeping genes are 
required as endogenous controls to normalise Ct values between samples, beta-
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actin was initially used (see Table 3.5 for primer sequences). All qPCR reactions 
were carried out in duplicates on a 96-well and BrightWhite plate (Primer Design 
Ltd, UK). 
! A qPCR reaction master mix was prepared for all reactions, which consisted 
of the following components: 10µL PrecisionPlus Master Mix (Primer Design Ltd, 
UK); 1µL Primers (forward + reverse) and 4µL DNase/RNase free water. 5µL of 
cDNA sample (25ng total) obtained through the protocols outlined in Sections 3.2 
and 3.3 was then added to the appropriate well, a total of 20µL per reaction. The 
primers used are listed in Table 3.5. The thermal cycling conditions were set as 
follows: enzyme activation at 95℃ for 2 minutes (x1 cycle), denaturation at 95℃ for 
15 seconds and data collection at 60℃ for 1 minute (x40 cycles). In order to check 
that only a single product (target cDNA) was amplified a melt curve was performed 
at 95℃ for 30 seconds, 72℃ for 1 minute and 95℃ for 30 seconds (see Section 
3.4.1).
! The ΔCt relative quantification method was applied because it calculates the 
fold difference in EN2 expression between a treated sample and a non-treated 
control sample (calibrator), absolute quantitation was not necessary (Livak & 
Schmittgen 2001). Next, assuming the PCR reaction is 100% efficient, every cycle 
of PCR resulted in a 2-fold increase or doubling in PCR product, therefore the 
relative ‘fold change’ in gene expression was expressed as ‘2(ΔCt)’. However, in order 
to determine the expression of EN2 normalised to β-actin expression the following 
formula was applied: 2(ΔΔCt) where ΔΔCT = (CtEN2-CtHKG)treated -(CtEN2-CtHKG)control, 
which is expressed as a fold change in gene expression relative to the control cells 
(and scaled up as required).  
3.4.1 Primer sequences and validation
! All primers used in this study have been detailed in Table 3.5. Primers (3.2µM 
stock) obtained from Primer Design Ltd. were designed and validated before 
receiving and the working concentration of these primers was 300nM in a 20µl 
reaction (Section 3.4). All other primers (10µM stock) were designed using the 
NCBI Primer3 and BLAST tool (Ye et al. 2012), purchased from Sigma, UK (stored 
at -20℃), the working concentration was 1µM in a 20µl reaction. 
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Name Accession
number
Sequence (5’-3’) Source
EN2 (8) NM_001427 Forward: 
GTGAGCTCGGACTCGGACAGCTCGCA
Reverse: 
GGCCGCTTGTCCTCTTTGTTCGGGTTC
Sigma-Aldrich, 
UK
β-actin NM_001101.3 Forward: ATGTACCCTGGCATTGCCGAC
Reverse: GACTCGTCATACTCCTGCTTG
Sigma-Aldrich, 
UK
EN2 Exon1 NM_001427 Forward: GAACCCGAACAAAGAGGACA
Reverse: CGCTTGTTCTGGAACCAAAT
Primer Design, 
UK
EN2 Exon2 NM_001427 Forward: GAACCCGAACAAAGAGGACA
Reverse: CGCTTGTTCTGGAACCAAAT
Primer Design 
Ltd, UK
EN2 (IS) NM_001427 Forward: GAACCCGAACAAAGAGGACA
Reverse: CGCTTGTTCTGGAACCAAAT
Primer Design, 
UK
GAPDH NM_002046.5 Forward: GAACCCGAACAAAGAGGACA
Reverse: CGCTTGTTCTGGAACCAAAT
Primer Design, 
UK
ATP5B NM_001686 Forward: GAACCCGAACAAAGAGGACA
Reverse: CGCTTGTTCTGGAACCAAAT
Primer Design, 
UK
qPCR EN2 
(pGenScript)
NM_001427 Forward: AGACAGAACCCTCCATGTGC 
Reverse: CCCAGTCCTCTTGCTTTCAG
GenScript, 
USA 
MAP1B NM_005909.4 Forward: GCCGGAGCGAGACACTTC 
Reverse: ACTTGCTGTCAAGGAAGCGG
Sigma-Aldrich, 
UK
COL8A1 NM_001850.4 Forward: CTGGGTCAGCAAGTACCTCA 
Reverse: GGACCTTGTTCCCCTCGTAA
Sigma-Aldrich, 
UK
INHBA NM_002192.3 Forward: TTTCTGTTGGCAAGTTGCTG 
Reverse: CGGGTCTCTTCTTCAAGTGC
Sigma-Aldrich, 
UK
EIF4E NM_001968.4 Forward: GCAGCCTGCATACACTCCTT 
Reverse: GCTGTCATTTCTCAAGACCGTG
Sigma-Aldrich, 
UK
TMEM204 NM_024600.5 Forward: CCCATACACCAACCTGTCCT
Reverse: GTTGATGGAGCGCTGAGAAG
Sigma-Aldrich, 
UK
Table 3.5. List of all qPCR primers in this study.  
! As outlined in Section 3.4 a melt curve was performed to ensure that the RT-
qPCR assay had resulted in a single, specific product. Furthermore, a ‘no template 
(cDNA) control’ well was always carried out for every set of primers used in that 
assay and this revealed whether they could create a false positive signal. For the 
EN2 primers these were further tested by serial dilution of EN2 plasmid DNA in 
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order to create a standard curve. After applying a line of best fit to the standard 
curve, the amplification efficiency (E) was calculated using the following formula: E= 
10(-1/slope (m)), where m is derived from y = mx + c. An efficiency of more than 105% 
indicated that another product was likely to be co-amplified and less than 90% 
indicated that the primers were poorly designed and thus, the reaction was not 
efficient (Rutledge & Côté 2003). 
3.4.2 Selecting house keeping gene/s for normalising RT-qPCR data 
! For accurate gene quantification, it is essential to normalise real-time PCR 
data to a fixed reference; one that is not affected by the experimental conditions. 
The geNORM kit measured the expression of 12 reference (house-keeping) genes 
in a range of representative samples. The geNorm software provided with the kit 
ranked the reference (house-keeping) genes in order of stability of expression. The 
panel of 12 validated HKGs were tested (included with the geNORM kit 
(Primerdesign Ltd., UK): SDHA; B2M; 18S; YWHAZ; EIF4A2; CYC1; ACTB; 
RPL13A; UBC; TOP1; GAPDH and AP5B. cDNA were a representative set of 
samples (1-10) that included cDNA from PC3 and WPMY-1 cell lines after EN2 
forced expression, GFP-EN2 stable expression and EN2 knockdown. The plate 
layout is depicted in Table 3.6.
Reference genes
Samples
HKG1 HKG2 HKG3
1 1 9 9 1 1 9 9 1 1 9 9
2 2 10 10 2 2 10 10 2 2 10 10
3 3 water water 3 3 water water 3 3 water water
4 4 4 4 4 4
5 5 5 5 5 5
6 6 6 6 6 6
7 7 7 7 7 7
8 8 8 8 8 8
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Table 3.6. geNORM RT-qPCR plate setup. Cell line cDNA samples were tested for each house 
keeping gene (HKG) 1 to 12 in order to calculate the most stable throughout these samples. 
! A qPCR reaction master mix was prepared for for each HKG primers to be 
used, which consisted of the following components: 10µL PrecisionPlus Master Mix 
(Primer Design Ltd, UK); 1µL Primers (forward and reverse) and 4µL DNase/RNase 
free water. Enough was made for duplicate samples, and aliquoted to the 
appropriate wells in a BrightWhite 96well plate. Subsequently, 5µl of cDNA sample 
was added to each assigned well. The same qPCR thermal profile was used as 
outlined in Section 3.4. For the analysis the software provided, Biogazelle 
qBasePLUS, created two graphs: a) M - the average expression stability value of 
each reference gene and b) V - the optimum number of reference genes required. 
The protocol was followed in accordance with the instructions provided. 
! The chosen HKGs were GAPDH and ATP5B, the sequences of which are 
listed in Table 3.5.
3.4.3 EN2 primer design 
!
! Each EN2 primer pair was verified by generating standard curves and 
calculating the amplification efficiency (E) as detailed in Section 3.4.1. For EN2 the 
results verified that E was more than 105%, which meant that there was co-
amplification. The qPCR products were also run on a 2% agarose gel that further 
confirmed the amplification of unspecific products. Therefore, new EN2 primers 
were designed, created and validated by Primer Design Ltd., UK to anneal as shown 
in Figure 3.4; the sequences are listed in Table 3.5.
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Figure 3.4. Schematic representation of EN2 mRNA and EN2 specific primer pairs. Green 
blocks highlight the protein coding mRNA exon regions, of which there is only two, and the thin black 
line depicts the intronic region. The diagram shows the boundaries that Exon 1 (1), Exon 2 (2) and 
Intron-Spanning primer pairs with the black bars. The intron-spanning primer anneals to part of Exon 
1 and Exon 2 and therefore the intron sequence must be fully excised in order for the RT-qPCR 
reaction to occur.
!  EN2 genomic DNA, depicted in Figure 3.4, is made up of two exons that are 
separated by a large intron sequence. EN2‘s mRNA would be made up on the two 
exons only, as the intron sequence is excised. Usually, qPCR primers are made to 
anneal over an exon-exon junction to avoid genomic DNA contamination as they 
could only anneal if these two exons sites had come together, which could then 
produce a single product (EN2 mRNA). Furthermore, mRNA splice variants could 
exist that contain, for example, only Exon 1 or only Exon 2 sequences.
3.4.4 Peptide sequences 
! Listed in Table 3.7 are the translated sequences of the EN2 plasmids that are 
transfected into cell lines in this study, for reference. 
Exon 1 Exon 2
Intron-spanning
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Name Source Peptide sequence (N- to C- terminus)
EN2 Origene, USA MEENDPKPGEAAAAVEGQRQPESSPGGGSGGGGGSSP
GEADTGRRRALMLPAVLQAPGNHQHPHRITNFFIDNILRPE
FGRRKDAGTCCAGAGGGRGGGAGGEGGASGAEGGGGA
GGSEQLLGSGSREPRQNPPCAPGAGGPLPAAGSDSPGD
GEGGSKTLSLHGGAKKGGDPGGPLDGSLKARGLGGGDL
SVSSDSDSSQAGANLGAQPMLWPAWVYCTRYSDRPSSG
PRSRKPKKKNPNKEDKRPRTAFTAEQLQRLKAEFQTNRYL
TEQRRQSLAQELSLNESQIKIWFQNKRAKIKKATGNKNTLA
VHLMAQGLYNHSTTAKEGKSDSE
EN2 
(pGenScript)
GenScript, 
USA
Same sequence as EN2 (above). 
EN2-GFP 
(tagged)
Life 
Technologies, 
UK
IEMEENDPKPGEAAAAVEGQRQPESSPGGGSGGGGGS
SPGEADTGRRRALMLPAVLQAPGNHQHPHRITNFFIDNIL
RPEFGRRKDAGTCCAGAGGGRGGGAGGEGGASGAEG
GGGAGGSEQLLGSGSREPRQNPPCAPGAGGPLPAAGS
DSPGDGEGGSKTLSLHGGAKKGGDPGGPLDGSLKARGL
GGGDLSVSSDSDSSQAGANLGAQPMLWPAWVYCTRYS
DRPSSGPRSRKPKKKNPNKEDKRPRTAFTAEQLQRLKAE
FQTNRYLTEQRRQSLAQELSLNESQIKIWFQNKRAKIKKA
TGNKNTLAVHLMAQGLYNHSTTAKEGKSDSESXKGNSAD
IQHSGGRSSLXMASKGEELFTGVVPILVELDGDVNGHKFS
VSGEGEGDATYGKLTLKFICTTGKLPVPWPTLVTTFSYGV
QCFSRYPDHMKRHDFFKSAMPEGYVQERTISFKDDGNY
KTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNYNS
HNVYITADKQKNGIKANFKIRHNIEDGSVQLADHYQQNTPI
GDGPVLLPDNHYLSTQSALSKDPNEKRDHMVLLEFVTAA
GITHGMDELYK
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Name Source Peptide sequence (N- to C- terminus)
GFP-EN2 
(tagged)
Origene, USA MSGGEELFAGIVPVLIELDGDVHGHKFSVRGEGEGDADY
GKLEIKFICTTGKL1PVPWPTLVTTLCYGIQCFARYPEHMK
MNDFFKSAMPEGYIQERTIQFQDDGKYKTRGEVKFEGDT
LVNRIELKGKDFKEDGNILGHKLEYSFNSHNVYIRPDKAN
NGLEANFKTRHNIEGGGVQLADHYQTNVPLGDGPVLIPIN
HYLSTQTKISKDRNEARDHMVLLESFSACCHTHGMDELY
RSGLRAIAMEENDPKPGEAAAAVEGQRQPESSPGGGSG
GGGGSSPGEADTGRRRALMLPAVLQAPGNHQHPHRITN
FFIDNILRPEFGRRKDAGTCCAGAGGGRGGGAGGEGGA
SGAEGGGGAGGSEQLLGSGSREPRQNPPCAPGAGGPL
PAAGSDSPGDGEGGSKTLSLHGGAKKGGDPGGPLDGSL
KARGLGGGDLSVSSDSDSSQAGANLGAQPMLWPAWVY
CTRYSDRPSSGPRSRKPKKKNPNKEDKRPRTAFTAEQLQ
RLKAEFQTNRYLTEQRRQSLAQELSLNESQIKIWFQNKRA
KIKKATGNKNTLAVHLMAQGLYNHSTTAKEGKSDSETR
Table 3.7. Peptide sequences. The peptide sequences of the EN2 protein variants that were forcibly 
over-expressed in cell lines, in order to validate antibody detection and observe cell behaviour - 
specific experiments are described in the following sections. Green amino acids make up the GFP 
peptide sequence, the blue amino acids make a linker sequence, in red are the restriction sites and 
black the EN2 peptide sequences.
3.5 Immunocytochemistry (ICC) for the detection of EN2 protein       
in cell lines 
! This is carried out in order to demonstrate both the presence and localisation 
of total EN2 in cells. It is performed on intact cells, ensured by ‘fixing’ the cells. This 
method relies on the high specificity of the primary antibody against the known 
target protein. The secondary antibody is conjugated to a fluorophore to allow 
visualisation under fluorescence with a Nikon A1M confocal microscope and NIS 
elements acquisition software (Nikon, UK). Images were processed with ImageJ.
Subcellular localisation of the antigen can also be determined when additional 
markers are used to demarcate the subcellular compartments. When the membrane 
is not forcibly permeated the antibodies can only bind to the cell surface providing a 
method to distinguish between cell surface and intracellular expression.  
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3.5.1 Cell fixation and staining 
! Adherent cell lines were initially grown overnight in an 8-chambered 
polystyrene culture treated glass slides (BD Biosciences, UK), in order to create a 
monolayer that is more than 70% confluent. Suspension cells and PBMCs were 
dropped onto microscope slides and left to dry for an hour before removing culture 
media. The cells were ‘fixed’ with 300µl/well of freshly prepared 4% 
paraformaldehyde solution (PFA): 0.8g paraformaldehyde (Sigma, UK) was 
dissolved in 20mL PBS (×1) (Fisher Scientific, UK) on a magnetic stirrer at 60°C 
until dissolved for 10 minutes. PFA was removed and cells were washed with 500µl 
PBS (x1) three times. Cells that were to be permeabilised were incubated with 
300µl/well 0.2% Triton X-100 (Sigma-Aldrich, UK) for 10 minutes, after which the 
cells were washed three times with 500µl PBS (x1). Next, the cells were incubated 
with an appropriate blocking serum (see Table 3.9) for 20 minutes. The serum 
carries antibodies that bind to reactive sites and thus, blocks non-specific binding 
sites from the secondary antibody. The blocking solution was removed and cells 
were incubated with 100µl/well primary antibody diluted at 1:100 in freshly made 
PBS/1% BSA at room temperature for 2 hours or overnight at 4°C. A ‘no primary 
antibody’ sample was also included containing 300µL PBS/1% BSA for use as a 
negative control. All primary antibodies used in this study for ICC are listed in Table 
3.8. In order to reduce unspecific binding and allow the detection of the protein of 
interest only, each primary antibody was optimised in order to get a clear signal with 
minimal unspecific binding. This meant the antibodies were serially diluted usually 
from 1:50 to 1:400 and tested with the positive and negative cell lines HL-60 and 
WPMY-1 respectively.
Name Type Supplier Dilution
Anti-EN2 Goat polyclonal, IgG Abcam, UK 1:100
Anti-EN2 All sheep polyclonal, IgG Bioventix, UK 1:50
Table 3.8. Primary antibodies used for ICC and their optimal dilution.
!
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Name Supplier Dilution Serum block
Donkey anti-goat 
AF488
Abcam, UK 1:200 10% horse serum (Jackson 
ImmunoResearch, USA)
Donkey anti-sheep 
AF488 
Abcam, UK 1:10,000 5% horse serum
Table 3.9. Secondary antibodies used for ICC and their optimal dilution.
! After primary antibody incubation, the cells were washed three times with 
500µl PBS (x1) and incubated with secondary antibody (see Table 3.9) in the dark 
for 45 minutes. After incubation cells were washed three times, chambers removed 
carefully using the white comb supplied (BD BioSciences, UK). The slides were 
mounted using 2-3 drops of propidium iodide (PI) Vectashield® mounting medium 
that stains the nucleus (Vector Laboratories, USA) and a cover slip was carefully 
placed over the top. The slides were imaged at X40 magnification using the confocal 
microscope. !
3.5.1.1 Wheat-germ agglutinin (WGA) membrane staining for EN2 co-
localisation analysis 
 
! In order to demarcate the cell membrane the WGA stain (Alexa Fluor® 647, 
Molecular Probes®, Life Technologies, UK) was added before fixation in Section 
3.5.1. A fresh working solution (1:200) of the 1mg/ml WGA stain in warm HBSS was 
made up. Media was removed from the 8-chambered slide and replaced with the 
WGA stain solution and incubated for 10 minutes at 37℃. The protocol outlined in 
Section 3.5.1 was followed with the addition of a 1:400 dilution of TO-PRO®-3 
(Molecular Probes®, Life Technologies, UK) with the secondary antibody incubation 
for a blue nuclear stain and thus, an empty Vectashield® (hard set) Mounting 
Medium (Vector Laboratories, USA) was used instead. 
!
3.6 Western blot analysis for EN2 detection in cell lysates
! Similarly to Section 3.5.1 a western blot (WB) uses an antibody for its high 
specificity to detect a known protein of interest, however, the secondary antibody is 
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tagged to a chemiluminescent molecule instead of a fluorophore. Proteins are 
separated according to their size on a membrane. The antibody will only ‘stick’ to the 
membrane if the protein of interest is present. The chemiluminescent molecule 
attached to the secondary antibody undergoes a chemical reaction when a substrate 
is added, and bands appear that can be captured. The size of the band on a blot is 
dependent on the amount of protein available and thus, it can be semi-quantified 
relative to a house keeping protein (such as GAPDH). 
3.6.1 Whole cell lysate preparation
! Cells were washed twice with ice-cold PBS, harvested in PBS using a cell 
scraper and centrifuged at 1500rpm for 3 minutes at 4℃. The supernatant was 
discarded and the cell pellet was resuspended in ice-cold RIPA buffer (Life 
Technologies, UK) containing Halt™ Protease and Phosphatase Inhibitor Cocktail 
(100X; Sigma-Aldrich, UK) and EDTA, usually used at a 1X final concentration. Cells 
were kept on ice, vortexed and sheared using 21G needles before being centrifuged 
at 13,000rpm for 15 minutes at 4℃, after which the supernatant was collected and 
immediately stored at -80℃. The total amount of protein in the lysates were 
calculated using the Pierce™ BCA Protein Assay Kit (Life Technologies, UK) in 
accordance with the manufacturer’s instructions. To summarise, 25µl of lysate or 
albumin standard was pipetted into a 96-well plate and 200µl of the green working 
reagent was added to each well and incubated for 30 minutes at 37°C. The green 
working reagent turns purple when protein is present and this change was 
measured at 562nm on the VariskanⓇ Flash plate reader (Thermo Scientific, UK). 
The albumin standards create a standard curve from which the unknown protein 
concentrations can be interpolated. 
3.6.2 Protein separation by sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE)
! Samples were diluted in RIPA buffer to the same concentration in 13µl and 
supplemented with 5µl NuPAGE lithium dodecyl sulfate (LDS) Sample Buffer (4X; 
Life Technologies, UK) and 2µl NuPAGE Sample Reducing Agent (10X; Life 
Technologies, UK). The XCell Surelock™ Mini-Cell Electrophoresis apparatus (Life 
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Technologies, UK) was assembled with a pre-cast polyacrylamide NuPAGE® Novex 
4-12% Bis-Tris Protein Gel (Life Technologies, UK) and NuPAGE® MOPS SDS 
running buffer (Life Technologies, UK), diluted 1:20 in water. The samples were 
denatured by heating for 10 minutes at 95℃ before being loaded into the pre-cast 
polyacrylamide 4-12% Bis-Tris protein gel (Life Technologies, UK). 10µL Novex® 
Sharp prestained markers (Life Technologies, UK) and 20µL lysate samples were 
loaded onto the lanes of the gels. Gel electrophoresis was performed at 200V for 
approximately an hour using a PowerPac (Bio-Rad, UK). 
! The recombinant EN2 (rEN2), purified from E.Coli, was used as a positive 
control and runs at 45kDa. The rEN2 was produced within the Oncology department 
with the following protocol: EN2 cDNA with optimized codon usage (GenScript, 
USA) was re-cloned into the pQE31 plasmid (Qiagen, UK), placing it under a T7 
promoter and tagged the protein with histidine. This plasmid was transformed into E. 
coli host strain (M15; Qiagen, UK), the histidine tags allowed purification of rEN2 by 
affinity chromatography on Ni-NTA resin (Qiagen, UK) under denatured conditions 
(Annels et al. 2014). 
3.6.3 Protein transfer, blocking and detection 
! Following SDS-PAGE, the separated proteins were transferred onto a 
nitrocellulose membrane by electroblotting at 20 volts for 7 minutes using the iBlotⓇ 
gel transfer system (Life Technologies, UK). The membrane was then blocked with 
blocking buffer (5% milk powder in PBS, 0.1% Tween-20 (Sigma-Aldrich, UK)), 
overnight at 4℃ with gentle shaking. It was then probed with primary antibody 
(diluted in blocking buffer) for 2 hours at room temperature, with gentle shaking. All 
optimal antibody dilutions were initially determined by serial dilution (Table 3.10). 
After three 10-minute washes with PBS/ 0.1% Tween-20, the membrane was 
incubated with an appropriate secondary Horseradish peroxidase (HRP)-conjugated 
antibody (listed in Table 3.11), diluted in blocking buffer. 
Name Type Supplier Dilution Molecular 
Weight (kDa)
Anti-EN2 Goat polyclonal, IgG
Sheep 
Abcam, UK
Bioventrix, UK
1:1667
1:250
33kDa
33kDa
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Name Type Supplier Dilution Molecular 
Weight (kDa)
anti-α-tubulin Mouse monoclonal, 
IgG
Sigma-Aldrich, UK 1:4000 50kDa
Anti-pan 
cadherin
Mouse polyclonal 
IgG
Abcam, UK 1:200 135kDa
Anti-mGFP Mouse monoclonal, 
IgG
Origene, USA 1:1000 27kDa
Anti-
HaloTag®
Mouse monoclonal, 
IgG
Promega, UK 1:1000 34kDa
Anti-
NanoLuc® 
Rabbit polyclonal, 
IgG
Promega, UK 1:5000 19kDa
Anti-GAPDH 
antibody, 
clone 2D9
Mouse monoclonal 
IgG
Origene, USA 1:2000 35.9kDa
Table 3.10. Primary antibodies used for WB analysis and their optimal dilution. 
!
Name Supplier Dilution
Donkey anti-goat, HRP-
conjugated 
Jackson ImmunoResearch 
Laboratories, Inc.
1:10,000
Rabbit anti-mouse-
HRP-conjugated
Jackson ImmunoResearch 
Laboratories, Inc.
1:2,000
Donkey anti-sheep, 
HRP-conjugated
Jackson ImmunoResearch 
Laboratories, Inc.
1:10,000
Goat anti-Mouse IgG, 
HRP-conjugated
Origene, USA 1:1000
Goat anti-rabbit IgG-
HRP
Abcam, UK 1:5000
Table 3.11. Secondary antibodies used for WB analysis and their optimal dilution. 
! Lastly, three 10-minute washes in PBS/0.1% Tween-20 were carried out and 
the blot was covered in West Pico chemiluminescence substrate (Life Technologies, 
UK) for 5 minutes. The resultant protein bands were imaged using the ChemiDoc-It2 
imager (UVP, UK). The weight of the protein bands were identified by comparing 
them to the standards from the Novex® Sharp pre-stained marker. The blot was 
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carefully stored in PBS/ 0.1% Tween-20 and stored at 4°C for stripping at a later 
time (Section 3.6.5).
3.6.4 Membrane stripping for loading control detection  
! The membrane was washed three times for 10 minutes before decanting 15 
ml of Restore™ PLUS stripping buffer (Fisher Scientific, UK) onto the membrane, 
rotating slowly for 20 minutes. The membrane was then quickly rinsed before being 
washed a further three times for 5 minutes. The detection process (outlined in 
Section 3.6.3) was then repeated with a mouse monoclonal anti-GAPDH antibody, 
clone 2D9 (Origene, USA). GAPDH was used as the loading control thereafter and 
membranes were not stripped more than three times. 
3.6.5 Densitometry analysis
 
! Blot images taken by the ChemiDoc-It2 imager (UVP, UK) were further 
analysed by Image Studio™ Lite Version 4.0 software (LI-COR Biotechnology, UK). 
The individual bands were outlined, the band density quantified and then normalised 
to the band density of the loading control in order to directly compare the protein 
expression level between samples. The relative protein density in each sample was 
then plotted graphically. 
3.7 Lipid-mediated transfection of EN2 plasmid in cell lines 
! Cell lines were transfected with a DNA plasmid created using the full-length 
human EN2 cDNA (accession number: NM_001427) and pcDNA CMV6 vector 
(TrueClone® OriGene, USA). Lipofectamine LTX (Life Technologies, UK), 
Lipofectamine® 2000 (Life Technologies, UK) and ViaFect™ (Promega, UK) are 
cationic lipid transfection reagent that mediates the interaction of the positively 
charged nucleic acid with the negatively charged cell surface membrane and the 
DNA is then endocytosed. The lipid-mediated transfection is highly dependent on  
the amount of transfection reagent as this can be toxic to the cells. Therefore, each 
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cell line was first tested with each transfection reagent and optimised, the results are 
listed in Table 3.12. 
Cell line Transfection reagent Ratio of Transfection reagent (µl) :DNA (µg) 
PC3 ViaFect™ 3:1
LnCaP ViaFect™ 5:1
WPMY-1 ViaFect™ 
Lipofectamine® LTX
6:1
1.4:  0.1 
+ with 0.6µl of PLUS reagent (Life 
Technologies, UK) 
Du145 Lipofectamine® 2000 6:1
SKMEL5 ViaFect™ 5:1
Table 3.12. Optimal transfection reagent and transfection reagent: DNA ratio for each cell line. 
! Cells were seeded either in a 8-chambered slide at 1x104cells/well (if the cells 
were to be analysed by ICC) at or in a 6-well plate at 1x105 cells/well (for all other 
analysis) and incubated with working media overnight to ensure at least 70% 
confluency. For ViaFect™, 1µg of DNA was typically diluted in 100µl of Gibco™ 
Opti-MEM™ I Reduced Serum Media (Opti-MEM I, Life Technologies, UK), mixed 
and incubated for 5 minutes. After 5 minutes, ViaFect™ was added straight to the 
diluted DNA and gently mixed. Lipofectamine® 2000 reagent was first diluted in an 
equal volume of Opti-MEM I and then mixed with the diluted DNA. For 
Lipofectamine LTX the protocol is depicted in Figure 3.1. A ‘media only’ control and 
transfection reagent only control (Life Technologies, UK) were prepared, which had 
no plasmid DNA.
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Figure 3.1. Plasmid transfection protocol for WPMY-1 cells using Lipofectamine LTX reagent. 
! The lipid:DNA complexes were then incubated for up to 30 minutes before 
being pipetted directly into the cell culture media and gently mixed. The 
transfections were typically left for 48 hours. The visual appearance of the cells was 
checked under a light microscope for signs of cytotoxicity before RNA was extracted 
from the cells (Section 3.2) in order to ensure forced EN2 mRNA had been 
achieved. cDNA was synthesised from the RNA and an RT-qPCR performed as 
described in Sections 3.3 and 3.4 respectively. Furthermore, the protein 
overexpression was clarified either by ICC and WB, as described in Sections 3.5 
and 3.6 respectively. 
3.8 Lipid and siRNA-mediated EN2 knockdown in cell lines
! Short interfering RNA (siRNA) is a double stranded RNA molecule that 
operates within the RNA interference pathway (RNAi) and directs the RISC complex 
to a particular mRNA to be degraded, which then induces short-term silencing. 
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! Optimisation was necessary as the siRNA transfection efficiency is highly 
influenced by cell density and the concentration of the transfection reagent. 
Therefore, the KDalertTM GAPDH Assay kit (Life Technologies, UK) was employed in 
order to obtain optimal conditions for an EN2 knockdown of more than 80%. 
3.8.1 GAPDH siRNA knockdown for optimisation of transfection conditions
! The KDalertTM GAPDH Assay kit silences glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) in cultured cells, which is ubiquitously and constantly 
expressed in all cells, and measures GAPDH siRNA efficiency. The negative control 
siRNA (Life Technologies, UK) included is a good indicator of cellular toxicity when 
varying the assay conditions. The KDalertTM bypasses the need for RT-qPCR and 
instead uses the GAPDH’s endogenous reaction during which NAD+ is converted to 
NADH. Under these assay conditions the rate of NADH production is proportional to 
the amount of GAPDH enzyme present. 
! Cells were first trypsinised and resuspended in working media at 1.5x105cells/
well and further diluted to make 4x103, 8x103, 12x103 cells per well (80µl per well) 
and stored at 37℃ and 5% CO2 until required. The siPORTTM NeoFXTM transfection 
reagent (Invitrogen, UK), another lipid-based reagent (similar to those in Section 
3.7), was diluted in Opti-MEM I medium (Life Technologies, UK) to a total volume of 
10µl/ well at three different concentrations (0.2, 0.5 or 0.8 µl/ well). Both the GAPDH 
siRNA and negative control siRNA were resuspended to 2µM in nuclease-free water 
(Life Technologies, UK). For each siRNA 1.5µl was then mixed with 8.5µl Opti-MEM 
I (Life Technologies, UK) to give a total volume of 10µl/well, and incubated for 10 
minutes at room temperature. The diluted siPORTTM NeoFXTM reagents were mixed 
with the diluted siRNA samples in a 1:1 volume ratio and incubated for 10 minutes at 
room temperature. Therefore, a total of 20µl siPORT NeoFX:siRNA complexes were 
made per well. In addition to the negative control siRNA, which essentially has no 
specific target, there was also a media only control (no siRNA). The transfection was 
carried out by a reverse transfection method whereby the transfection reagents are 
added to the cells before the cells have adhered to the bottom of the well, as 
depicted in Figure 3.2. 
104  
Figure 3.2. Reverse siRNA transfection protocol using siPORTTM NeoFXTM reagent.
! The plate was then incubated at 37°C for 24 hours before being replaced with 
100µl fresh working media for another 24 hours. A KDalert™ master mix was then 
prepared on ice as per manufacturer's instructions. In summary, the visual 
appearance of the cells was first viewed by a light microscope to check for any signs 
of toxicity. The wells were emptied of media and replaced with lysis buffer (100µl/
well) and incubated for 20 minutes at 4℃. The lysates were then transferred to a 
new 96-well plate and additional water only control wells were made; 90µl of the 
master mix were added to these and incubated for 15 minutes at room temperature. 
The absorbance was then measured at 620nm using the Variskan® Flash plate 
reader (Thermo Scientific, UK). The GAPDH activity was calculated by subtracting 
the average absorbance at 620nm of the water only control well from the average 
absorbance at 620nm of the sample wells. These values were then used to 
calculate the percentage of GAPDH remaining by dividing the GAPDH activity in the 
GAPDH siRNA sample by the GAPDH activity in the negative control siRNA sample 
and multiplying by 100. 
?
1. Dilute siPORT NeoFX 
in Opti-MEM I and incubate
for 10 minutes
2. Dilute siRNA 
in Opti-MEM I and 
incubate for 10 minutes
3. Add diluted siPORT NeoFX to 
diluted DNA (1:1 ratio) and 
incubate for 10 minutes
Day 1: 
Day 2: Remove transfection and replace with fresh growth medium
4. Seed cells and DNA-lipid 
complex, mix using plate shaker 
and incubate at 37
Day 3: Analyse cells
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! The conditions that resulted in the maximum GAPDH knock-down whilst 
lessening transfection-associated toxicity were used thereafter (see Section 3.8.2)
3.8.2 EN2 siRNA knockdown (siPORT NeoFX) and western blot analysis 
! For PC3 cells the optimal conditions were, for a 96-well plate, 8x103 cells/ 
well (80µl/well) in normal culture media, 0.8µl/well of EN2 siRNAs (listed in Table 
3.13) and negative control siRNA at 2µM and 0.8µl/well of transfection reagent. The 
cells were resuspended in media, siRNAs and siPORT NeoFX solution were each 
diluted in Opti-MEM media to make an 1:1 volume ratio with a total overall volume of 
20µl/well. The protocol outlined in Figure 3.2 was carried out and cells were 
analysed by RT-qPCR as described in Section 3.4, 48-96 hours after transfection. 
Simultaneously, cells were lysed for western blot analysis (Section 3.6) in order to 
evaluate EN2 protein levels using the goat anti-EN2 antibody and GAPDH antibody 
as the loading control.
mRNA sequence 
accession number
EN2 siRNA Targeted Exon siRNA location (bp)
NM_001427.3 4674 2 946
4675 2 967
4676 2 1110
Table 3.13. EN2 siRNAs and their target location on EN2 mRNA. 
3.8.3 EN2 siRNA knockdown for ICC analysis using Lipofectamine 2000 in a 8-
chambered slide 
! The transfection volumes per well were increased to make a total of 50µl for 
efficient knockdown in 8-chambered slides. Therefore, 2µl siPORT NeoFX diluted in 
25µl per well and 3µl siRNA diluted in 25µl per well. ICC staining was carried out as 
described in Section 3.5.1 with the goat anti-EN2 antibody. These were visualized 
under a confocal microscope (X40 magnification). RT-qPCR was carried out on a 
duplicate 8-chambered slide as described in Section 3.4.
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! ! ! ! ! ! ! ! ! ! ! !
3.9 Protein analysis: Kyte-Doolittle Hydropathy plot
 
! The Kyte-Doolittle hydropathy plot (or hydrophobicity/ hydrophilicity plot) is 
essentially a method to display the hydrophobic and hydrophilic regions of a protein 
sequence. The software, found at http://web.expasy.org/protscale/, scans through 
sections along the protein sequence to evaluate the average hydrophobicity or 
hydrophilicity of the amino acids. Each amino acid has been assigned a score 
between -4.5 and 4.5 (Kyte & Doolittle 1982). The EN2 protein sequence (accession 
number: P19622) was run through the program and its hydropathy scores were 
graphically displayed. 
3.10 Generating EN2-GFP using pcDNA3.1/CT-GFP-TOPO vector 
! pcDNA3.1/CT-GFP-TOPO expression vector kit (TOPOⓇ vector, Life 
Technologies, UK) was used for cloning EN2. EN2 could then be expressed tagged 
with green fluorescent protein (GFP) to the C-terminus. Therefore, EN2 could be 
directly visualised under fluorescence using the confocal microscope. 
3.10.1 EN2 PCR amplification             
! Primers (Sigma Aldrich, UK) were designed to amplify the EN2 sequence 
within the synthetic EN2 plasmid (GenScript, USA) using MacVector primer design 
software. EcoRI (5’) and Xbal (3’) restriction sites were inserted into the PCR 
product. The T at the 5’ of the reverse primer is added so that the product has ‘A’ 
overhangs. The sequences designed are as follows: forward 5’-
ATCGAATTCGCCACCATGGAGGAAAACGACCCCAAG-3’ and reverse 5’-
TTCTAGACTCGCTATCGGACTTGCCCT-3’ (Sigma-Aldrich, UK), collectively 
labeled EN2 TOPO primers. The primers are designed so that Taq polymerase 
(within the PCR mix) adds a single deoxyadenosine (A) to the 3’ end of the PCR 
products which is required because the vector has overhanging thymidine residues. 
The binding of these two residues is catalysed by an activated topoisomerase 
enzyme covalently attached to the vector. 
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! The PCR reaction was made with 1µl DNA template (synthetic EN2 plasmid), 
4µl of EN2 TOPO primers, 7.5µl distilled water and 12.5µl SYBR® Green 
JumpStart™ Taq ReadyMix™(Sigma-Aldrich, UK). The PCR product was then 
purified using QIAquick PCR Purification Kit (Qiagen, UK) and the manufacturer’s 
instructions were followed. The purified product was then evaluated by agarose gel 
electrophoresis with a 1.2% pre-cast E-gel (Invitrogen, UK) and the samples were 
diluted in E-Gel® Sample Loading Buffer, (1X; Invitrogen, UK) and also run 
alongside a 1 Kb Plus DNA ladder (Invitrogen, UK) to check that the PCR product 
was the correct size for EN2 (1 Kb). The gels were visualized and imaged under UV 
light by a BioDoc-ItTM Imaging System (UVP, UK). 
3.10.2 Plasmid transformation and amplification
! The following cloning reaction was made up: 2µl fresh PCR product (from 
Section 3.10.1); 1µl salt solution; 2µl sterile water and 1µl TOPOⓇ vector. As a 
negative control, no PCR product was included. The reaction was mixed gently and 
incubated for 5 minutes at room temperature and then placed on ice. 2µl of this 
reaction was placed into a vial of 50µl One ShotⓇ TOP10 Chemically Competent 
Escherichia coli (E. coli (Life Technologies, UK)), mixed gently and incubated for 10 
minutes on ice. Cells were heat-shocked for 30 seconds at 42℃ after which they 
were immediately placed back on ice. 2µl of the transformed bacteria was then 
added to 250µl of warm Super Optimal Broth (SOC) medium (Sigma-Aldrich, UK). 
This was placed on a shaker at 200rpm at 37℃ for 1 hour. Approximately 140µl of 
this was then spread onto a pre-set and pre-warmed Luria Broth (LB, Sigma-Aldrich, 
UK) agar plate and incubated overnight at 37℃. 
! The overall cloning procedure is depicted in Figure 3.3 below, DNA was 
extracted and purified from the overnight cultures of individually picked colonies.
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Figure 3.3. Molecular cloning protocol with E. coli. The next day, after plating, approximately 8 
colonies were picked and placed into separate vials of 5ml LB broth (plus ampicillin at 1:1000 
dilution). These were then cultured overnight on a shaker at 200rpm at 37℃. To extract and purify the 
DNA the cultures were spun down at 2500rpm for 20 minutes at 4℃ before using the WizardⓇ 
Genomic DNA Purification Kit (Promega, UK), the protocol was followed according to the 
manufacturer’s instructions.  
! To make sure that the insert was the correct size for EN2 (approximately 1Kb) 
the following digest reaction was set up for 2 hours at 37℃: 1µl of EcoRI restriction 
enzyme; 1µl of XbaI restriction enzyme; 2µl Buffer H; 14µl of distilled water and 2µl 
of the PCR product. The 5µl loading buffer was added to each 20µl digests and run 
on a 1.2% agarose gel. To make sure the PCR product was cloned into the vector in 
the correct reading frame and without substitutions or deletions the product was also 
sent for sequencing along with the appropriate primers. These were sequenced by 
DNA Sequencing & Services (Scotland). A glycerol stock was made for each colony 
and stored at -80℃.
3.10.3 EN2-GFP transfection into cell lines and protein analysis 
! 0.5µg of EN2-GFP plasmid DNA, diluted in Opti-MEM I, was transfected into 
WPMY-1 or PC3 cells/ well using the protocol outlined in Section 3.7, in a 8-
chambered slide. The control vector with GFP alone and a sample with Opti-MEM I 
alone were used as positive and negative controls respectively. These complexes 
Incubated overnight at 37  
Colonies picked
and transferred
Overnight culture at 37
DNA 
purification
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were added straight to the working media to make a total of 500µl per well. After 24 
hours the culture media was removed, cells were washed and stained as detailed in 
Section 3.5.1.1. However, antibodies were not necessary and in short: WGA stain 
was added to demarcate the membrane, the cells were then fixed with 4% PFA and 
incubated with TO-PRO®-3 in order to stain the nuclei and finally coverslipped with 
empty Vectashield® (hard set) Mounting Medium and imaged by confocal 
microscopy with X40 magnification. A duplicate assay was carried out with the same 
cell lines and transfection parameters in a 24-well plate (instead of an 8-chambered 
slide). After 24 hours, cell lysates were prepared for western blot analysis as 
outlined in Section 3.6 and detection was carried with the goat anti-EN2 antibody 
and anti-mGFP antibody. 
3.11 GFP-EN2 (N-terminal tag) de novo expression and protein 
analysis in prostate cell lines
! Cell lines were transfected with a DNA plasmid created using Myc-DDK-
tagged ORF clone of Homo sapiens engrailed homeobox 2 (EN2) as transfection-
ready DNA (accession number: NM_001427) and PrecisionShuttle mammalian 
vector with N-terminal mGFP (OriGene Technologies, USA), which enabled the 
expression of N-terminal GFP-tagged EN2. The transfection was carried out in both 
WPMY-1 and PC3 using ViaFect™ (Promega, UK) lipid-mediated transfection (the 
parameters for individual cell lines are found in Table 3.10) and evaluated by ICC 
and WB, all carried out as described in Section 3.10.3 using the goat anti-EN2 
antibody and anti-mGFP antibody. 
3.12 Stable expression of GFP-EN2 in PC3 cell line for siRNA 
evaluation 
!  Unlike transient transfections that persist for a few days only, the DNA can 
persist for much longer by using antibiotic selective pressure. This pressure selects 
those that have incorporated the DNA into its genome and go on to pass it onto their 
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progeny; these cells express the vector that includes both the antibiotic resistant 
gene and GFP-EN2. Therefore, under fluorescence microscopy all cells fluoresced 
green. As a positive control a stable cell line expressing GFP only was created in the 
same way using the PrecisionShuttle mammalian vector with N-terminal mGFP 
(OriGene Technologies, USA). For this vector the antibiotic resistant gene was 
Neomycin, which confers resistance to G418 (Geneticin disulfate salt) antibiotic 
(Sigma-Aldrich, UK). In order to select the correct concentration of G418 a dose-
response experiment (kill curve) was carried out. G418 was serially diluted in cell 
culture medium (replaced every 2 days) and each dilution was tested over time by 
examining the cells under a light microscope for signs of a ‘large kill’. For PC3 the 
lowest concentration of G418 that was able to kill all cells within a week was 700µg/
ml.
! In order to generate a stable cell line the transfection was carried out as 
outlined in Section 3.11 but instead 1µg DNA was transfected into 5x105 cells in a 
6-well plate. 24 hours later the cells were checked for GFP-EN2 and GFP 
fluorescence. The cells were trypsinised and reseeded in a 10cm tissue culture petri 
dish in normal culture working media and incubated at 37°C. Once the cells had 
adhered, usually 24 hours later, the media was replaced with culture media 
containing 700µg/ml G418. The media was replaced with fresh G418-containing 
culture media every 2-3 days until a ‘large kill’ was achieved (of cells that had not 
taken up the plasmid) and from which point, spherical colonies would start to 
appear. The colonies were picked with a pipette tip and transferred to a v-shaped 
bottom well that contained 50µl of trypsin before being transferred to a flat-bottom 
96-well plate that contained 150µl of G418-containing culture media. Subsequently, 
those that grew confluent and were seen to be expressing GFP under the 
fluorescence microscope were transferred to culture wells of increasing surface 
area, still under selection pressure through incubation with G418-containing media. 
Once the expression levels had been established (after several passages) through 
RT-qPCR (Section 3.4) and western blot with the goat anti-EN2 antibody and anti-
mGFP antibody (Section 3.6), early passages of the clones were stored in liquid 
nitrogen (Section 3.1.7). !
! The GFP-EN2 stable clones were then used to test the efficiency of the EN2-
specific siRNAs by repeating the protocol outlined in Section 3.8.3 however, no 
antibody staining was necessary and the cells were simply imaged (X20 
magnification) under the fluorescence microscope as EN2 was tagged to GFP.  
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3.13 HaloTag® -EN2 expression in prostate cell lines for specific 
EN2 detection (with the anti-HaloTag® antibody)
! HaloTag® -EN2 (N-terminal tag) plasmid was purchased from Promega (UK) 
and the sequence can be found here: http://www.kazusa.or.jp/kop/vd/
pFN21AB8957/. HaloTag® -EN2 was transfected into cell lines as described in 
Section 3.7, and its expression was assessed by detecting the increased 
expression of EN2 mRNA by RT-qPCR (as described Section 3.4) and western blot 
analysis using the monoclonal antibody to HaloTag® (Promega, UK), in order to 
determine the size of the tagged protein. Western blots were carried out as 
described in Section 3.6 and according to manufacturers instructions, which meant 
that 5% BSA in PBS/ 0.1% Tween was used as the blocking buffer and antibody 
diluent instead of the 5% milk powder. In addition, non-denatured western blot 
analysis was performed where the samples were not boiled prior to being loaded 
onto the gel and thus, the proteins were kept in their native state.
3.13.1 Preparation of cell supernatants for western blot analysis 
! The flask of cells were initially washed with PBS twice, and then incubated 
with 15mls of serum-free culture media at 37°C. After 48 hours, the supernatant was 
transferred to a 10ml Universal tube and centrifuged at 1500rpm for 3 minutes to 
remove cellular debris. The supernatant, approximately 15ml starting volume, was 
transferred into a Amicon Ultra-15 tube (Merck Millipore, UK) with a 10 molecular 
weight cutoff (MWCO) and so anything larger than 10 kDa was retained. This was 
centrifuged at 4000 x g using a swinging bucket rotor at 25°C. The sample volume 
would reduce to approximately 200µl. The Halt™ Protease and Phosphatase 
Inhibitor Cocktail was immediately added at a 2X final concentration due to a higher 
presence of proteases in the supernatant and the samples were immediately stored 
at -80°C. A BCA assay and WB were performed as detailed in Section 3.6. 
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3.14 Identification of protease sites within EN2 protein
! PeptideCutter software was used to assess the EN2 protein sequence 
(accession number P19622), found at: http://web.expasy.org/peptide_cutter/. The 
software predicts potential cleavage sites cleaved by proteases or chemicals in a 
given protein sequence. The results mapped and listed the potential proteases/
chemicals and their corresponding cleavage sequence on the protein. 
 
3.15 Membrane fraction preparation and western blot analysis
! A flask of cells was initially washed in ice-cold PBS and harvested in 5ml ice-
cold PBS using a cell scraper. These were then centrifuged at 1500rpm for 5 
minutes at 4℃ and resuspended with 1ml of TE buffer (10mM Tris, 1mM EDTA, pH 
7.4). Cells were then disrupted by passing through a 25G fine needle twice and 
additionally homogenized using a hand-held Teflon-on-glass homogenizer. The 
samples were centrifuged at 1000rpm for 10 minutes and the resultant pellet 
(containing nuclei and debris) was discarded. The supernatant was subjected to 
centrifugation at 50,000rpm for 30 minutes using a Beckman Optima™ LE-80K 
Ultracentrifuge (Beckman Coulter, UK). The membrane pellet was resuspended in 
0.2-1ml of TE buffer, depending on size, and a BCA assay was performed (Section 
3.6.1).
 ! A western blot was carried out as previously described (Section 3.6). 
Additionally, to confirm that the membrane fraction was not contaminated with 
cytosolic proteins and that it was a pure membrane fraction the western blots were 
carried out in triplicates. One was probed for EN2, the other pan-cadherin 
(membrane marker) and the other with ⍺-tubulin (cytoplasmic marker), all primary 
and secondary antibodies and their dilutions can be found in Tables 3.8 and 3.9, 
respectively. Importantly, during protein transfer to the nitrocellulose membrane the 
gel that was to be probed by anti-pan-cadherin antibody (due to pan-cadherins high 
molecular weight) required an additional incubation step with transfer buffer, this 
was made up according to manufacturers instructions (Life Technologies, UK) and 
the gel was incubated for 20 minutes submerged in transfer buffer on a shaker. in 
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addition, a longer 9 minute transfer with the iBlotⓇ gel transfer system (Life 
Technologies, UK) was required. 
3.16 Fluorescent intensity line profile to evaluate co-localisation of 
GFP-EN2 and WGA membrane stain  
! Cells are stained as outlined in Section 3.13. Within the Z-stack function in 
the NIS elements acquisition software a line is drawn over the cell to be analysed, 
demarcating the diameter of the cell. In addition, a lower and upper boundary can be 
set (corresponding to the top and bottom of the cell) as well as the number of slices 
(images) to be taken as it moves through the cell (top to bottom). This was further 
assessed by plotting the fluorescence intensities, of both the GFP and WGA 
membrane stain, along the line profile. 
3.17 Analysis of extracellular epitopes by confocal microscopy
! Each sheep IgG antibody (Bioventrix, UK) listed in Table 3.14 binds to a 
different EN2 epitope across the length of the protein from the C- to the N-terminal, 
each epitope is 20 amino acids long and overlaps the next by 10 amino acids. 
These antibodies were generated in sheep using a nested peptide series 
conjugated to the metalloprotein, KLH. 
Antibody name Epitope location 
(amino acid)
Peptide sequence (N’-C’ terminal)
Ab33 330 - 310 AVHLMAQGLYNHSTTAKEGK
Ab32 320 - 300 KKATGNKNTLAVHLMAQGLY
Ab31 310 - 290 IWFQNKRAKIKKATGNKNTL
Ab30 300 - 280 ELSLNESQIKIWFQNKRAKI
Ab29 290 - 270 EQRRQSLAQELSLNESQIKI
Ab26 260 - 240 NKEDKRPRTAFTAEQLQRLK
Ab25 250 - 230 RSRKPKKKNPNKEDKRPRTA
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Antibody name Epitope location 
(amino acid)
Peptide sequence (N’-C’ terminal)
Ab24 240 - 220 RYSDRPSSGPRSRKPKKKNP
Ab23 230 - 210 MLWPAWVYCTRYSDRPSSGP
Ab21 210 - 190 DSDSSQAGANLGAQPMLWPA
Ab17 170 - 150 PGDGEGGSKTLSLHGGAKKG
Ab16 160 - 140 GPLPAAGSDSPGDGEGGSKT
Ab12 120 - 100 GGEGGASGAEGGGGAGGSEQ
Ab10 100 - 80 RRKDAGTCCAGAGGGRGGGA
Ab8 80 - 60 QHPHRITNFFIDNILRPEFG
Ab6 60 - 40 DTGRRRALMLPAVLQAPGNH
Ab4 40 - 20 PESSPGGGSGGGGGSSPGEA
Ab2 20 - 0 MEENDPKPGEAAAAVEGQRQ
!
Table 3.14. Sheep polyclonal IgG antibodies that bind to different epitopes along the EN2 
protein.
! HL-60 cells and NIH/3T3 were used as the positive and negative controls, 
respectively. For each sheep antibody the staining described in Section 3.5 was 
performed. An additional ‘no primary antibody’ control was carried out to highlight 
any unspecific binding from the secondary antibody.
!
3.18 Validation of sheep anti-EN2 antibodies by western blotting
! The western blots were carried out as described in Section 3.6 to test a few 
of the anti-EN2 sheep antibodies: Ab2, Ab4, Ab8, Ab16, Ab24 and Ab32. These were 
compared to the Goat anti-EN2 antibody and APS2 anti-EN2 antibody, which has 
been used to detect EN2 in an ELISA assay (R. Morgan et al. 2011). The samples 
tested were the EN2 positive control whole cell lysate from: SKMEL-5, PC3 
transiently overexpressing (untagged) EN2 and PC3. In addition, a EN2 fragment 
was used, which is a synthetically produced peptide consisting of 100 amino acids 
of EN2’s C-terminus (Biosynthesis Inc., USA) and used as the control in the EN2 
ELISA (R. Morgan et al. 2011). WPMY-1 whole cell lysate was used as the negative 
control.  
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3.20 Time-lapse confocal microscopy 
! The cells were seeded in a 4-chamber (35mm) glass-bottom dish (MatTek, 
USA) and 24 hours later the cells were transfected with usually 0.5µg of GFP-EN2 
and GFP (control) as described in Section 3.7. 24 hours after transfection the cells 
were observed under light microscopy and fluorescence to make sure cells were still 
viable and the transfection efficiency was substantial. In addition, stains were added 
to demarcate the subcellular compartments of the cell such as: NucBlue® Live 
ReadyProbes® Reagent fluorescence dye (ThermoFisher, UK) and the WGA 
membrane stain - these could both be used without fixing the cells. The media was 
also changed to Gibco® FluoroBrite™ DMEM (Life Technologies, UK) to enhance 
the fluorescent signal. The correct size adaptor was fitted in the confocal 
microscope in order to accommodate the 35mm dish. The confocal integrated 
incubator was then set to 37°C and 5% of CO2. The corresponding lasers were 
selected: 488nm, 595nm and 642 nm to excite GFP-EN2 or GFP (green), WGA 
(red) and TO-PRO®-3 stain (blue), respectively. The cells in the dish were focused 
from X10 magnification up to X40 magnification. The conditions were set 
automatically in accordance with the fluorescence dye in the scanning unit and the 
individual bandwidths optimised to detect fluorescence for each channel. The most 
suitable imaging conditions based on the fluorescent dye selection using the 
acquisition software. Time-lapse mode was selected and the areas to be imaged 
were chosen by focusing on the cells, labeling and setting the X and Y parameters. 
Images were set to be taken every 5 minutes over 24 hours. 
!
3.21 Tracking EN2 in real-time using NanoGlo assay
!
! NanoLuc® (Nluc) is a smaller tag, only 19kDa, highly stable, ATP 
independent, bioluminescent protein and thus, a highly sensitive screening system 
when used with the Nano-Glo® Luciferase Assay. The Nano-Glo® Luciferase Assay 
generates a glow-type signal in the presence of NanoLuc® luciferase by simply 
mixing substrate and buffer together. The reagent contains a lysis buffer, which 
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allowed the measurement of NanoLuc®EN2 directly in cells or the culture media 
when NanoLuc®EN2 was secreted.
3.21.1 Cloning EN2 into NanoLuc vector to create NanoLuc-EN2
! The HaloTag®-EN2 FlexiVector (Section 3.14; pFN21A HaloTag® CMV-amp) 
and the native NLuc® FlexiVector® (pFN31K Nluc CMV-neo) from Promega (UK) 
both contain rare restrictions sites SgfI-PmeI as part of the FlexiVector system. This 
system provides an easy method for directional cloning of protein coding regions 
between N-terminus tagged (such as the HaloTag®-EN2 FlexiVector®) and native 
FlexiVectors (such as the NLuc® FlexiVector®), as depicted in Figure 3.5. The native 
vectors also contain a lethal barnase coding region that means there is a positive 
selection for those that have inserted the protein-coding sequence as expression of 
barnase is lethal to bacteria such as E.coli and thus, the cloning system is highly 
efficient. The donor vector HaloTag®-EN2 contains the resistant gene to ampicillin 
antibiotic and was amplified using the Wizard® Plus SV Minipreps DNA Purification 
System (Promega, UK) and eluted at approximately 100ng/µl. The acceptor vector 
was native NLuc® (Promega, UK; 100ng/µl) contains the resistant gene to 
kanamycin antibiotic. 
Figure 3.5. Transferring protein coding regions in the Flexi® Vector Systems. Protein-coding 
regions can be shuttled between vectors using two rare-cutting restriction endonucleases, Sgf I and 
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Pme I. The Flexi® Vectors contain a lethal gene, barnase, for positive selection of the protein-coding 
sequence and an antibiotic resistance marker for selection of colonies containing the Flexi® Vector. 
Taken from the Flexi® Vectors Systems technical manual at www.promega.co.uk. 
! The protocol was followed according to the manufacturers instructions. To 
summarise: both the donor and acceptor vectors were digested and ligated in the 
same reaction, the vectors that retained the lethal barnase gene were eliminated 
once the reactions were transformed into E.coli. The E.coli transfected with the 
donor vectors were positively selected by plating the reactions onto kanamycin 
plates. A ‘background’ control was included where the acceptor vector only was 
digested, ligated and plated onto a kanamycin plate, the vector does not have the 
kanamycin resistant gene and so there should have been no growth. The ligation 
reaction was then transformed into One ShotⓇ TOP10 Chemically Competent E. coli 
(Life Technologies, UK) and plated onto LB plates supplemented with 25µg/ml 
kanamycin antibiotic (Sigma-Aldrich, UK). At least 4 colonies were screened by 
digesting with SgfI and PmeI and ran on a 1.2% pre-cast E-gel (Invitrogen, UK) to 
make sure the insert was at 1 Kb (EN2). Furthermore, sequencing primers, 
recommended by Promega (UK), were designed to anneal to the the promoter (Flexi 
R2) and NLuc tag to ensure the insert was fully sequenced and that it had the 
correct tag. These were sent to Cambridge Sanger Sequencing (UK) for DNA 
sequencing. 
!
3.21.2 Nano-Glo® Luciferase Assay for tracking NLuc®-EN2 
!
! First, the NLuc®-EN2 construct was transfected into LnCaP cells and a WB 
was carried out in order to evaluate the size of the protein. The anti-NLuc® antibody 
was a kind gift from Promega (USA). The protocol outlined in Section 3.6 was 
loosely followed, except the membrane was blocked overnight with TBST + 5% 
BSA. After 3 washes, the membrane was incubated with Rabbit anti-Nluc IgG 
(1:5,000) overnight (in TBST + 5% BSA). After 3 washes (TBST) the blot was 
incubated with anti-rabbit IgG-HRP (1:2,500) for 60 min (TBST + 5% BSA), washed 
3 times with TBST, and developed for 5 minutes with West Pico chemiluminescence 
substrate (Life Technologies, UK). Images were taken using ChemiDoc-It2 (UVP, 
UK). The size of the proteins were determined by comparing to the prestained 
markers.
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! The LnCaP cell line was then transfected with serially diluted NLuc®-EN2 
DNA plasmid and the Nano-Glo® Luciferase Assay was performed on the cell 
culture media, 24 hours later, according to the manufacturers instructions. In 
summary: first, the Nano-Glo® Luciferase Assay Reagent was prepared by 
combining one volume of Nano-Glo® Luciferase Assay Substrate with 50 volumes 
of Nano-Glo® Luciferase Assay Buffer; cells were removed from the tissue culture 
incubator and gently shaken (100rpm for 2 minutes) to remove concentration 
gradients that may have existed in the culture medium; 10µl aliquots for each 
sample were dispensed in triplicate to a white 96-well plate and these were made up 
to a final volume of 100µl with distilled water; 100µl Nano-Glo® Luciferase Assay 
Reagent was added to each well (equal to the volume of the sample) and mixed for 
optimal consistency and after 3 minutes the luminescence was read by the 
VariskanⓇ Flash plate reader.
!
3.22 Antibody internalisation assay 
The pHAb amine reactive dye (Promega, UK) are pH sensor dyes that have very 
low fluorescence at pH more than 7 and undergo a dramatic increase in 
fluorescence as the pH of the solution becomes acidic (less than 7).
! First, the antibodies to be tested for internalisation were conjugated to the 
pHAb amine reactive dye. All solutions were made and protocols carried out 
according to the manufacturer’s instructions via the on-bead conjugation method. 
Once completed the Dye-to-Antibody (DAR) ratio was calculated using the following 
formulae: 
• Antibody Concentration (mg/ml) = A280 - (A532 x 0.256)/1.4 
• DAR = (A532 x 150,000)/ (Ab Concentration (mg/ml) x 75,000)
Where the molecular weight of antibody is 150,000, the extinction coefficient of 
pHAb Reactive Dye is 75,000 and the correction factor for pHAb Reactive Dye is 
0.256.  
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! To show that the antibody was still intact, a small volume was denatured for 
10 minutes at 95 ℃ with (LDS) Sample Buffer (4X; Life Technologies, UK) and 2µl 
NuPAGE Sample Reducing Agent (10X; Life Technologies, UK). The denatured 
antibody was then loaded onto a NuPAGE® Novex 4-12% Bis-Tris gel and run for 50 
minutes at 120V. After which, SimplyBlue™ SafeStain (Invitrogen), to visualise 
protein bands, was then poured over the gel on a rotator and left to incubate for an 
hour or more. An image was then taken when the heavy and light chains of the 
antibody became visible. Once this was established, cells were seeded at 1x104 
cells/well (100µl) in normal culture media in a flat, clear bottom black 96-well black 
plate (Figure 3.6). 
 
Figure 3.6. The plate layout of the antibody internalisation assay. A black plate was required for 
fluorescence reading of pHdye-Ab that fluoresces when the pH lowers such as an endosome after 
the antibody is internalised. The clear bottom of the wells allowed the cells to be imaged by a 
confocal microscope and the viability of the cells to be assessed by a light microscope.
! Once the cells had adhered, the antibody was initially vortexed and spun 
down to get rid of antibody aggregates and 15nM of it was added per well and 
directly to the culture media. Cells were incubated, 37℃, 5% CO2, inbetween 
reading the fluorescence at excitation wavelength: 532nm and emission wavelength: 
560nm using the VariskanⓇ Flash plate reader (Thermo Scientific, UK).
1 2 3
A
B
4 5 6 7 8 9 10
1
1
1
2
C
D
E
F
G
H
Cell lines
pH4/10 
buffer
pHdye-Ab (duplicates) including IgG isotope control + cell only control 
Flat, clear bottom black plate
120  
!
3.23 Exosome isolation and analysis 
! All cell culture media used in the following experiments had no FBS - FBS 
contain exosomes that would contaminate the experiment - and were incubated with 
cells in T-75 flasks for 48 hours prior to use. 
!
3.23.1 Ultracentrifugation
!
! The protocol was adapted from the methodoogy outlined by Thery et al. 
(Théry et al. 2006) and depicted in Figure 3.7 below.
Figure 3.7. Flow chart for the exosome purification procedure. Taken from (Théry et al. 2006). 
! The 10,000 x g for 30 minutes step was not carried out and instead the 
samples were concentrated using Amicon Ultra-15 tube (Merck Millipore, UK) with a 
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100 MWCO and filtered through a 0.2 μm filter to remove particles larger than 200 
nm. The samples were imaged by electron microscopy (Section 3.23.4). 
3.23.2 Norgen exosome isolation
!
! The Norgen’s Exosome RNA Isolation Kit (Norgen, Canada) is based on spin 
column chromatography that employs Norgen’s proprietary resin. The protocol was 
followed according to the manufacturer’s instructions however, the kit does not leave 
the exosomes intact in order to obtain the RNA so it was at this point the protocol 
was stopped and so the exosomes remained intact.
3.23.3 Size exclusion chromatography (SEC)
!
! qEV size exclusion columns (Izon, UK) contain a resin with an approximately 
75 nm pore size. Proteins and other contaminating molecules smaller than EVs 
enter the pores of the resin and are delayed in their passage through the column, 
eluting in later fractions. The protocol was followed according to the manufacturer’s 
instructions. The cell culture media samples were overlaid on qEV size exclusion 
columns followed by elution with PBS. 500µl fractions were collected, and particle 
and protein concentrations determined by Nanoparticle Tracking Analysis (Section 
3.23.5).
3.23.4 Electron Microscopy (EM)
! This was carried out by David Jones within the MicroStructural Studies Unit at 
The University of Surrey using a scanning electron microscope (SEM). 
The samples were prepared as outlined in (Théry et al. 2006). In summary, the 
isolated pellets (either from Sections 3.23.1, 3.23.2 or 3.23.3) were resuspended in 
50µl of 2% PFA, a drop (approximately 5µl) of each sample was placed onto clean 
Parafilm (Sigma-Aldrich, UK) and the Formvar-carbon coated EM grids (Agar 
Scientific Ltd, UK) were carefully placed on a drop using a sterile Dumont no. 5 
forcep (Agar Scientific Ltd, UK), with the coated side facing the suspension, and left 
to dry for 20 minutes. The grids were then transferred to float on top of 100µl PBS 
drops to wash and then to a 50µl drop of 1% glutaraldehyde (Sigma-Aldrich, UK) for 
5 minutes, which ‘fixed’ the samples. 
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!
3.23.5 Nanoparticle Tracking Analysis (NTA)
! This was carried out by Dr Rebecca Townsend within the Department of 
Mechanical Engineering Sciences at The University of Surrey using a NanoSight 
machine (NanoSight LM10; Malvern, UK). The instrument is able to analyse the size 
distribution and concentration of all types of nanoparticles from 10nm to 2000nm in 
diameter. Samples were sonicated for 5 minutes in order to break up aggregated 
particles just before they were injected into the machine. 
3.24 Apoptosis evaluation after forced EN2 expression 
3.24.1 Caspase-3/7 detection 
! CellEvent® Caspase-3/7 Green ReadyProbes® Reagent (Life Technologies, 
UK) is a fluorogenic, no-wash indicator of activated caspase-3/7 for live- and fixed-
cell applications. Activation of caspase-3 is an early indicator of apoptosis. 
! Time-lapse confocal microscopy was set up as outlined in Section 3.20, cells 
were seeded in the 35mm Glass-bottom dish, transfected with EN2 plasmid from 
Section 3.7. Two drops of the ReadyProbes® Reagent was added per ml of 
FluoroBriteTM DMEM media and this was incubated for up to 1 hour at 37℃ before 
imaging the cells. 
3.24.2 Cell titre 96® aqueous non-radioactive cell proliferation (MTS) assay
! CellTiter 96® AQueous One Solution Cell Proliferation Assay (Promega UK) is 
a colorimetric method for determining the number of viable cells in proliferation. The 
assay contains an MTS (3-(4,5- dimethylthiazol-2-yl)-5-(3 carboxymethoxyphenyl)-2-
(4-sulfophenyl)-2H-tetrazolium) compound and an electron coupling reagent 
phenazine ethosulfate (PES). PES combines with MTS to form a stable solution, 
MTS is bio-reduced by cellular oxidoreductase enzymes into a coloured formazan 
product, which can be measured by absorbance at 490nm and is directly 
proportional to the number of living cells in culture.
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! The cells were seeded in a 96-well plate and transfected with EN2 plasmid 
from Section 3.7 and using the same protocol. A duplicate plate was made in order 
to assess EN2 overexpression by RT-qPCR (Section 3.4). Each sample was carried 
out in triplicates, unless otherwise stated. The MTS reagent was made up in 
RPMI-1640 media with only 2% FBS (as it contains less phenol red that could 
interfere with the colorimetric assay) and hence there was a media only control with 
cells and a media only control without cells, the latter would be the ‘background’ 
control to be taken away from all readings. 
3.25 Investigating the cell autonomous (transcriptional) effects of 
EN2  
! The relative expression of Inhibin Beta A (INHBA), Collagen Type VIII Alpha 1 
(COL8A1) and Transmembrane protein 204 (TMEM204), in prostate cell lines both 
transiently and stably expressing EN2 was determined. These were just a few genes 
aberrantly expressed as part of a microarray carried out in the Oncology 
department. The microarray was carried out in order to investigate gene expression 
after the overexpression of EN2 in ovarian cancer cell lines (McGrath 2015). The 
microarray results suggested a role for EN2 in cell invasion and metastasis, 
particularly in the process of epithelial-mesenchymal transition (EMT). Furthermore, 
EN2 has been implicated in this study in cell fusion and cell-in-cell action and all 
three genes (INHBA, COL8A1 and TMEM204) have a role in cell adhesion. The RT-
qPCR was carried out as detailed in Section 3.4. 
3.26 Co-culture  
3.26.1 WPMY-1 incubation with conditioned media incubation over time 
! To generate the conditioned media the cells were grown in T-25 flasks with 
10ml cell culture working media without FBS for 48 hours. The media was collected 
and initially spun down to get rid of any cellullar debris. The media was then 
transferred to an Amicon Ultra-15 tube (Merck Millipore, UK) with a 10 molecular 
weight cutoff (MWCO) and so anything larger than 10 kDa was retained. WPMY-1 
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were seeded in a 96-well plate and subsequently incubated with 100µl  of 
conditioned media. After 24, 48 and 72 hours incubation the viability was measure 
using the MTS assay, as outlined in Section 3.24.2. Two technical repeats were 
performed for each conditioned media.                                          
3.26.2 Direct co-culture using stable cell lines 
! All stable cell lines were produced as outlined in Section 3.13.
The following stable clones were created for WPMY-1: HaloTag (native) and , 
LifeAct® (Ibidi, Germany), which highlighted the cytoskeleton red as visualizes F-
actin within fixed and living cells and does so without compromising cellular 
processes. For PC3, stable LifeAct® clones were created. All cells were seeded in 
6-well plates at half the normal density (1x105 cells/well) in normal DMEM culture 
media. The TMR ligand (Promega, UK) was required to enable the imaging of the 
HaloTag protein under fluorescence and this was carried out according to 
manufacturer’s instructions. The images were taken using a fluorescence 
microscope at X20 magnification. NucBlue® Live ReadyProbes® Reagent was 
added to demarcate the nucleus. The media was subsequently changed to fresh 
media every two days. 
3.26.3 Transwell and Nano-Glo® Luciferase Assay
! Essentially this experiment mimicked the direct co-culture assay in Section 
3.26.2, as the two cell lines shared the same medium however, the donor (Nluc-EN2 
expressing) cells and the acceptor cells were separated by a membrane. The 
ThinCert™ Cell Culture Inserts (Greiner Bio-one, Germany) were employed and 
these had a 0.4µm pore-sized polycarbonate membrane to ensure that proteins 
could freely pass through the membrane but the cells could not. The donor cells 
were initially transfected with Nluc-EN2 and seeded in 6 well plates before being  
reseeded in the hanging insert (within a 24-well plate). An outline of the protocol is 
shown in Figure 3.8. 
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Figure 3.8. Evaluating intercellular transfer of EN2 in prostate cell lines by Transwell® 
(ThinCert™) assay. The setup separated the donor and the acceptor cells and so for EN2 to transfer 
between cells it would have had to do it without direct cell-cell contact. The transfer of Nluc®-EN2 was 
measured using the Nano-Glo® Luciferase Assay at different points in the experiments, outlined on 
the image. In order to know the amount of Nluc®-EN2 that was available in the media, a control was 
carried out in which there were no cells seeded at the bottom of the 24-well plate and would act as a 
reference. To normalise the difference in the rate of secretion and internalisation of proteins a positive 
control was employed, secNluc (Promega, UK) that was constitutively secreted and transfected into 
cell lines at the beginning of the experiment.
3.28 HXR9 treatment 
! The treatment was carried out as described by Morgan et al. where HXR9 
and CXR9 (control peptide) were incubated with PC3 and WPMY-1 cells (in vitro) for 
2 hours only (R. Morgan et al. 2014). In addition, stably expressing PC3 GFP-EN2 
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ThinCerts (0.4um)
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No cells control
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and GFP cell lines were used in this study. The MTS was carried out as described in 
Section 3.24.2. A dose-response curve was plotted, which indicated the percentage 
cell survival relative to increasing concentrations of HXR9 (and CXR9). 
3.29 Data analysis 
! All values are carried out as duplicates for two technical repeats and two 
biological repeats to calculate the mean value and ± standard error (SEM) where 
possible. The GraphPad Prism software was used to draw the graphs and to apply a 
p value, usually by a Student's' t Test, where possible as follows p<0.05=* 
p<0.01=**; p<0.001=***. Many of the biological repeats were analysed at the protein 
level in a qualitative form such as ICC and western blot, no quantifications were 
made and therefore no statistical model could be applied.
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Chapter 4: 
Investigating the expression 
of EN2 in prostate cancer
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4. Investigating the expression of EN2 
in prostate cancer 
4.1 Introduction
! This chapter presents the current understanding of EN2’s expression and 
localisation in development and cancer and, more importantly, the areas requiring 
further exploration. Following this, the objectives and hypothesis are stated. The 
experimental results are analysed and discussed. These emphasise that EN2’s 
expression and localisation in cancer cells are still not well-defined and this is partly 
due to the ambiguous nature of the antibody used against EN2. It is concluded that 
EN2’s potential as a therapeutic target remains undecided and a deeper 
understanding of its localisation and function is required before proceeding to 
develop an antibody-drug conjugate against EN2. 
4.2 Background
	 EN2 in cancer falls under the unique umbrella of expression-restricted 
developmental proteins; reported to be both cell autonomous and non-cell-
autonomous owing to its ability to be secreted and internalized (Joliot et al. 1998). 
EN2 expression is largely switched off after embryonic development though low 
levels remain in the adult nervous system, specifically in Purkinje neurons, for a 
purpose yet to be fully elucidated (for more details see Section 2.3.2). One 
hypothesis is that it inhibits the formation of neuronal dendrites through its ability to 
affect vesicle transport and cell morphology (Holst et al. 2008). Another report 
suggests a role in the continued survival of mesencephalic dopaminergic (mDA) 
neurons (Albéri et al. 2004). Elevated expression levels of EN2 at mRNA and 
protein levels have been reported in various cancers, which are listed in Table 5 
(Section 2.3.3). 
! Potentially, there is huge scope for EN2 to be used as a cancer biomarker with 
the right detection assay. However, fundamental quantitation and definition has been 
difficult to obtain and interpret, largely due to the lack of understanding about its 
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function (for more detail see Section 2.3.2.1). Early cancer reports suggest that it is 
an oncogene and works to increase proliferation and aggressiveness of the disease 
(Martin et al. 2005; Bose et al. 2008). However, recent reports instead suggest that 
EN2 plays an anti-oncogenic role as more EN2 is detected in the surrounding 
tumour microenvironment than the tumour itself (Lai et al. 2014). Currently little 
evidence exists to show that EN2 expression correlates with increasing tumour 
grade but actually suggests the opposite: EN2 exogenous detection in biofluid 
surrounding the tumours increases with tumour volume and grade (Pandha et al. 
2012; Guibinga et al. 2012). The extracellular detection is similar to PSA (see 
Section 2.3.2), detected instead in urine, and also provides rationale for further 
investigating EN2 as a diagnostic marker either alone or to supplement PSA. 
! Traditionally, polyclonal antibodies have been used as a generic means to detect 
and semi-quantify proteins , though in some cases these antibodies lack the 
necessary specificity (Lipman et al. 2005), further expandd upon in Section 2.2.4. 
Some of the EN2 commercial antibodies have been investigated and as a 
consequence an unspecific protein product, detected by a few but not identified, was 
dubbed ‘non-EN2’ (Lai et al. 2014), or a potential artifact that coincidentally matches 
the size of the IgG heavy chain. The goat anti-EN2 antibody used in this 
investigation was deemed to be specific to EN2. It is important to note, however, that 
it detects EN2 at 50kDa (results unpublished) instead of 40kDa, as previously 
reported in the literature (Martin et al. 2005). This study, foremost, sought to answer 
why there is apparent protein detection when there are no mRNA transcripts and to 
validate the goat anti-EN2 antibody. 
! If it is assumed that EN2 is the 50kDa protein band, instead of 40kDa, then EN2 
must have tight regulation of expression, translationally or post-translationally, which 
differs from that in embryonic development. An inverse correlation between levels of 
EN2 promoter methylation (gene silencing) and levels of protein expression has 
been reported (James et al. 2013). This finding is unusual as gene silencing typically 
results in lower protein expression.and further confirms EN2’s complex regulation. 
This inverse correlation is one of only a few published data available for EN2 
promoter methylation status, the majority of which are in the context of neurological 
and developmental disorders. In addition, the research in this area has largely 
focused on EN1, where a similar pattern was found. The study revealed, in human 
salivary gland adenoid cystic carcinoma, EN1 high promoter methylation status with 
high protein detection (D. Bell et al. 2011). They hypothesised that this may be due 
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to a cyclical feedback mechanism. When a certain level of protein is obtained the 
promoter becomes hypermethylated; mRNA is no longer transcribed until the protein 
levels subsequently dip down to a certain threshold triggering promoter 
hypomethylation and mRNA transcripts are produced again. It is possible that EN2 
is regulated under a similar feedback mechanism to EN1. 
! If EN2 is 50kDa then a possible explanation for the larger than predicted size is 
post-translational modification (PTM). PTM adds groups to proteins such as a 
phosphate group or a glycosyl group in order to control its localisation (Duan & 
Walther 2015). Investigations into post-translational modifications such as 
deglycosylation (that removes the glycosyl group) showed some shift in size but the 
results were not conclusive (McGrath 2015). It is possible that EN2 is regulated by 
microRNA’s - another area of investigation left unexplored despite an EN2 targeting 
microRNA having been reported - miR181a (Guibinga et al. 2012). Another 
possibility is that EN2 has mRNA splice variants, though this is unlikely as EN2 has 
just two exons, but is yet to be investigated. Whilst most of these investigations are 
beyond the scope of this study, they will be addressed in the discussion as part of 
the results may support these.
! Taking into consideration EN2’s ability to be secreted and internalised, it is then 
pertinent to ask: could protein isoforms exist? Is EN2 secreted in vesicles? Does 
EN2 undergo post-translational modification such as proteolytic cleavage and how 
much of what is detected at protein level is the result of internalisation or intercellular 
transfer? 
! De novo expression of fluorescently tagged EN2 allows EN2 to be tracked 
without using antibodies in order to further clarify its expression; subcellular 
localization; trafficking and regulation. These were mainly carried out through 
western blot and imaging experiments.
4.3 Chapter objective, hypothesis and approach 
! The following objective was made (taken from Section 1.5):
1. to determine EN2‘s expression and localisation within cancer cells.
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! In order to investigate this the following experiments were performed:
‣ Engrailed-2 mRNA expression by RT-qPCR was carried out in order to 
confirm the presence of higher EN2 mRNA levels in cancer cell lines 
compared to normal cells
‣ Immunocytochemistry and western blot analysis of cell surface EN2 
expression on cell lines was performed in order to confirm the RT-
qPCR results and show higher levels of EN2 protein in cancer cell 
lines compared to normal cells 
‣ Goat anti-EN2 antibody validation was necessary to confirm the 
specificity of the antibody to EN2
‣ Further investigation into the goat-anti-EN2 antibody specificity: Kyte-
Doolittle Hydropathy plot 
‣ Further investigation into the goat-anti-EN2 antibody and the 
subcellular localisation of EN2 using GFP tagged EN2 de novo 
expression in prostate cell lines 
‣ House keeping gene optimisation as EN2 forced expression showed 
the creation of EN2-containing vesicles and so EN2 likely influences 
the cell’s cytoskeletal network of proteins including the house keeping 
gene beta-actin 
‣ Engrailed-2 primer design of exon-specific primers that are validated 
prior to RT-qPCR experiments and to explore the possibility of EN2 
splice variants 
‣ GFP-EN2 stable expression for EN2 siRNA validation in order to 
ensure that the EN2 siRNA succesfully knock down EN2 at the protein 
level and confirm the detection of a unknown antigen at 50kDa
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‣ HaloTag® -EN2 expression in prostate cell lines for highly specific EN2 
detection with the anti-HaloTag®  antibody 
‣ Identification of protease sites within EN2 protein to provide further 
rationale to the detection of cleaved fragments of EN2 
‣ Goat anti-EN2 antibody re-evaluation as the 50kDa protein is not likely  
to be EN2  
4.4 Results
! It was imperative to reconfirm the findings that had been reported about EN2 
in the literature in order to ensure that EN2 detection and expression patterns could 
be repeated in vitro, with prostate cancer cell lines. This began with qRT-PCR for 
EN2 mRNA detection and immunocytochemistry and western blot assays for EN2 
protein detection. These included the necessary controls for quality assurance such 
as primer design, primer efficiency and further validation at protein levels with 
knockdown and overexpression experiments to determine antibody specificity. 
4.4.1 Engrailed-2 mRNA expression by real-time quantitative PCR 
! EN2 mRNA expression was calculated from the extraction of total RNA and 
the synthesis of cDNA in order to quantify the amount of EN2 upregulated between 
cancer and normal (immortalised) cell lines (WPMY-1) and normal primary cells 
(fibroblasts) in Figure 4.1.
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Figure 4.1. EN2 mRNA detection in various cell lines. Human cancer cell lines are: HL-60 
(leukemia), SKMEL5 (melanoma), PC3 (prostate), Du145 (prostate), LnCaP (prostate), T47D 
(breast). Normal immortalised cell line WPMY-1 (prostate stroma) and primary fibroblast cells, both of 
which are human, were used as negative controls. mRNA detection is depicted here as relative to the 
house keeping gene beta-actin (x100000).
! Comparing the cell lines in Figure 4.1, SKMEL-5 had considerably larger 
amounts of EN2 mRNA and WPMY-1 had no detectable EN2 mRNA. The fibroblasts 
had low amounts though some EN2 mRNA were still detectable compared to 
WPMY-1, which may have been a technical error as the primer pair was found to 
create primer-dimers and therefore this data is unreliable.
4.4.2 Immunocytochemistry and western blot analysis of cell surface EN2          
expression on cell lines
! The goat anti-EN2 antibody (Abcam) was used to develop the EN2 ELISA 
test (R. Morgan et al. 2011). In order to verify the EN2 RT-qPCR data in Section 
4.4.1, EN2 protein expression in a number of cell lines was assessed by 
immunocytochemistry (ICC) using the goat anti-EN2 antibody. Subsequently, a 
western blot assay was performed to observe the size of the protein detected and 
verify the detection of EN2 (Figure 4.2). 
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Figure 4.2. EN2 detection in cancer cell lines and normal WPMY-1 cell line with goat anti-EN2 
antibody. a) ICC cell surface staining (X40 magnification) of various cancer cell lines (labeled) and 
their ‘normal’ equivalent WPMY-1; derived from the same tissue or the periphery. b) Western blot 
analysis of EN2 in whole cell lysates, recombinant EN2 (rEN2) was the positive control and WPMY-1, 
PBMCs and fibroblasts (Fibros) were used as negative controls. ⍺-tubulin house keeping protein was 
chosen as the loading control. 
! In Figure 4.2, the negative controls (no primary antibody) gave no 
background or unspecific green staining produced by the secondary antibody. The 
secondary antibody is raised against the species of the primary antibody but it can 
sometimes detect different species or proteins (known as cross-reactivity) and 
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requires further dilution in order to prevent false-positive results. The top panel (a) 
showed the primary antibody detection of EN2 (c-terminus) on the cell surface of 
SKMEL5 and PC3 cancer cell lines. The normal (immortalised) cell line WPMY-1 
revealed, subjectively, a lower amount of green staining compared to the cancer cell 
lines but nevertheless it was positive (Figure 4.2a). These observations were 
reproduced in the western blot analysis below (Figure 4.2b) - WPMY-1 was positive 
for the 50kDa band. A strong 50kDa band was detected in PC3 and LnCaP cell 
lysates only because a higher amount of protein was loaded onto the gel, revealed 
by the alpha-tubulin loading control. Healthy PBMCs were also positive for a band at 
50kDa and much less was detected in fibroblasts. 
!
4.4.3 Goat anti-EN2 antibody validation by EN2 plasmid expression and 
mRNA knockdown
! These results (Section 4.4.2) indicate that the western blot data is spurious 
and the antibody may only be useful for immunocytochemistry, but required 
validation nonetheless. Consequently, the goat anti-EN2 antibody specificity was 
further tested. To carry this out EN2 was transiently overexpressed in WPMY-1 cell 
line (no EN2 mRNA detected). 0.1µg and 0.05µg of EN2 plasmid (Origene) was 
used for transfection before repeating the ICC and western blot assays with the goat 
anti-EN2. 
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Figure 4.3. WPMY-1 EN2 plasmid transfection. a) qPCR analysis of EN2 RNA expression after 
transfection with 0.1µg, 0.05µg of EN2 plasmid (OriGene Technologies, USA) and Lipofectamine only 
control (Lipo only) and media only control. b) qPCR analysis of EN2 plasmid transfection carried out 
on an 8-chambered slide. c) Subsequent ICC cell surface analysis (X40 magnification) with 0.1µg 
and 0.05µg plasmid DNA; error bars represent the SEM of two repeats.
! Transfection with an increasing amount of plasmid resulted in an increasing 
amount in EN2 mRNA expression (Figure 4.3a), which was reflected in the ICC 
(Figure 4.3b). To semi-quantify this and confirm the size of EN2, a western blot was 
performed showing that the over-expressed EN2 was detected at 41kDa - 
complementing the literature (Martin et al. 2005). However, the 50kDa band did not 
change and instead stayed uniform - this indicated the detection of a extremely 
stable isoform of EN2 (that was present in almost all cell lines) or unspecific binding 
by the antibody and was in need of further investigation.
WP
MY
-1
PC
3 
Du
14
5
Ln
Ca
P
0
3
6
9
500
1000
1500
2000
Cell lines
EN
2 
C
t r
el
at
iv
e 
to
 G
ap
dh
 (x
10
00
)
EN2 overexpression
EN-2 O-E
Negative
EN2
rEN2
α-tubulin
50kDa
40kDa
b)
PC3WPMY-1 Du145 LnCaP rEN2
137  
! To further confirm the specificity of the anti-EN2 antibody, siRNAs were 
employed as a negative control. The siRNA’s were used to knock down EN2 mRNA 
in PC3 prostate cancer cell line (moderate EN2 mRNA expression). 
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Figure 4.4. siRNA mediated knockdown of EN2. a) with qPCR analysis of EN2 RNA expression 
(top) and subsequent protein analysis with goat anti-EN2 antibody (X40 magnification) (bottom). b) 
carried out in an 8 chambered slide with subsequent protein analysis with goat anti-EN2 antibody 
(X40 magnification); error bars represent the standard error of the mean (SEM) of two repeats. c) 
PC-3 cells underwent EN2 siRNA treatment with the 4676 EN2 siRNA for 48-96 hours, plotted both 
relative to B-ACTIN and GAPDH mRNA. The peaks on the graph are numbered 1-9 and correspond 
to the lanes on the western blot, found directly underneath; a negative (scramble) siRNA and media 
only repeats were carried out as controls. 
! Three different siRNAs were tried, and Figures 4.4a confirmed that an 
approximately 80% mRNA knockdown was achieved using the 4676 EN2 siRNA, 
and this was used for all subsequent knockdown experiments. An 8-chambered 
slide bypassing the need to trypsinise the cells showed a better reflection of the EN2 
knockdown at the cell surface (Figure 4.4b) but was extremely subjective and far 
from conclusive. Subsequently, the experiment was repeated using a western blot 
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instead. The 50kDa band was not knocked down but again stayed uniform 
throughout all samples. 
! It is possible that mRNA regulation of EN2 (transcriptional control) is 
independent of protein regulation (translational control) or this particular protein 
isoform is highly stable. If it is the latter than either a longer knockdown assay or a 
stable knockdown should show a difference at the protein level. 96 hours after 
siRNA transfection again showed no reduction at 50kDa (Figure 4.4c). Only a 60% 
EN2 stable knockdown clone was obtained, which was not reflected at the protein 
level with the 50kDa band remaining (data not shown).
4.4.4 Further investigation into the goat-anti-EN2 antibody specificity:                 
Kyte-Doolittle Hydropathy plot
! Upon closer examination off the EN2 immunogen against which the goat anti-
EN2 targets confirms that it binds close to the c-terminus. Analysis of the protein 
sequence by a Kyte-Doolittle Hydropathy plot reveals that, just before the c-
terminus, EN2 is extremely sticky due to it being highly polarised, as demonstrated 
by the most negative hydropathy score (approximately -3.5) in Figure 4.5. 
EN2	C-term	100aaEN2	full	length	protein
Figure 4.5. Kyte-Doolittle Hydropathy plot (ExPAsy tool) of EN2 protein. Left - analysis of full-
length EN2 protein. Right - analysis of the 100 amino acids at the EN2 C-terminus commonly used as 
the immunogen for commercial EN2 antibodies available.
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! Occasionally, the size of the antigen targeted by an antibody raised against a 
specific target is too small and the specificity decreases. Thus, an antibody that 
targeted a larger antigen of EN2 (80 - 220 aa) that was centre of protein (away from 
the c-terminus) was tried on the positive control cell line: SKMEL-5 (Figure 4.6). 
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Figure 4.6. EN2 siRNA knockdown in SKMEL5 cells for detection by mouse monoclonal 
antibody to EN2 (Abnova, UK). a) qRT-PCR confirming the mRNA knockdown of EN2 using a EN2 
siRNA (4676) after 48 hours. b) A western blot using the protein lysate from cells treated with the 
EN2 siRNA  after 48 hours. The controls were media only, ViaFect™ transfection reagent only and a 
negative (unspecific) siRNA. 
! However, three different band sizes were detected. The 40kDa band is the 
correct size for EN2, but no reduction was detected. Due to the lack of specificity to 
EN2 after the siRNA knockdown and the other two unspecified bands the antibody 
was not used any further.  
4.4.5 Further investigation using GFP tagged EN2 de novo expression in         
prostate cell lines
! At this point, an approach that did not rely on antibody detection was required 
and EN2 was studied by expressing it (de novo) in cell lines tagged to GFP. EN2 
was initially cloned into a C-terminus GFP TOPO vector (Figure 4.7).
GFP	only GFP	only
WGA	(membrane)
TO-PRO-3	(nuclear)
WPMY-1 PC3
EN2-GFP EN2GFP
a)
142  
Figure 4.7. GFP-tagged EN2 expression in PC3 and WPMY-1 prostate cell lines. Both GFP-EN2 
and EN2-GFP were transiently transfected into PC3 and WPMY-1 and a) were stained with WGA 
membrane dye, fixed and imaged by confocal microscopy at X20 magnification, b) the mRNA and 
protein lysate after 48hrs were collected for a RT-qPCR assay (top) and western blot assay (bottom).  
The peaks on the graph are numbered 1-8 and correspond to the lanes on the western blot, found 
directly underneath; rEN2 was used as a positive control. The western blot was probed with both the 
goat anti-EN2 antibody from Abcam and a GFP antibody.
! Figure 4.7a  shows that, for WPMY-1, EN2-GFP’s protein was localised at 
the nucleus in most cells, whereas, PC3 EN2-GFP expression was generally much 
less and vesicles could already be seen to be forming 24 hours post-transfection 
(Figure 4.7b and c). Unfortunately, the CT-GFP-EN2 expression was low and most 
commercial antibodies to EN2 bind to the c-terminus that would be obstructed by the 
bulky GFP - a limitation that should be taken into consideration at all times. 
Furthermore, the homeodomain and penetratin peptide is located at the c-terminus 
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(Figure 2.13) where these are crucial to EN2’s ability to secrete and internalise - a 
GFP tag is likely to interfere with this. 
! Following N-terminal GFP-EN2 transient transfection, large amounts of EN2 
mRNA were detected in WPMY-1 cells (Figure 4.8a), which subsequently 
underwent cell death (data not shown), addressed later in Chapter 5. 
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Figure 4.8. N-terminal GFP-tagged EN2 expression in prostate cell lines. GFP-EN2 were 
transiently transfected for 48 hours into a) LnCaP, PC3 and WPMY-1 cells and EN2 mRNA was 
detected by RT-qPCR and b) LnCaP and PC3 cells, the protein lysate was used for a western blot 
assay and probed with an anti-mGFP antibody. c) PC3, LnCaP, SKMEL5 and WPMY-1 cells and 
imaged by fluorescence microscopy at X20 magnification. 
! Similarly to the c-terminal GFP-tagged expression (Figure 4.7a), secretory 
vesicles, carrying EN2 were observed in PC3 cells, after N-terminal GFP-EN2 
expression. These micro-vesicles are unique to PC3 and not detected in the other 
prostate cell lines. Prostasomes are large vesicles that have frequently been 
reported to be secreted from PC3 cells in vitro (Llorente et al. 2004; Sandvig & 
Llorente 2012). 
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Figure 4.9. N-terminally GFP-tagged EN2 expression in PC3 cells. An enhanced picture of PC3 
cells after GFP-EN2 transfection and expression, which are aggressive and have high metastatic 
potential. The scale bar shows 44µm. 
! Secretory vesicles containing EN2 in the micro-environment have not been 
observed in this way or reported in the literature and thus, will be further investigated 
in Chapter 5. In Figure 4.8b, the stable GFP-EN2 PC3 cell line shows a second 
band at 33kDa, as GFP is only 26kDa, as seen in the GFP lane, EN2 could be 
cleaved.  
4.4.6 House keeping gene optimisation 
! Holst et al suggest a role for EN2 in cell morphology (Holst et al. 2008). A 
recent microarray (McGrath 2015) implicates a role in cytoskeletal re-organisation. 
Furthermore, the revelation that EN2 is secreted in vesicles meant that β-ACTIN, a 
cytoskeletal protein, may not be suitable as a RT-qPCR reference gene. Actin is 
fundamental to cytoskeletal rearrangement and vesicle formation (Sandvig & 
Llorente 2012). 
! Consequently, the geNORM kit (Primer Design Ltd) was employed to 
establish a more appropriate house keeping gene (reference) for normalisation.
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Figure 4.10. geNORM assay - reference gene selection. 12 reference genes were tested with a 
number of cell lines. The gene expression normalisation factor (M) is plotted against the set of 
reference genes.
! The 12 house keeping genes were tested across a range of samples 
(Chapter 3, Section 3.4.2) and analysed by qbase+ software (Biogazelle, BE) 
which ranked the genes according to increasing stability (left to right). GAPDH and 
ATP5B showed the least variability between the samples tested. Therefore, these 
two HKGs were used thereafter for all RT-qPCR assays in order to accurately 
compare EN2 expression across all cell lines used in this study. GAPDH Ct values 
was used for all normalisation calculations unless it showed too much variability, at 
which point ATP5B was used instead.
4.4.7 Engrailed-2 primer design 
! To further investigate the discrepancies in EN2 protein size shown in 
Sections 4.4.3, 4.4.4 and 4.4.5 and to explore the possibility of different EN2 
isoforms, exon-specific primer pairs were designed (Primer Design Ltd). This would 
also help to elucidate the possibility of EN2 mRNA alternative splicing. 
! Furthermore, ‘in-house’ intron-spanning (IS) primers produced an 
amplification efficiency (described in Section 3.4.1) of more than 105%, indicating 
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the co-amplification of an unspecific product (data not shown). The detection of low 
Ct values (or low mRNA detection) but high protein warranted the design of new 
EN2 primers pairs: exon-specific, in order to investigate splice variants, and intron-
spanning (Primer Design Ltd), which are usually used to avoid detection of 
contaminating gDNA. 
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Figure 4.11. Validation of exon-specific primers and intron-spanning primers. RT-qPCR were 
carried out in order to validate each primer by: a) generating a standard curve by EN2 plasmid serial 
dilution from 0ng to 10ng and plotting the raw Ct values against them;  b) generating cDNA from EN2 
overexpression assay using stably expressing PC3 GFP-EN2, PC3 GFP (control) and PC3 only 
(negative control), the Ct was normalised to GAPDH house keeping gene and the values were 
multiplied by 10000 and c) generating cDNA from EN2 siRNA assay, PC3 cells were treated with 
EN2 4674 siRNA, negative control siRNA (EN2 neg) and a media only (negative) control. The Ct 
values were normalised to GAPDH and multiplied by 100000.
! The Exon 1 specific primers produced very high Ct values and this suggests 
that they detected few EN2 transcripts, Exon 2 specific primers produced the lowest 
Ct values and so detected lots of EN2 and intron-spanning detected EN2 at values 
in between these two primer pairs. Accumulatively, this would imply that the intron-
spanning primer pair could not detect as many transcripts as the Exon 2 primers, 
perhaps due to improper splicing that would leave all or part of the intron sequence 
in the transcript and the primer pairs unable to anneal to it. Exon1 primers cannot 
pick up EN2 mRNA transcripts because the primers are unable to anneal to their 
target sequence; the standard curve revealed that the Exon 1 primers is inefficient 
as they could not pick up the EN2 plasmid and is most likely a sequence design 
issue (Figure 4.11b). The pattern of higher detection from Exon 2 over IS primers is 
unlikely to be gDNA contamination as DNase I (digests gDNA in sample) was used. 
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! Next, all three primers were used to detect EN2 in a range of cell lines. 
SKMEL5 and HL-60 cancer cell lines were used as positive controls (previously 
shown in-house to have high EN2 protein). WPMY-1 and COS-1 are normal 
(immortalised) cell lines that were used as negative controls. 
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Figure 4.12. EN2 mRNA expression in cell lines assessed by real-time quantitative PCR using 
validated exon-specific primers and validated intron-spanning primers. These primers have 
been validated using a standard curve and EN2 plasmid by Primer Design Ltd. They were designed 
to bind to either Exon 1 or Exon 2. Another intron-spanning primer pair were designed and validated, 
that would not detect any contaminating genomic DNA is detected. 
! SKMEL5 were shown to have the highest EN2 mRNA detection and PC3 
(most aggressive) had the highest EN2 mRNA detection out of the prostate cancer 
cell lines. WPMY-1 and COS-1 were calculated to have no or very little EN2 mRNA, 
respectively. Using Exon 2 and IS primers (Primer Design Ltd) it was possible to 
detect increasing EN2 plasmid DNA, creating optimal binding efficiencies (Section 
4.4.7). Exon 2 primers detected the highest expression of EN2 and were used 
thereafter.
! It is still not clear whether mRNA splice variants exist for EN2 from Figure 
4.12. It is interesting that the standard curve (Figure 4.11a) shows that IS primers 
detect the same amount of EN2 as the Exon 2 primer pair and notably, T24 showed 
no detection with IS primers but high detection with Exon 2 primers. The 
discrepancy between is inherent within the cell and is worth further investigating as 
another possible level of EN2 regulation. However, this study focused on EN2 as a 
protein biomarker and so progressed to look specifically at EN2 protein detection 
and regulation.
4.4.8 GFP-EN2 stable expression for EN2 siRNA validation
! Now that a reliable RT-qPCR assay was established it could be used to 
reconfirm that a large percentage of EN2 mRNA was actually knocked down by the 
4676 siRNA (Figure 4.13a). In addition, a stable GFPEN2 PC3 clone was employed 
as a positive control in order to verify that the 4676 siRNA resulted in a reduction of 
EN2 protein. Just 24 hours after siRNA transfection, there was considerable 
reduction in GFP fluorescence (Figure 4.13b). Importantly, the goat anti-EN2 
antibody was able to detect this GFP-EN2 siRNA knockdown via western blot, at the 
correct size of 33 kDa (if the 33kDa of the GFP protein is taken away from the total 
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size of the band, which is approximately 66 kDa). However, it is further confirmation 
(to what was observed previously in Figure 4.2) of cross-reactivity by the goat anti-
EN2 antibody and thus, it is likely that the antibody detects another antigen. 
! Notably, WPMY-1 failed to produce a stable GFP-EN2 cell line and this will be 
addressed in Chapter 6.
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Figure 4.13. EN2 siRNA knockdown in PC3 GFP-EN2 stable cell line assessed by fluorescence 
and western blot. a) All three new primers designed by Primer Design Ltd were tried on the EN2 
siRNA mRNA and all three show 80% or more knockdown of EN2 mRNA. b) This was repeated on 
PC3 GFP-EN2 stable cell line to test the siRNAs efficiency, after 48 hours these cells were imaged at 
X20 magnification using a fluorescence microscope. c) Protein lysates were obtained of each control 
and EN2 siRNA treated sample, twice for two biological repeats, and analysed by western blot assay 
(left) and probed for by the goat anti-EN2 antibody, the western blot was further analysed by 
densitometry, which measured the chemiluminescence of all bands that could then be plotted relative 
to its house keeping gene counterpart for accurate comparison. (1) EN2 4676 siRNA and the siRNA 
controls include (2) siRNA neg (scramble) and (3) media only, (4), (5) and (6) are biological repeats 
of (1), (2) and (3). 
! This result highlighted the efficacy of the siRNA, which can target and 
knockdown EN2 mRNA and subsequently knockdown the protein (that equates to 
33kDa as part of GFP-EN2 and not 50kDa) at 66kDa (GFP-EN2) completely 
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disappears when EN2 is expressed de novo (Figure 4.13c, image on the left). 
However, the 50kDa does not decrease. 
! To make sure that no reduction occurred at 50kDa, the intensity was 
measured over the loading control. This time GAPDH was used as the loading 
control because EN2 has been implicated in cytoskeletal rearrangement and 
GAPDH had been shown to be one of the optimal house keeping genes in Section 
4.4.6. Even still, no reduction was calculated (Figure 4.13b). 
4.4.9 HaloTag® -EN2 expression in prostate cell lines 
! To further investigate the potential cleavage of EN2 shown in Figure 4.8b, 
EN2 was N-terminally tagged to HaloTag® , which has a high specificity monoclonal 
antibody for detection. This high specificity also meant that EN2 detection in the 
culture media was possible (Figure 4.14b and c). 
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!
Figure 4.14. HaloTag® -EN2 expression in prostate cancer cell lines. a) PC3, LnCaP and Du145 
were transfected with HaloTag® -EN2, HaloTag®  control and media only control and analysed by RT-
qPCR for EN2 mRNA detection (left), all values were normalised to Gapdh; the lysates were 
analysed with a western blot (right) and probed with an anti-HaloTag® antibody. b) The protein 
variants were further investigated by looking at their detection in both LnCaP cell lysate and culture 
media/ supernatant (super) as well a denatured and undenatured samples. c) To provide further 
confirmation that EN2 was being detected in lysate and culture media (super) from LnCaP 
(transfected with HaloTag® -EN2), antibodies against EN2 were used to detect the protein construct.
! HaloTag® -EN2 was expressed in prostate cancer cell lines PC3, LnCaP and 
Du145 with RT-qPCR confirming expression. A western blot performed 
simultaneously revealed protein expression, HaloTag® -EN2 was detected at the 
correct size, approximately 70kDa, and HaloTag®  alone at 35kDa. A similar pattern 
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to GFP-tagged EN2 expression emerges: high expression at the mRNA level results 
in relatively lower protein expression. Surprisingly, different sized bands are 
revealed, exclusive to HaloTag® -EN2, with LnCaP cells only. This time, EN2 is 
detected in the culture media although cleaved, as these bands are sized 
approximately 53, 45 and 41kDa and HaloTag®  is only 35kDa. 
! To further investigate these variants, the western blot was repeated: 
denatured and non-denatured; with the HaloTag®  to confirm EN2 specificity and 
was then further investigated with C-term and N-term specific anti-EN2 antibodies 
(Figure 4.14b and c). From denatured to non-denatured there was an increase in 
intensity of bands sized 70kDa and approximately 41kDa. The N-term specific EN2 
antibody detects the cleaved bands in the lysate at 70, 53, 41k and 35kDa and 
supernatant at 41kDa only. This would suggest that the c-terminus of EN2 is being 
cleaved. However, it is clear that the EN2 antibodies are not exclusively specific to 
EN2 as Ab2 has detected the HaloTag®  protein alone in the cell lysate only. 
Therefore, further confirmation is required by mass spectrometry.
4.4.10 Identification of protease sites within EN2 protein  
! To identify potential proteases and their cleavage sites within EN2 and to 
confirm, if any, the production of corresponding sized bands, EN2 protein sequence 
was ran through the PeptideCutter (ExPASy) program (Figure 4.15).
a)
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Figure 4.15. Proteases cleavage sites within EN2 identified by PeptideCutter (ExPASy). a) EN2 
protein sequence highlighted with enzyme cleavage sites, listed underneath. b) A list of positions and 
segments of EN2 to highlight where on EN2 MMP-9 could cleave it and the resulting fragment size.
! The program confirmed that MMP-9 cleaves towards the N-terminus and 
would produce a peptide of the right size, 6.5kDa (Figure 4.15b). Other proteases 
cleave EN2 (Figure 4.15a) and so there are a few possibilities but this, at least, 
provides rationale for further investigation. 
 
4.4.11 Goat anti-EN2 antibody re-evaluation  
! Knowing that EN2 detection should be approximately 33-40 kDa and is 
capable of being detected by the goat anti-EN2 antibody perhaps it was missed 
(Figure 4.16) because the band was ‘overshadowed’ by the 50kDa band thought to 
be EN2. 
!
b)
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Figure 4.16. Reevaluation of EN2 protein detection via western blot with goat anti-EN2 
antibody. The yellow boxes highlight a band at approximately 40kDa that could be EN2. 
! There is a band present with SKMEL5 above and below the large 50kDa 
band. The band below, at 40kDa, is the correct EN2 size. Similarly, PC3 also 
produces a band at 40kDa below the 50kDa. 
4.5 Discussion
! The goals stated in Section 4.3 were to develop a more reliable assay for 
EN2 detection and quantitation in cell lines; to validate the anti-EN2 antibody; and to 
shed light on EN2’s regulation. In so doing, to gain a better understanding of its 
function and thus make better use of EN2 as a protein biomarker. It is not known 
how and when the cell starts secreting EN2 along the tumorigenesis timeline. 
Answers to these fundamental questions are undeniably pertinent to pursuing a 
more tailored and informative EN2 clinical test. 
! This study focused on looking at EN2 in vitro, limited by a 2D environment, 
and sought to answer whether endogenous EN2 protein is really being detected in 
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these cell lines. It also enquired as to why there is apparent protein detection when 
there are no mRNA transcripts; and ultimately intends to explain how EN2 could be 
tightly regulated.
! ICC surface staining of cell lines with the goat anti-EN2 antibody revealed 
positive staining on all cell lines including a WPMY-1 normal cell line that had almost 
no EN2 or mRNA, and thus required further investigation. The western blot provided 
the same result: bands appeared at 50kDa with normal cell lines that were revealed 
to have almost no or very low levels of EN2 mRNA transcripts. Therefore, the 
antibody successfully detected EN2 but could not be used further to reliably 
discriminate EN2 regulation and quantitation between cell lines. For future studies, 
an EN2 CRISPR knockout kit could be employed, to knock the EN2 gene out 
completely (Sander & Joung 2014), this would then ideally be verified by mass 
spectrometry before using an EN2 antibody (Sections 7.4.2.1 and 7.4.2.2). 
Preferably, each antibody should be verified for its specificity this way otherwise it 
leads to questionable results, especially for EN2 antibodies that were recently 
investigated (Guan et al. 2014).
 ! When comparing GFP-tagged EN2 between PC3 and WPMY-1 cell lines, it 
became apparent that EN2 was differentially regulated. PC3s were visibly 
unaffected, found to be true of all cancer cell lines used here, but EN2 caused a 
large amount of cell death to WPMY-1 cells after expression of GFP-EN2 (further 
explored in Chapter 6). PC3 cells were able to quickly down-regulate EN2 (as there 
was a reduction in GFP fluorescence) whereas WPMY-1 cells could not and this 
resulted in large EN2 overexpression at mRNA and protein levels, which was only 
detected in the nucleus. This suggests that the PC3 cells have mechanisms in place 
to down-regulate EN2, with regards to mRNA and protein levels, and translocate 
EN2 out of the nucleus (further explored in Chapter 6). Furthermore, GFP-EN2 
transfection in PC3 cells did not reveal high protein expression via western blot, 
which supports the above finding. This pattern of expression differed to LnCaP cells, 
a less aggressive prostate cancer cell line, where high EN2 protein was detected. 
However, a stable PC3 GFP-EN2 cell line was able to be produced, which resulted 
in higher protein detection, presumably because of EN2‘s constitutive expression. 
Furthermore, the stable cell line also revealed another possible level of EN2 
regulation, post-translationally, as you find an additional shorter band that suggests 
that the protein was cleaved (Figure 4.8b). 
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! The pattern of protein expression mentioned above is reproduced with 
HaloTag® -EN2 expression: high mRNA expression in PC3 and LnCaP that 
produces low protein in PC3 cells and high protein detection in LnCaP cells (Figure 
4.14a, image on the right). It is interesting to compare EN2 de novo expression 
between the most aggressive cell line: PC3; and the least aggressive, LnCaP. This 
expression reveals that EN2 is regulated differently between cell lines. LnCaP 
reveals high protein expression, both lysate and supernatant (via western blot) but 
also highlights the large amount of proteolysis EN2 underwent - shown by the 
production of multiple bands (Figure 4.14a, right image). This supports earlier 
findings that EN2 is cleaved within these prostate cancer cell lines (Figure 4.8b) - 
as a post-translational means of regulating EN2. Exploring this, by revealing 
potential cleavage sites, further showed that EN2 is actually highly susceptible to a 
number of proteases. Bands depicting the correct size on the western blot can be 
produced this way, notably through MMP-9 cleavage. However, further confirmation 
is required by cutting out the bands for mass spectrometry due to EN2 antibody 
ambiguity. If this is true and EN2 is largely cleaved, it would be important to discover 
whether this is by a regulated or random process as it would have important 
implications to the ELISA test (or any detection test) whereby EN2 is detected in 
urine. Employing antibodies, especially monoclonal antibodies, to detect a cleaved 
target is not the most efficient method as the are made using only one B lymphocyte 
and all detect the same epitope in the native conformation (Section 2.2.4). 
! Exclusive to PC3, EN2 is secreted in microvesicles (further explored in 
Chapter 5) . This secretion is perhaps another means of decreasing EN2 post-
translationally. The other cell lines in figure , including LnCaP, showed no signs of 
vesicle formation. Overall, these results show that PC3 cells - the most aggressive 
cell line - and to a lesser extent, the other cancer cell lines, do not readily express 
and/or retain EN2 protein - they instead immediately dispel EN2. This would suggest 
that the protein is redundant in these cancer cell lines or play a role outside the cell. 
The large amount of proteolytic cleavage found with LnCaP cells suggests that it is 
likely to be the former, however, the encapsulation within vesicles formed by PC3 
cells suggests the latter, and the vesicles could be used as a means of protection 
from proteolysis. Surprisingly, EN2 detection in the supernatant was only found with 
LnCaP, albeit cleaved, and not PC3. Perhaps, with PC3, EN2’s protection by these 
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robust microvesicles made EN2 inaccessible or kept the protein in a native state that 
was simply unable to be detected by the antibody. 
! It was important to establish EN2 detection within culture media or 
supernatant (Figures 4.14b and c) as this formed the basis of the EN2 ELISA (R. 
Morgan et al. 2011). This confirmed that some EN2 must be released freely and 
without association to vesicles, although this is seemingly cell dependent. The 
antibodies used thus far may not have been sensitive or specific enough to detect 
what little of full-length (and free) EN2 is secreted into the environment with in vitro 
conditions and this is presumably a lot less than in vivo conditions. 
! The only way to be sure that these bands (detected with HaloTag® ) are 
cleaved EN2, is to carry out mass spectrometry. In addition, future work would need 
to confirm the cleavage of EN2, without the tag, to rule out the chance that the tag 
itself causes an unusual confirmation of EN2, which then exposes it to proteolytic 
cleavage. Overall, this provides good evidence that EN2 cleavage could influence 
EN2’s translation into the clinic and is therefore worth further investigating. 
! Unfortunately, if the 50kDa protein band is confirmed to be unspecific binding, 
it is possible that endogenous EN2 has not been successfully detected here within 
these cell lines. EN2 protein is not expected to be present in normal cell lines and 
perhaps not in cancer cell lines if EN2 is secreted quickly and efficiently in late-stage 
tumours; and within high-density vesicles (Nédélec et al. 2004). EN2 seemingly 
becomes redundant or switches to a role outside the cell, such as cell-cell 
communication, and so more should be detected exogenously. However, without 
reliable antibodies, this is difficult to quantitate and tagging EN2 comes with its own 
set of limitations such as GFP interference with structure and function as a bulky 
protein and toxicity due to fluorescence (Jensen 2012). EN2’s tight regulation still 
seems to be keeping mRNA expression, perhaps low EN2 protein expression, within 
these cancer cell lines, perhaps too low or varied to be detected by methods that are 
not very sensitive (for example antibody-based detection assays). This is especially 
true when taking into consideration the finding here that EN2 is regulated post-
translationally and likely to be cleaved. The shRNA clones made in this study 
underwent cell death after only a few passages (no data was able to be collected). 
Similar findings have been made with EN1 where blocking peptides against EN1 
caused a rapid and strong apoptotic response in tumour cells (A. S. Beltran et al. 
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2014), implicating EN1 as a pro-survival factor. This might be why 100% knockdown 
of EN2 has been difficult to achieve thus far. 
! Figure 4.16 shows bands that may be endogenous EN2 (40kDa) within these 
cancer cell lines that have been shown to have high amounts of EN2 mRNA. Thus, 
one possibility about the lack of detection by the goat anti-EN2 antibody at the 
correct size is, the antibody preferential binds to the ‘unknown target’ over the small 
amount of EN2 protein within these cell lines and EN2 is consequently overlooked. 
! Ideally, to study EN2 protein dynamics (shown here to be highly complex), an 
in vivo or 3D cell culture environment is required as 2D in vitro cell culture is far too 
limited - especially when studying a protein that undergoes intercellular transfer - 
and thus prevents proper observation of EN2 regulation. Furthermore, due to the 
ambiguous nature of the antibodies available commercially (Guan et al. 2014), mass 
spectrometry should be employed for accurate and reliable quantitation; and 
antibody validation.  
4.6 Conclusion
! This preliminary investigation has indicated that EN2 protein is ectopically 
expressed in cancer and is subsequently downregulated at a later stage. The in vitro 
experiments carried out here suggest that this is mostly by post-translational 
mechanisms and extracellular transfer with increasing grade or aggressiveness 
(also referred to as metastatic potential). Consequently, only a low amount of full-
length EN2 remains within these cancer cell lines, this however, has been 
overlooked due to unspecific binding by the goat-anti-EN2 antibody and has led to 
significant confusion. We show here that the goat anti-EN2 antibody binds to an 
unspecific protein product that needs to be verified by mass spectrometry. These 
findings here have serious implications for the use of EN2 as a protein biomarker, 
this is especially true if future work confirms that EN2 is cleaved and cleaved 
randomly. 
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Chapter 5: 
Exploring the potential of 
EN2 a target in prostate 
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5. Exploring the potential of EN2 a 
target in prostate cancer
5.1 Introduction
! In this chapter the reasoning behind EN2 as a candidate target for 
monoclonal antibody therapy is explained. The following section sets out the 
objectives and hypotheses. Section three presents the results obtained, which 
overall reveals that more work is needed to ensure EN2 is suitable as a target for a 
monoclonal antibody drug-conjugate, particularly for high grade tumours. The 
discussion brings together the findings of this chapter and proposes other avenues 
of immunotherapy that could be explored and that the significant gap in the 
understanding of EN2’s function, particularly in cancer, is obstructing its utility. 
5.2 Background
! The rationale behind EN2’s potential utility as a cancer target for 
immunotherapy originated from an immunohistochemistry staining of prostate 
cancer tissue, where EN2 seemed to be located within microdomains at the 
membrane (R. Morgan et al. 2011). There have been several reports of EN2’s 
subcellular localisation within the cell membrane. These include an association of 
EN2 with caveolae-like domains (Joliot et al. 1997). Joliot et al drew similarities 
between neuronal microdomains and the apical domain of epithelial cells to show a 
common pattern of localisation and a possible role of EN2 in axonal transport. 
! Joliot et al also stated that the importance of the tissue and cellular 
distribution of EN2 had been overlooked due to a lack of specific EN2 antibody. 
Thus, cellular distribution is a focus of this chapter. However, the report also noted 
that only a small fraction of EN2 was associated with these domains, making it more 
difficult. Furthermore, an even smaller fraction of EN2 is known to be secreted and 
protected from proteinase K or trypsin proteolysis. In Chapter 4 (Figure 4.14) the 
proteolysis of EN2 in LnCaP cells (and PC3 stably expressing GFP-EN2) and the 
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encapsulation of EN2 in microvesicles within PC3 cells were reported. These results 
therefore agree with the conclusions of Joliot et al that only a small percentage of 
full-length EN2 is secreted and accessible to the environment (Joliot et al. 1997). It 
also highlights the importance of defining the EN2 antigen that is accessible from 
the environment in order to effectively engineer a monoclonal antibody-drug 
conjugate. The antigen is likely to be at the C-terminus: L Carlier et al placed the 
EN2 homeodomain into a membrane-mimetic environment and observed the tertiary 
structure unfold but not the secondary, which allowed the Trp-48 to insert directly 
into the membrane; Trp-48 is located towards the C-terminus (Carlier et al. 2013). 
However, it is possible that proteolysis is a mechanism that allows for the controlled 
release of EN2 into the environment:
! ‘A second possibility is that it reflects the capability of homeoprotein isoforms 
! or fragments to be released from cells and passaged into other cells through 
! a paracrine mechanism.’ (Derossi et al. 1994). 
This could be a problem especially when targeting EN2 with a monoclonal antibody, 
which recognises only one epitope.
! EN2, intriguingly, has a nuclear localisation signal (NLS) and a nuclear export 
sequence (NES) but no classical secretory signal though it is still capable of 
translocating out of the cell. EN2 most likely resides within the cytoplasm prior to 
being trafficked to the membrane, from which some is subsequently released into 
the environment (R. Morgan et al. 2011). However, there is little consensus as to 
how this final step is achieved, although it may involve association of EN2 with 
microdomains (R. Morgan et al. 2011), cavealoe-like domains or luminal vesicles 
(Prochiantz & Joliot 2003). The mechanism is still poorly characterised and this is 
mainly because research has focused on the utility of the penetrating peptide (third 
helix) as an intercellular carrier (Prochiantz 2010) rather than its function in 
development and disease. 
! The membrane penetrating part of EN2, mentioned above, has been 
pinpointed to the third helix of its homeodomain (Derossi et al. 1994). As this is the 
most conserved region of all the homeodomains, it was hypothesised that this 
property (of intercellular transfer) could be common to all homeodomain containing 
proteins, and subsequently additional homeodomain-containing proteins including 
OTX2, ISL-1 and VAX1 have indeed been shown to be secreted from cells (Kim et 
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al. 2014; Di Giovannantonio et al. 2014). More recently, it was shown that the whole 
of the homeodomain was required for efficient EN2 secretion (Carlier et al. 2013). 
! Substantial evidence of EN2’s ability to be secreted exists, however, much 
less is known regarding its internalisation, mainly how it is taken up by the cell and 
why. The ambiguous nature of its translocation mechanism (and the unspecific 
nature by which it is subsequently internalised). It is conceivable that EN2 transport 
might involve exosomes or other microvesicles such as prostasomes that are 
thought to be mediators of intercellular communication (G. K. Ronquist et al. 2012). 
It would be advantageous as EN2 would no longer be susceptible to proteloysis, 
which bypasses the problem associated with EN2 ‘stickiness’. If EN2 were not 
encapsulated the paracrine function would be inefficient because the protein is too 
sticky and too susceptible to proteolysis. It has been reported that EN2 
internalisation can happen at 4℃ and 37℃ though this it is not via the conventional 
endocytic pathway and is receptor-independent (Maizel et al. 2002). It could be a 
highly unspecific mechanism and therefore might be problematic when injecting an 
antibody-drug conjugate (ADC) to target EN2 that may end up in a normal cell. With 
this in mind, the next question is: Is EN2 internalisation targeted or non-targeted?
! The rationale behind EN2 as a therapeutic target also comes from an 
investigation into its immunogenicity, which is the the ability to induce a systemic 
immune response (Annels et al. 2014). This study was able to show that 
autoantibodies against EN2 were present in the sera of patients but not healthy 
volunteers. It was found that the quantitation of such was not useful as a diagnosis 
or prognosis tool. However, EN2 was naturally able to produce an immune 
response. If it were the case that the antibody-drug conjugate was not internalised 
and therefore could not kill the cancer cell than these findings would provide a 
rationale to explore other immunotherapy options. This could include using an anti-
EN2 antibody for its binding specificity and modifying the other end, not with a drug, 
but with the aim of boosting an already existing immune response and homing T 
cells to the tumour site. 
! The paracrine activity of homeoproteins (including EN2) have been studied in 
detail (Joshi, Ibad, et al. 2011; Layalle et al. 2011). EN2 has been reported to bind to 
PBX, non-cell autonomously and during development, to pattern the brain (Rampon 
et al. 2015).This would suggest that EN2 secretion, in prostate cancer, is regulated 
and carries out a specific function. Regardless, an EN2 ELISA detection assay has 
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been developed to detect secreted EN2 in urine and by doing so detecting prostate 
cancer with a sensitivity and specificity of 66% and 88.2% respectively (R. Morgan 
et al. 2011). Without a defined role it is difficult to know how best to utilise EN2. EN2, 
for now, could fit into a panel of biomarkers to better facilitate the diagnosis of 
prostate cancer. To make advances in this area, this study sought to define EN2’s 
regulation and function. By knowing how EN2 relates to cancer (cell) progression 
makes EN2 much more useful by gaining more information than simply the 
presence or absence of cancer, such as prognosis. 
! Ultimately, this present study sought to confirm and quantify the presence of 
EN2 on the cell membrane to further validate it as a target for an antibody-drug 
conjugate; mainly through immunocytochemistry and live cell imaging experiments. 
In addition, it sought to identify a suitable antibody, which recognised a small antigen 
on EN2, to take forward (and engineer into an ADC). 
5.3 Chapter objectives, hypotheses and approach
! The objectives of this chapter (taken from Section 1.5) were to: 
1. determine EN2‘s expression and localisation within cancer cells.
! !
2. further define EN2’s secretion and internalisation mechanisms. 
3. identify a suitable EN2 antibody for development into an antibody-
drug conjugate. 
4. carry out preliminary in vitro experiments on the candidate antibody-
drug conjugate to direct the next set of experiments.
! In order to investigate these the following experiments were performed:
‣ Co-localisation analysis by immunocytochemistry using the goat anti-
EN2 antibody and a membrane marker, the combined fluorescent 
signal would be confirmation that EN2 can be found on the membrane 
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‣ Subcellular fractionation by ultracentrifugation and western blot 
analysis of PC3 and WPMY-1 cell lines using the goat anti-EN2 
antibody, to semi-quantitatively measure EN2’s presence on the 
membrane
‣ Confirmation of the subcellular localisation of EN2 using GFP-EN2        
de novo expression, due to the unspecific nature of the goat anti-EN2 
antibody, using confocal microscopy co-localisation analysis
‣ Defining the extracellular epitopes of EN2 using polyclonal sheep          
anti-EN2 epitope-specific antibodies and immunocytochemistry, in 
order to identify the antibody to take forward and engineer into an ADC
‣ Validation of sheep anti-EN2 antibodies by western blotting due to the 
unspecific nature of polyclonal antibodies and the chance of cross-
reactivity 
‣ GFP-EN2 secretion and internalisation by PC3 cells to gain a better 
understanding of the limitations and challenges that may need to be 
overcome when using EN2 as a therapeutic target 
‣ pH-dye conjugated EN2 antibodies to determine EN2 antibody         
internalisation
‣ Tracking EN2 secretion and internalisation from prostate cancer           
cell lines with NanoLuc®EN2 de novo expression and Nano-Glo® 
detection assay
‣ Identifying GFP-EN2 containing microvesicles from PC3 cells
‣ Tracking EN2 secretion and internalisation from prostate cancer           
cell lines with NanoLuc®EN2 de novo expression and Nano-Glo® 
detection assay
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5.4 Results
5.4.1 Co-localisation analysis by immunocytochemistry using a membrane        
marker
! Chapter 4 concluded that the subcellular localisation of EN2 was different 
between cancer and normal (immortalised) cell lines, and between the most 
aggressive and least aggressive prostate cancer cell lines. It was therefore 
important to observe its subcellular localisation in more detail, particularly as EN2 is 
a candidate target for therapy. 
!
Figure 5.1. Investigating EN2’s subcellular localisation in vitro using immunocytochemistry 
and wheat germ agglutinin membrane marker. Immunocytochemistry was performed using the 
goat anti-EN2 antibody, WGA membrane stain (red) and TOPRO-3 nuclear staining (blue) with 
HL-60, PC3 cell lines and Fibroblast (Fibros) cells, this was carried out at X40 magnification. 
! The cells were initially co-stained with a red membrane marker, wheat-germ 
agglutinin (WGA), TOPRO-3 nuclear stain that fluoresced blue and an anti-EN2 
antibody (green fluorescence) (Figure 5.1). In all the cancer cell lines, co-
localisation of EN2 with the cell membrane was detected through the combined 
fluorescent signal. There was a high level of EN2 at the cell membrane. No EN2 
was observed in normal fibroblast cells. 
HL-60 PC3 Fibros
WGA	(membrane)
EN2
TO-PRO-3	(nuclear)
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5.4.2 Subcellular fractionation by ultracentrifugation and western blot analysis 
of PC3 and WPMY-1 cell lines
! To semi-quantify EN2 membrane localisation, PC3 and WPMY-1 cells were 
first ultracentrifuged in order to isolate the membrane fraction (as detailed in 
Chapter 3, Section 3.15) and analysed by western blot assay. To make sure a pure 
membrane fraction was obtained, pan-cadherin membrane marker was used as a 
positive control. Alpha-tubulin cytoplasmic marker was used as a negative control. 
This western blot was also compared to the whole cell lysate (Figure 5.2).
Figure 5.2. Western blot of isolated membrane fractions of prostate cell lines PC3 and 
WPMY-1. PC3 and WPMY-1 membrane fractions compared to whole cell lysate, additional controls 
include pan-cadherin membrane marker (middle), ⍺-tubulin cytoplasmic marker (bottom) and rEN2 in 
the last lane. 
! The cytoplasmic marker was not detected in the preparation indicating that it 
mostly consisted of membrane components. There was a slight enrichment of the 
membrane marker compared to the whole cell lysate within both cell lines. EN2 was 
also detected in the membrane of both cell lines. However, taking into consideration 
previous western blot results from Chapter 4 (where the antibody likely detected an 
unspecific product) it cannot be stated that more EN2 is detected in the PC3 cancer 
cell line than the WPMY-1 normal (immortalised) cell line. Therefore, this western 
blot analysis is both limited and unreliable. 
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5.4.3 Confirmation of the subcellular localisation of EN2 using GFP-EN2             
de novo expression and confocal microscopy co-localisation analysis
! An alternative method for assessing EN2 localisation GFP-EN2 was both 
transiently and stably expressed in PC3 cells and transiently expressed in WPMY-1 
cells (due to apoptosis that will be explored in Chapter 6). In Figure 5.3 both cell 
lines were stained with WGA membrane marker. 
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Figure 5.3. Co-localisation analysis of wheat-germ agglutinin and GFP-EN2 using confocal 
microscopy. The fluorescence intensity was plotted against the distance in µm across the cell, which 
are highlighted with red arrows in the confocal images to the left of the plots. Cells were stained with 
a red WGA membrane marker to show that green GFP-EN2 fluorescence co-localised with the red 
fluorescence of the membrane, at the same site in the cell. This was carried out in a) PC3 cells 
transiently expressing GFP-EN2 (left) and GFP (right) and b) WPMY-1 cells transiently expressing 
GFP-EN2 (left) and GFP (right) and c) stable PC3 GFP-EN2 and GFP cell lines.
! De novo expression of GFP-EN2 showed a large difference in EN2 
expression and localisation between PC3 and WPMY-1 cell lines; despite the 
limitations associated with tagged proteins. PC3 cell fixation after 24 hours showed 
EN2 as located in the nucleus, cytoplasm and membrane within these cancer cell 
lines. The easy discrimination between the three subcellular localisation domains is 
due to the lower amount of EN2 detection within the PC3 cells as opposed to normal 
(immortalised) WPMY-1 cells. WPMY-1 expressed large amounts of GFP-EN2 
(when compared to PC3 or GFP only control) that is seemingly ubiquitous (Figure 
5.3b, left). The co-localisation analysis and imaging for PC3 showed that GFP-EN2 
largely resided at the membrane and occupied discreet areas unlike GFP only and 
WPMY-1 GFP-EN2 expression, particularly after stable expression in Figure 5.3c 
(right). GFP was located universally within both cell types.
!
5.4.4 Defining the extracellular epitopes of EN2 using polyclonal sheep               
anti-EN2 epitope-specific antibodies and immunocytochemistry
! When designing an efficient monoclonal antibody that can be used as an 
antibody-drug conjugate, it is important to define the immunogen to which it will bind. 
To do this, a panel of 19 polyclonal sheep antibodies, Ab2 - Ab33, were made to 
target short EN2 peptides along the whole of the protein from the N- to the C-
terminus. 
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Figure 5.4. ICC for EN2 surface and intracellular staining using epitope-specific antibodies 
from N-terminal to C-terminal. (X40 magnification). Each number represents a 20 amino acid 
peptide that overlaps its neighboring peptides by 10 amino acids. The outside images depict 
intracellular staining and the innermost images are surface staining only. All slides were fixed with 
propidium iodide (red) nuclear stain.
! In Figure 5.4 the PC3 (left) and WPMY-1 (right) showed the clearest epitope 
distinction with Ab32 corresponding to an epitope located between amino acids 
310-330. Predominantly, a lower amount of EN2 was detected at the N-terminal half 
of the protein in both PC3 and WPMY-1 cells. This suggests that either: the N-
terminus is not accessible from the outside of the cell, the N-terminus has been 
cleaved off (a possibility due to the results in Chapter 4, Section 4.4.5) or the 
antibodies that target the C-terminus are unspecific and cross-react to bind another 
antigen, enhancing the fluorescent signal.
5.4.5 Validation of sheep anti-EN2 antibodies by western blotting 
! In order to verify the specificity of these EN2 antibodies, those that detected 
EN2 in section 5.4.4 above were analysed further using western blotting (Figure 
5.5).
Ab8Ab32	C-termGoat	Ab (ELISA)
C-term
Ab2	N-term
APS2	(ELISA)
C-term
Ab4	N-term Ab16 Ab24
70
53
41
30
22
70
53
41
30
22
SK
M
EL
5
PC
3	
	E
N2
	O
-E
PC
3
W
PM
Y1
SK
M
EL
5
PC
3	
	E
N2
	O
-E
PC
3
W
PM
Y1
SK
M
EL
5
PC
3	
	E
N2
	O
-E
PC
3
W
PM
Y1
SK
M
EL
5
PC
3	
	E
N2
	O
-E
PC
3
W
PM
Y1
C-
te
rm
	1
00
	a
a
C-
te
rm
	1
00
	a
a
C-
te
rm
	1
00
	a
a
C-
te
rm
	1
00
	a
a
178  
Figure 5.5. Western blot analysis of cell lines using the Sheep anti-EN2 antibodies. First lane is 
the protein standard marker. The ELISA peptide (detects the last 100aa of EN2’s C-terminus) was 
used as a positive control for the c-terminus targeting antibodies and negative control for n-term 
targeting antibodies. All cell lines are labeled above the lanes and the antibodies used are labeled on 
each western blot. 
! These western blot results highlighted the lack of specificity for some of these 
EN2 sheep antibodies. In particular: Ab24; Ab4; Ab2; and the goat anti-EN2 
antibody. However, Ab16, APS2 and Ab32 detected a single band at 40kDa, which 
corresponds to the size of EN2 that has been detected in the literature (Martin et al. 
2005). Ab2, Ab4 and Ab16 detected much more of the EN2, at 40kDa, from EN2 
plasmid transfected PC3 cells, but were not as specific. However, this may have 
been due to differences in antibody concentration and so individual optimisation 
would have been beneficial. 
5.4.6 GFP-EN2 secretion and internalisation by PC3 cells 
! The observation that EN2 was contained within microvesicles indicated that it 
might be less accessible to a therapeutic antibody. EN2 secretion from PC3 was 
therefore further investigated in order to better understand the mechanisms by 
which it was internalized using live cell imaging. 
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Figure 5.6. Time-lapse confocal microscopy of PC3 cells transfected with GFP-EN2. a) 
Internalisation of the microvesicles was observed in GFP-EN2 expressing cells only (depicted by the 
white arrows) b) Staining with WGA (red) membrane marker seemingly revealed that the direct 
intercellular transfer of GFP-EN2 was dependent on cell-cell contact and the subsequent migration 
and aggregation of cells. The arrows highlight the cells that are involved in the EN2 transfer when 
they are in contact. Live cell imaging was carried out with X40 magnification and up to 24 hours. 
! ! EN2 containing vesicles were again observed (Figure 5.6a) that were 
seemingly only taken up by other GFP-EN2 expressing cells. The images also 
revealed that EN2 was able to transfer inter-cellularly via multiple mechanisms, 
although it is unclear whether other mechanisms exist for PC3 cells and whether the 
direct transfer of EN2 (Figure 5.6b) is exclusive to PC3 cells. 
! Taken together, Figure 4.8c (Chapter 4) and Figure 5.6a showed that PC3 
was the only cell line of those tested that produced EN2 containing vesicles.
a)
b)
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5.4.7 pH-dye conjugated EN2 antibodies to determine EN2 antibody         
internalisation 
! Using the information gained in Sections 5.4.5 and 5.4.6 experiments the 
goat EN2 antibody, Ab32 and Ab2 were used for the internalisation assay. The goat 
anti-EN2 antibody was used to further investigate its specificity. The sheep 
antibodies were both shown to detect EN2 by ICC and western blot assays (Figure 
5.5); and bind to opposite ends of the protein. The cell lines tested were LnCaP, 
PC3 and WPMY-1; all of which have shown in this study to regulate EN2 differently. 
These antibodies, along with the relevant isotype IgG control antibody, were 
conjugated to a pH amine reactive dye that fluoresced at low pH. 
Figure 5.7. pH amine-reactive dye conjugation verification. a) The newly conjugated pH-
antibodies were denatured and loaded onto a gel for coomassie staining, lane 1 is the protein 
b)
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standard marker, the blue arrow points to the repeat coomassie staining of the goat anti-EN2 
antibody conjugated and unconjugated both native and denatured. b) Conjugated antibodies were 
then tested for their ability to fluoresce under low pH. c) Fluorescent image of antibody aggregates 
that can contaminate assays by producing a false signal.
! The antibodies were found to still be intact after conjugation as both the 
heavy (50kDa) and light (23kDa) chains could be detected using coomassie staining 
(Figure 5.7a). However, the goat anti-EN2 antibody failed to denature correctly at 
the first attempt. After further repeating the assay, the conjugated goat antibody 
successfully denatured and the heavy and light chains were detected at the correct 
size. However, the control, unconjugated antibody (even without denaturation) had 
broken down and created a number of artefacts contaminating the blot. This 
suggests that the antibody is either not stable at -20℃ or that it became unstable 
before it was loaded onto the gel.
! The conjugated antibodies fluoresced after changing the media to pH 4 
(Figure 5.7b). Under fluorescence microscopy, these antibodies aggregated and 
created artefacts. This problem was subsequently overcome by vortexing and 
spinning down the antibody to collect the aggregates at the bottom of the tube prior 
to use. In order to optimise the methodology a time-course assay was performed 
using the pH-conjugated anti-clathrin antibody as a positive control; and a range of 
cell lines were included (Figure 5.8a). The fluorescence emitted was measured as 
this equated to the amount of antibody internalisation. 
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Figure 5.8. pH internalisation assay optimisation. a) pHAb-conjugated antibody was incubated for 
18, 36 and 42 hours to find the optimal time needed for the antibody to be internalised enough to 
! emit a strong enough signal to be picked up. b) The cells were imaged at 36 hours at X20 
magnification to capture the fluorescent signal emitted, alongside a blue (fluorescent) nuclear dye to 
identify the cells. 
! In Figures 5.8a and b the optimal detection time was shown to be 
between18-36 hours as cells appeared to begin apoptosis at 42 hours (Figure 
5.8a). Clathrin plays a major role in endocytosis and so the anti-clathrin antibody 
was included as a positive control (McMahon & Boucrot 2011). Fluorescent imaging 
and direct fluorescent measurements after 36 hours incubation revealed an increase 
in fluorescence, whilst there was decreased fluorescence with the EN2 antibodies 
compared to the anti-clathrin antibody. This is most likely due to the variability of 
dye-to-antibody ratio (DAR) and the quality of antibodies. These limitations made it 
difficult to optimise the assay for all antibodies in one experiment. Consequently, 24 
hours was chosen as the optimal time for incubation. 
! In addition, a sheep IgG control was used under the same conditions to 
measure background (unspecific) internalisation, which differed markedly between 
cell lines (Figure 5.9a and b). This allowed the fluorescence to be normalised for a 
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more accurate comparison. The optimum time the conjugated antibodies was then 
normalised further by using the same concentration of each for each sample. 
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ratio. b) The fluorescence microscope captured red fluorescence emitted from Sheep (anti-EN2) Ab2 
and Ab32 under artificial pH4. c) Cells were imaged under a fluorescence microscope at X20 
magnification after 24 hours incubation with the EN2 pH-conjugated antibodies, Ab2 (top) and Ab32 
(bottom). Ab2 showed a higher amount of red fluorescence with LnCaP cells than WPMY-1 cells and 
the Ab32 assay. To the right of both figures the fluorescent images for LnCaP were enhanced by 
increasing the exposure. 
! The results shown in Figure 5.9c revealed LnCaP had the highest antibody 
internalisation with Sheep Ab2, (anti-EN2) antibody. This was not unexpected as 
LnCaP produced the highest protein expression with HaloTag®-EN2 and revealed a 
high degree of proteolysis that could still be detected with Ab2. PC3 antibody 
internalisation was very low for both EN2 antibodies (Ab2 and Ab32), which might 
reflect the secretion of GFP-EN2 in microvesicles in this cell line that could prevent 
antibody binding. The PC3 GFP-EN2 stable cell line did not produce more 
fluorescence or antibody internalisation compared to non-transfected PC3 cells 
(data not shown). 
5.4.8 Identifying GFP-EN2 containing microvesicles from PC3 cells
! Figure 4.9 (Chapter 4) shows GFP-EN2 encapsulated within microvesicles 
from PC3 cells. No secretory vesicles were seen with LnCaP, which is derived from 
a less aggressive cell line. In order to further characterise these microvesicles, 
secretion was observed over time using live cell imaging.
! Live cell imaging over 24 hours captured vesicle secretion from PC3 GFP-
EN2 transiently-transfected cells (Figure 5.10a). Figure 5.10b is a plot of the ratio 
of fluorescent change over time. The spike at 60,000 seconds is consistent with the 
secretion captured in the image stills (Figure 5.10a). This rapid secretion of a large 
number of microvesicles would suggest that EN2 secretion is a regulated process, in 
agreement with the findings of Maizel et al (Maizel et al. 2002).   
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Figure 5.10. PC3 GFP-EN2 (transient) time-lapse confocal microscopy stills. a) Stills of PC3 
after transient transfection with GFP-EN2 live cell imaging up to 24hrs with X40 magnification. b) 
GFP-EN2 fluorescent detection of PC3 after transient transfection with GFP-EN2 live cell imaging up 
to 24 hours. c) Images of the vesicles formed within the cell which contain GFP-EN2. Far right image: 
the scale bar is 50µm wide. DOI: https://dx.doi.org/10.6084/m9.figshare.4076337.
! If these microvesicles were to be used as a source of EN2 detection, perhaps 
as an additional or alternative biomarker test, it is important to further define them. 
The scale bar suggests that these vesicles are approximately 1-2µm, which is 10 
times the normal size of exosomes (Figure 5.10c). These microvesicles are also 
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seemingly created within the cell as opposed to forming at the cell surface (Figure 
5.10c). 
! After isolating the microvesicles, electron microscopy was used to image 
them. Microvesicles isolated from PC3 cell culture media appeared to have been 
disrupted by ultracentrifugation. On the left (Figure 5.11a), the vesicles were 
obtained using the Norgen kit only (which used precipitation, as outlined in Chapter 
3, Section 3.23.2) and have a distinct round shape whereas in the right picture 
(Figure 5.11a), the microvesicles were obtained through ultracentrifugation and 
appear flattened and unevenly shaped. 
!
Figure 5.11. Electron microscopy of fixed microvesicles. a) Left image: microvesicles were 
obtained without ultracentrifugation and concentrated with 100MWCO concentrator only. Right 
image: microvesicles were obtained by ultracentrifugation. Both were imaged at 15kV, x30,000 
magnification. b) Left image: commercially bought PC3 exosomes were used as a positiive control. 
Right image: microvesicles were obtained from a serum sample obtained from a healthy volunteer. 
The Norgen (precipitation) kit was used to isolate the microvesicles and imaged at 15kV, x45,000 
magnification.
PC3	commercial	exosomes	
(15kV,	x30000)
- ultracentrifuge +	ultracentrifuge
Healthy	serum	
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b)
(15kV,	x45000)
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! The Norgen Exosome Purification Kit ensured that the microvesicles stayed 
intact (Figure 5.11b) and so the kit was used thereafter. The isolated microvesicles 
were further investigated to determine their exact size and to quantify their CD9 
expression, which is an exosomal marker (Caby et al. 2005; Mizutani et al. 2014) in 
Figure 5.12 below. 
Figure 5.12. Further analysis of PC3 isolated microvesicles. a) CD9 ELISA for CD9 detection in 
microvesicles isolated from a positive control (PC3 media spiked with 10µg of purified exosomes), 
PC3 media alone and patient serum. b) NanoSight analysis of serum isolated by the Norgen 
Exosome purification kit. c) NanoSight analysis of patient serum fraction 8 after isolation by size 
exclusion chromatography. d) NanoSight analysis of microvesicles from PC3 GFPEN2 stable cell 
media (fraction 8) after isolation by size exclusion chromatography. 1st, 2nd and 3rd data sets 
represents three repeats of the same sample and reveal particle aggregation over time. 
! A lower amount of CD9 was detected in the microvesicles from PC3 culture 
media and patient serum compared to the spiked (purified exosomes) control 
a) b)
c) d)
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(Figure 5.12a). These isolated vesicles probably represent a mixed population, 
which is verified by nanosight analysis of the patient serum (Figure 5.12b). The 
nanosight revealed the population, isolated by the Norgen kit, to be made up largely 
of microvesicles sized between 200-800nm (Figure 5.12b). Thus the vesicles seen  
in live cell imaging were unlikely to be exosomes. 
! Size exclusion chromatography was used to separate the different sized 
vesicles. The nanosight showed that fraction 8 consisted mainly of vesicles sized 
approximately 55nm, for both serum and PC3 cell culture media (Figure 5.12c and 
d). Therefore, it is possible to analyse these different sized populations and to 
further define them if necessary. The isolated fractions were analysed by mass 
spectrometry, to confirm the presence of EN2 - as of writing we are still awaiting the 
results.
5.4.9 Tracking EN2 secretion and internalisation from prostate cancer cell          
lines with NanoLuc®EN2 de novo expression and Nano-Glo® detection assay
! To track EN2 secretion and to investigate the differences between cell lines 
regarding EN2 regulation EN2 was tagged to NanoLuc®. This allowed EN2 to be 
detected, in real-time, whereby the amount of luminescence given off could be 
normalised to calculate the relative amount of EN2 present (in the media or within 
cells). 
! EN2 was first cloned into the N-terminus NanoLuc® vector (Nluc®-EN2) and 
serially diluted for expression in LnCaP cells. The correct EN2 protein size was 
initially verified through a western blot (Figure 5.13a) that included the positive 
control secNluc, a constitutively-secreted protein. The mRNA and luminescent 
detection in media increased as the amount of EN2 plasmid (µg) increased (Figure 
5.13b), indicating that the assay was specific for EN2. This was carried out using an 
anti-NanoLuc® antibody which detected a single band only. NanoLuc® is 19kDa and 
the fusion protein was detected around 55kDa, corresponding to the predicted mass 
of EN2 (approximately 36kDa). Figure 5.13c shows the bioluminescent signal 
captured by the NanoGlo® detection assay from LnCaP when transfected with 
secNluc, Nluc®-EN2 and media only (no transfection) after 48 hours. 
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Figure 5.13. NanoLuc®-EN2 expression in LnCaP. a) The size of EN2 was confirmed after cloning 
EN2 into the NanoLuc® plasmid (N-terminus tag) by a western blot assay using a rabbit anti-
NanoLuc® antibody (Promega, UK) and goat anti-EN2 antibody (Abcam). b) The Nano-GLO® assay 
was tested for its specificity to NanoLuc®-EN2 detection (in LnCaP cell culture media) by serial 
dilution of the NanoLuc®-EN2 plasmid transfected into LnCaP cells that was confirmed by RT-qPCR 
and calculated as a fold increase from media only transfected LnCaP. c) LnCaP cells were 
transfected with the NanoLuc®-EN2 and secNluc and the protein expression was measured 48 hours 
later with the NanoGLO® assay. 
! ! The rabbit anti-NanoLuc® (Nluc) antibody was not commercially 
available and was kindly provided by Promega (US). However, this meant that the 
antibody had not been optimised, the detection signal was quite weak and would not 
be sensitive enough for additional downstream analysis such as detection after 
inter-cellular transfer. 
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! In order to determine whether the uptake of EN2 varied between cell lines the 
experiment was designed to explore whether there was preference, in EN2 
internalisation, between the most aggressive cell line (PC3) and least aggressive 
cell line (LnCaP); and also between a normal (immortalised) cell line (WPMY-1) and 
the two cancer cell lines. 
Figure 5.14. Nano-GLO® detection assay for regulated internalisation of Nluc-EN2. The Nano-
GLO® reagent measured the amount of luminescence emitted from the sample, secNluc was used 
as the positive control and a media only negative control was included. a) Nluc-EN2 was detected in 
the media to ensure that similar amounts of EN2 were present for each cell line at the beginning of 
the experiment. This was plotted as a fold increase against the media only control and the average of 
three repeats. b) Nluc-EN2 was detected 36hrs later in the cells. This was plotted as a fold increase 
against the media only control and the average of three repeats. c) Regulated internalisation was 
determined by calculated the selective uptake of Nluc, which meant normalising values to the 
secNluc positive control in order to take into account differences in the rate of internalisation between 
the cell lines. 
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! The results show that the same amount of secNluc and NLuc-EN2 were 
present in the conditioned media as the experiment began. EN2 is generally taken 
up by all cells as a luminescent signal is detected within the cells, which was made 
visible with NanoGlo® (Figure 5.14b). 
! In order to determine whether there was regulated uptake, the signal was 
normalised to the secNluc positive control, to account for the rate of internalisation 
between the cell lines. The results revealed that differential uptake of Nluc-EN2 as 
PC3 internalised the least and LnCaP took up the most Nluc-EN2. Importantly, this 
supports the observation that the more aggressive cancer cell line the more 
redundant EN2’s role. The results also revealed that WPMY-1 internalised EN2 and 
thus, this process may not be regulated. The unspecific nature of EN2 internalisation 
must be taken into consideration when using EN2 for therapy as EN2 targeted drugs 
may not exclusively be internalised by the cancer cells and thus, this requires further 
investigation.
! In addition, the results of Figure 5.14 support those of the pH internalisation 
assay that also revealed LnCaP to have the highest rate of EN2 internalisation. It is 
yet to be defined whether this is due to intercellular transfer, cell surface localisation, 
or the accessibility of EN2.
!
5.5 Discussion
! The aims of the work described in this chapter were to quantify EN2 on the 
cell membrane of prostate cancer cells, investigate the mechanism and regulation of 
EN2 secretion and internalisation, validate EN2 as a marker, and provide a rationale 
for utilising EN2 as a target in prostate cancer.
! The initial experiments used to determine the membrane localisation of EN2 
were carried out using the goat anti-EN2 antibody previously referred to in Chapter 
4, which was shown to produce spurious western blot data. Nevertheless, the ICC 
experiments showed EN2 co-localisation with the WGA membrane marker, and 
GFP-EN2 was used to confirm the antibody finding. This was carried out with 
transient and stable expression of GFP-EN2 and a GFP only control in prostate cell 
lines. Although PC3 cells could stably integrate the GFP-EN2 plasmid, WPMY-1 
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cells underwent apoptosis when transfected with GFP-EN2 (this finding is explored 
further in Chapter 6). The co-localisation studies were able to show that GFP-EN2 
protein occupied discreet areas of the membranes on PC3 cells transiently or stably 
expressing GFP-EN2, which was not the case for WPMY-1 cells or GFP only 
controls (transient and stable). 
! In order to follow up on this observation that EN2 was present in discreet 
areas of the membrane, the portion of EN2 on the cell surface was identified using a 
series of antibodies to establish whether it would be ultimately possible to generate 
an EN2-targeting antibody for therapy. In Chapter 4 it was determined that EN2 was 
highly susceptible to proteolysis (Figure 4.14), in LnCaP cells (at the N-terminus). 
Furthermore, Figure 4.5 (Chapter 4), showed that EN2 C-terminus was highly 
polarised, which means that it is ‘sticky’ and has an increased likelihood of binding 
to another membrane-bound protein; the C-terminus was hypothesised to be 
accessible on the membrane (Section 5.3). Correspondingly, it was found that the 
antibody that detected the most EN2 on the cell surface of the PC3 cells was sheep 
Ab32 that binds very close to the C-terminus. The panel of sheep antibodies were 
then further tested for EN2 specificity using a western blot analysis. This showed 
that the Ab32 was specific only to the EN2 41kDa band (in line with the literature, 
(Martin et al. 2005)) and did not detect any of the unspecific bands that the other 
antibodies also picked up. Interestingly, Ab32 was one of the few that did not pick up 
the 50kDa band. Ab2 was also used in the next assay as it recognised an epitope at 
the opposite end of the protein, this was especially important because EN2 was 
found to be cleaved at the N-terminus. The fact that some antibodies detected a 
greater number of non-specific bands than others (such as Ab2) could have been 
due to the differences in antibody concentration.
! As the end-goal is to attach a drug to Ab32, it was imperative to know 
whether the antibody could be internalised by the cancer cell. Unfortunately, if Ab32 
could not be internalised, then the drug would most likely concentrate itself outside 
the cancer cell or be taken up by normal cells close by, both of which could cause 
large cytotoxic effects at a later stage. If this is the case and the antibody is further 
determined to not be internalised, engineered T cells against EN2 might be a better 
option such as chimeric antigen receptor (CAR) T cells (Fesnak et al. 2016). To 
develop these, the antigen binding regions of the monoclonal antibody (anti-EN2) 
are fused to the T cells however, it would not rely on the antigen localising (stably) 
on the cell surface or on antibody internalisation, in order to be effective. Instead, 
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these CAR T cells detect the MHC-EN2 complex and not EN2 alone (Sadelain et al. 
2013; Guo et al. 2016). Alternatively, if it could be proved that blocking EN2 
secretion had the potential to cause large-scale cell apoptosis or significantly halt 
tumour progression alone (explored further in Chapter 6), than another option would 
be to use the antibody without modification to simply block EN2 secretion or a 
blocking peptide similar to EN1 (A. S. Beltran et al. 2014). 
! In order to determine the extent of antibody internalisation, Ab32, Ab2, and 
the goat anti-EN2 antibody were each conjugated to the pH amine-reactive dye 
along with their IgG control antibodies. This dye fluoresced at low pH (such as the 
environment of an endosome). The greatest fluorescent signal was observed in 
LnCaP cells after incubation with Ab2, which binds towards the N-terminus of the 
protein. As EN2 is secreted and internalised, it is difficult to know whether EN2 was 
stable on the cell surface and subsequently internalised with the antibody or whether 
the antibody was internalised during intercellular transfer. If the latter proved true, 
further investigation would be needed to make sure that the EN2 intercellular 
transfer was cancer cell specific a regulated process. Alternatively, the extracellular 
EN2 could have been a hindrance to antibody internalisation. In either case, it was 
important to establish whether EN2 was taken up through a regulated process by 
the cancer cells or normal cells in the tumour microenvironment.  
! To investigate whether EN2 was taken up by a regulated process once in the 
tumour microenvironment and to understand more about its regulation, Nanoluc® 
technology (Promega, UK) was employed. Tagging EN2 to Nanoluc® allowed EN2 to 
be detected by a simple luminescence assay. However, because EN2 is a ‘sticky’ 
protein (as shown in Chapter 4, Figure 4.5) EN2 could still have been present on 
the cell surface despite several washes because of strong protein-protein 
interactions with a membrane bound protein. This in turn would make it more difficult 
to determine whether it is truly membrane bound. Consequently, EN2 that was still 
on the membrane were unavoidably ‘cell-associated’ rather than free (in the culture 
media). The likely limitation here is not being able to factor in the differences in cell 
surface area, especially when EN2 extracellular detection has been shown to 
positively correlate with tumour volume (Pandha et al. 2012). WPMY-1 has a large 
surface area and could potentially have a larger amount of EN2 binding to the 
outside of the membrane without actively taking up EN2. This could also explain 
why more EN2 is detected within WPMY-1 over PC3 cells (a much smaller cell). 
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Therefore, is it not clear whether there is regulated uptake of EN2 between normal 
cells and cancer cells. 
! When exploring the transfer of EN2 between cells, the results indicate that 
the source of EN2 is important. The Nanoluc® results show that the mechanism of 
free EN2 transfer favours EN2 intake by LnCaP over PC3. In both chapters 
(Chapter 4 and 5) it was shown that PC3 cells secreted EN2 protein in vesicles, 
most likely in order to protect it from proteolysis (Figure 4.9 (Chapter 4) and Figure 
5.6). Conversely, LnCaP cells (which was used to produce EN2 in this chapter) had 
detectable cleaved amounts of EN2 that was also secreted into the media (as 
proven in the western blot in Figures 4.14 (Chapter 4) and 5.13. Furthermore, EN2 
housed within large secretory vesicles (approximately 2µm) would not have been 
detected by this assay because the pore size of the membrane was too small (only 
0.4µm). It was therefore not surprising that EN2 was not efficiently taken up by PC3 
cells from conditioned media. However, detectable levels of free EN2 are secreted 
from the LnCaP cell line only based on the western blot (Chapter 4, Figure 4.14) 
and NanoGLO® analysis of media after transfection (Figure 5.14a). In hindsight, an 
additional control that could have been carried out was to repeat the same 
NanoGLO® assay using PC3 as the source of EN2, which could have confirmed the 
inefficiency of EN2 transfer between PC3 cells when simply transferring media. 
Based on these considerations, PC3 cells (for EN2 transfer) may rely heavily on 
microvesicles as a form of regulated internalisation or intercellular transfer (to be 
investigated in Chapter 6); PC3 cells do not readily take up free EN2 from the 
media, when compared to LnCaP cells. It also again reflects the limitations of the 2D 
experimental setup, and provides a rationale for further investigation in a 3D setting.
! Morgan et al showed that, in urinary bladder (R. Morgan et al. 2013) and 
prostate cancer (R. Morgan et al. 2011), higher grade tumours produced less EN2 
protein. They hypothesised that this is due to the poor (and highly undifferentiated) 
structure of high grade tumours which consequently allows for a more effective 
release of EN2. The in vitro results in Chapters 4 and 5 also reflect this, as EN2 
was more readily secreted from PC3, a highly metastatic cell line with an aggressive 
phenotype, compared to LnCaP (a less metastatic cell line). However, the artificial 
insertion of EN2 does not reflect true EN2 behaviour in vivo and the significance that 
tumour structure plays compared to the regulated secretion of EN2 (within 
microvesicles) in the total amount of EN2 that is secreted is unclear. 
196  
! Based on all of these considerations, the following EN2 regulatory 
mechanism is proposed (depicted in Figure 5.15): low grade tumours cannot 
efficiently shut down or down-regulate EN2 protein expression and protein 
production is upregulated, which means that as EN2 is being secreted it is 
replenished within the cell. However, as the tumours progress to higher grades EN2 
is no longer required and therefore EN2 protein production is shut down. 
Consequently, as EN2 is secreted it is not being replaced and so the levels of EN2 
within the cell decreases and eventually EN2 detection in the urine (media) 
deceases. Thus, the ability to utilise EN2 as a biomarker in the urine of prostate 
cancer patients is likely restricted. EN2 detection in the urine positively correlates 
with tumour volume at early stages and is unlikely to correlate with tumour grade 
due to the promoted secretion of EN2 and protein down-regulation as tumours 
progress. 
Figure 5.15. Proposed EN2 mechanism of regulation from low to high grade prostate tumours. 
EN2 mRNA stays fairly consistent whilst EN2 protein, along the tumorigenic pathway, is heavily 
downregulated and consequently the secretion of EN2 also declines later on. Blue line is the amount 
of EN2 secretion; the redline is the amount of EN2 protein being translated and the grey line is the 
amount of mRNA present. 
! The stage at which EN2 starts to be tightly regulated (pre- or post- 
transcription or translation) is not clear. As detectable levels of EN2 mRNA are still 
present in PC3 cells it is conceivable that it occurs at a post-transcriptional level and 
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involves a process such as alternative splicing, RNA editing and microRNA 
translational repression (Ryazansky et al. 2011) but further work is needed to 
confirm this.
! As more aggressive tumours secrete more EN2 but retain correspondingly 
less of this protein (western blot data), increased EN2 should be correspondingly 
detected outside in the urine or in stromal cells in the microenvironment (Guan et al. 
2014). Brunet et al showed that EN2 is released as a means to guide retinal axons 
extracellularly, and Joliot et al showed that EN2 was associated with caveolae-like 
domains (Brunet et al. 2005; Joliot et al. 1997). Therefore, EN2 is secreted from live 
cells for a purpose yet to be explained in cancer, but EN2 is highly likely to be 
involved in cell-cell communication (Prochiantz & Joliot 2003; Brunet et al. 2005). To 
take this forward it would be beneficial to determine whether: EN2 is more likely to 
be taken up by normal cells, once secreted, in order to aid the tumorigenesis 
process; or whether it is internalised by neighbouring cells, where it could have a 
secondary tumorigenic role most likely involving local protein synthesis (Nédélec et 
al. 2004). Unfortunately, due to the sticky properties of EN2 and the limitations of a 
2D experimental setup, the results presented here do not allow a firm conclusion to 
be drawn, and further study is needed.
! The findings of the experiments on microvesicle secreted from PC3 cells also 
failed to define them unambiguously. The electron microscopy and NanoSight 
analysis revealed a mixed population that mainly consisted of vesicles 10 times too 
big (approximately 2µm instead of 0.2µm) to be exosomes. It was not possible to 
confirm whether EN2 was present within them as there was no reliable or sensitive 
antibody to do so. Perhaps, after learning that the vesicles clumped together (as 
shown by the NanoSight analysis in Figure 5.12) and the 100MWCO spin 
concentrators were actually reducing the amount of exosomes in the sample, it 
would have been beneficial to repeat the experiments without concentrating the 
media. 
! The isolation of a specific population of vesicles was successful from serum 
and cell culture media (Figure 5.11 and Figure 5.12). The best methodology to do 
so was precipitation and size exclusion chromatography. Despite not defining the 
large vesicle population GFP-EN2 is still present within them (fluorescence 
detection) and this study provides both a protocol for isolating a specific population 
and a rationale for further investigating EN2 in these microvesicles.
198  
! The functions of microvesicles in cancer, predominantly exosomes, have 
been reported to be the transport of molecules between cells and the modification of 
the tumour microenvironment. It has also been reported that a large population of 
microRNA’s are present (J. Zhang et al. 2015) within them. It may be possible to use 
mass spectrometry to identify a signature panel of biomarkers (miRNA, mRNA and 
proteins) within a subset of these vesicles. This could make a much more sensitive, 
robust and non-invasive diagnostic and/or prognostic test. Due to the size of these 
microvesicles there is a possibility that they are ‘prostasomes’, which have recently 
been reported in the literature to be released from PC3 cell lines (G. K. Ronquist et 
al. 2012; Llorente et al. 2004) and internalised by them too. 
5.6 Conclusion
! ! Further work is needed before it can be satisfactorily demonstrated 
that EN2 can be used as a target for an antibody-drug conjugate. It is evident that 
EN2 has the ability to transfer between cells in culture, but the exact mechanism 
and the significance for this remain unclear. In Chapter 4, it was shown that the cell 
lines differed markedly in the way they regulated and secreted EN2, which is further 
confirmed in this chapter. 
! LnCaP cells that cleave EN2 were able to internalise Ab32 and Ab2, 
suggesting that free EN2 is transferred between the cells are easily accessible to 
these antibodies as opposed to vesicle-associated EN2. Alternatively, there is 
altogether a larger amount of EN2 present on LnCaP membranes. As LnCaP cells 
represent low grade prostate cancer it falls in line with the theory that the rate of 
EN2 secretion increases with increasing metastatic potential. Therefore, for PC3 
cells that encapsulate EN2 within microvesicles, both Ab32 and Ab2 were unable to 
show internalisation. Furthermore, there is likely to be low amounts of EN2 on the 
cell surface as the PC3 cell line is highly metastatic (representing high grade 
prostate cancer). 
! When EN2 is secreted within microvesicles they are readily taken up by other 
GFP-EN2 PC3 cells (live cell imaging) and thus, providing further evidence for 
differential uptake of PC3 secreted microvesicles, EN2 transfer being a regulated 
process and hints at an involvement in cell-cell communication. 
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6. Exploring the role of EN2 in cancer
6.1 Introduction
! In order to further identify the pathophysiological effects of EN2 in cancer, this 
chapter focused on exploring both the cell autonomous and cell non-autonomous 
roles of EN2. The reports on EN2 in the literature, in regards to development and 
cancer, have been used to guide the experiments designed in this section. The 
findings of this study support a role for EN2 in cell-cell communication that relies on 
its regulation and localisation, with differences between normal, low and high grade 
tumours, and indicates that EIF4E is a candidate downstream effector. 
6.2 Background 
! EN2 in development has, thus far, been assigned to or implicated in the 
following roles: segment-polarity (Millen et al. 1995), axon guidance (Brunet et al. 
2005), vesicle formation and transport (Holst et al. 2008), transcriptional activation/ 
repression (Gemel et al. 1999) and translational regulation (Nédélec et al. 2004). 
EN2 expression continues in the adult, although its expression is restricted to the 
Purkinje cells (Albéri et al. 2004) and it is expressed at low levels only, and is 
believed to be required for the continued survival of neurons (Fuchs et al. 2012), 
where they showed that low levels were retained. It could be that cancer cells 
require EN2 to promote and enhance cell survival, which was identified for EN1 (A. 
S. Beltran et al. 2014)). The function of EN2 is further detailed in Section 2.3.2.
! During development EN2 functions primarily as a transcriptional repressor (Choi 
et al. 2011) and regulates cell identity and differentiation, functions that it may also 
have in cancer cells. As the purpose of EN2 expression in cancer cells is not yet 
known, a better understanding of its spatial and temporal expression patterns (along 
the tumorigenic pathway) and its localisation, could help further our understanding. 
Recent reports from (Lai et al. 2014) and (Guan et al. 2014) support the findings in 
Chapter 4 and 5, which suggests that larger amounts of EN2 are found in the 
tumour microenvironment and that lower expression in the tumour is indicative of 
poor prognosis (R. Morgan et al. 2013; Lai et al. 2014). This unusual and highly 
complex expression pattern, found in prostate cancer (McGrath, Michael, et al. 
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2013) and other cancers (Lai et al. 2016), which may reflect the tight special and 
temporal control during development. 
! In Chapter 4, we found that EN2 seemingly caused apoptosis in WPMY-1 cells 
and this will be further explored in this Chapter. The apparent pro-apoptotic function 
of EN2 may explain why a GFP-EN2 WPMY-1 stable cell line was unable to be 
created, though this was not the case for PC3. It was therefore imperative to look at 
the relationship between EN2 expression and apoptosis in these cell lines. Further 
evidence is provided by (Lai et al. 2014), which revealed that EN2 inhibition led to 
reduced apoptosis. This is an interesting finding as EN2 is required for neuron 
survival in the adult. Thus, EN2 could act as a switch between cell survival and 
apoptosis. 
! It was important to further uncover the mechanism by which EN2 is secreted and 
internalized; and to establish whether it is a regulated process or not. This would 
ensure minimal side effects are endured during therapy because if EN2 were to 
transfer unspecifically to any cell (including healthy cells) it could also take up the 
EN2-ADC complex. It is already well-known that there is a general increase in 
nuclear-cytoplasmic transport in cancer (Hill et al. 2014) and it is conceivable that 
this might also be true for protein secretion. 
! However, evidence in Chapter 5 reveals that EN2 is packaged into large 
vesicles (and are likely protected from proteolysis) and taken up by neighbouring 
cells. This is only seen in PC3 cells, which are highly metastatic and therefore 
representative of high grade tumours. The EN2 homeodomain (HD) has been 
recently studied in a membrane mimicking environment to observe its interaction 
and insertion into lipid micelles (representative of vesicles) (Carlier et al. 2013). This 
study revealed that EN2 HD forms a tight protein:micelle complex, deeply 
embedding each helical segment at the core (Carlier et al. 2013). 
! It is known that factors in the tumour microenvironment have an important role in 
regulating RNA and protein expression - the signals exchanged between the stroma 
and other neighbouring cells can dramatically alter cell signaling (Quail & Joyce 
2013; M.-Q. Gao et al. 2010). EN2, in development, is able to manipulate the 
environment by building an external gradient that repels optic axons and attracts 
nasal axons (Brunet et al. 2005). In addition, it was found that extracellular EN2 was 
able to make growth cones more sensitive to Ephrin A5. This action is vital to the 
patterning of retinal axon terminals during development (Stettler et al. 2012). It is 
plausible that EN2 has a similar role in cancer (when in the microenvironment) but 
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the exact role is unclear, particularly in the context of prostate cancer. Similarly, the 
role of EN2 once it is internalised by surrounding cells - prostate epithelial cells or 
other cancer cells -  it not completely understood.    !
! The results of Chapter 4 and 5 confirmed that secretion was a regulated 
process, especially in highly metastatic or aggressive cell lines such as PC3 as EN2 
was secreted within microvesicles. Chapter 5 explored regulated internalisation but 
the results are unclear. However, this could be because media conditioning and 
transferring does not allow for cell-cell communication. Time-lapse confocal 
microscopy in Chapter 5 revealed that the intercellular transfer of EN2 occurred 
through direct contact between cells or through vesicle transfer. Moreover, the 
antibody internalisation assay (Figure 5.8) was not highly successful with PC3 
showing little or no antibody internalisation. Thus, in order to make an antibody-drug 
conjugate or any drug, further evidence is required to show selective uptake by 
cancer cells over normal cells; taking into consideration the experimental setup that 
should allow for cell-cell communication and contact. 
! Few reports exist that have explored the pathophysiological effects of EN2 in a 
cell autonomous manner and those identified thus far are: loss of contact inhibition; 
slowed proliferation; increased apoptosis and weakened invasive ability (Martin et 
al. 2005; Bose et al. 2008; Lai et al. 2014). Bose et al reported PAX2 as an 
activating transcription factor of EN2 that is potentially regulated by a feedback 
mechanism as a result of EN2 expression (Bose et al. 2008). In contrast, the non-
autonomous effects of EN2 are largely unexplored in cancer (Section 2.3.3). EN2 
has been shown to induce rapid phosphorylation of proteins involved in translation 
initiation (Brunet et al. 2005), which could include EIF4E (Nédélec et al. 2004). 
! Intriguingly, for cell lines such as PC3 that are derived from highly metastatic 
disease, EN2 is primarily cytoplasmic (Chapter 4 and 5), indicating that it might in 
fact regulate translational rather than transcription, especially as it can bind to the 
EIF4E translational initiation factor (Topisirovic & Borden 2005; Nédélec et al. 2004). 
EIF4E is usually the rate-limiting factor in protein translation and its increased 
availability and/ or overexpression have been associated with tumour progression 
(Xu et al. 2016) and thus, can be considered as an oncogene (Carroll & Borden 
2013; Konicek et al. 2008). There have been several reports of homeoproteins 
residing close to or on the cell surface and affecting local protein synthesis during 
development, such as VAX1 (Kim et al. 2014), EMX2 , OTX2 and EN2 (Nédélec et 
al. 2004) all of which have been found in axons. Furthermore, EMX2 was shown to 
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bind to EIF4E in vesicles near the cell surface where it interacts with EIF4E. Both 
Emx2 and EIF4E proteins failed to detach from ‘high-density fractions enriched in 
vesicles and granular structures’ even after treatment with detergent and RNase 
(Nédélec et al. 2004). These large vesicles could be similar to the vesicles secreted 
by PC3 cells in Chapters 4 and 5 (Figures 4.6 and 5.8). It was suggested that 
Emx2 could be regulating mRNA localisation and local protein synthesis to aid 
axonal growth through its interaction with EIF4E (Nédélec et al. 2004). EN2 and 
EIF4E could carry out similar functions to Emx2 and EIF4E. Interestingly, some of 
the downstream targets of EIF4E include pro-survival proteins (BCL-2, Survivin) and 
tumour invasion and metastasis proteins (MMP-9, heparanase) (Konicek et al. 
2008).
! A recent report identified the PBX binding domain of EN2 as being integral to its 
ability to transfer between cells (in a zebrafish model), and that EN2’s secretion has 
both intracrine and paracrine activity that work towards the same goal, patterning 
the brain, but do so using distinct mechanisms (Rampon et al. 2015). Another 
downstream effector of interest is MAP1B due to its ability to regulate the 
cytoskeleton, and induce vesicle formation and membrane blebbing, all of which 
have featured in this study. More importantly, MAP1B is has been reported to be 
under the transcriptional control of homeoproteins (Montesinos et al. 2001). 
6.3 Chapter objective, hypothesis and approach 
! The objective of this chapter (taken from Section 1.5) was to:
5. further investigate EN2’s cell autonomous and cell non-autonomous role
! In order to test this, the following experiments were performed:
‣ Time-lapse confocal microscopy of EN2-GFP (C-terminus tag)              
transiently transfected into prostate-derived cell lines in order to 
observe the intercellular transfer of EN2 and cell behaviour
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‣ Time-lapse confocal microscopy after GFP-EN2 (N-terminus tag) 
transient transfection in prostate cell line WPMY-1 in order to observe 
evaluate the effects of EN2 expression 
‣ Apoptosis evaluation after EN2 (untagged) transient transfection in 
WPMY-1
‣ Exploring the cell autonomous role of EN2 in prostate cancer cell lines
‣ Exploring the cell non-autonomous function of EN2 in prostate cell 
lines by co-culture assays
‣ Investigating the intercellular transfer of EN2 using co-culture assays
‣ Evaluating intercellular transfer and mechanism of EN2 in prostate cell 
lines by Transwell® (ThinCert™) assay
‣ Preliminary experiments to study the downstream effects of EN2 
forced expression both cell autonomously and non-autonomously
6.4 Results
6.4.1 Time-lapse confocal microscopy of EN2-GFP (C-terminus tag)              
transiently transfected into prostate-derived cell lines
! In order to explore the effects of over-expressing EN2 within a cancer cell line 
compared to a normal (immortalised) cell line (with no detectable EN2 mRNA) EN2-
GFP was transfected into PC3 and WPMY-1, respectively. These transfected cells 
were imaged intermittently to create a time-lapse confocal microscopy video. The 
GFP fluorescence emitted was also monitored over time. 
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Figure 6.1. Time-lapse confocal microscopy of WPMY-1 and PC3 cells after EN2-GFP 
transfection. a) EN2-GFP and GFP control monitored in WPMY-1 cells over time and plotted as a 
ratio over time zero (F/F0). b) Snapshots of WPMY-1 undergoing apoptosis after GFP-EN2 
transfection. c) GFP-EN2 and GFP control monitored in PC3 cancer cells and plotted as a ratio over 
time zero (F/F0).
! The time-lapse video revealed that the WPMY-1 cells quickly underwent 
apoptosis as EN2-GFP began to express. The EN2-GFP fluorescent signal rapidly 
disappears (Figure 6.1a, right image). This was not the case with the GFP control, 
which had a strong and consistent GFP expression profile (Figure 6.1b, left image). 
EN2-GFP and GFP expression were both reasonably consistent in PC3 cells 
(Figure 6.1c), neither of which caused a significant degree of apoptosis.
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6.4.3 Time-lapse confocal microscopy after GFP-EN2 (N-terminus tag) 
transient transfection in prostate cell line WPMY-1
! The N-terminus of EN2 was tagged with GFP (GFP-EN2) and this was 
transfected into WPMY-1 as it was previously observed in Chapter 4 that this was 
more active than the C-terminal version. This was also monitored closely for EN2 
localisation and transfer using the WGA membrane marker (red fluorescence).  
Figure 6.2. Analysis of WPMY-1 transfected with GFP-EN2. a) Image stills of time-lapse confocal 
microscopy of WPMY-1 cells after transfection with GFP-EN2 and co-stained with a red fluorescing 
membrane marker to depict the boundary of the cell. The white arrow shows points out the formation 
of seemingly EN2-containing apoptotic blebs.  b) WPMY-1 GFP-EN2 transiently transfected cells are 
again seen to traffic EN2 along membrane protrusions and furthermore, the cell expressing GFP-EN2 
has fused with a non-transfected cell. The white arrows show the two cells that undergo major 
morphological changes.  
a)
WPMY-1
b)
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! The membrane blebbing in Figure 6.2 is clearly visible as the image stills 
depict the creation of red and green blebs that come off at the cell surface as the 
cell starts to disintegrate. In addition, other cells formed membrane protrusions 
between cells and the images show that GFP-EN2 is transported across them. 
Apoptotic blebbing may be a potential mechanism for removing EN2 from the cell. It 
is not clear from Figures 6.2a and b whether EN2 is taken up by an adjacent cell 
that is connected and would require further investigation with a much more sensitive 
assay than antibody detection. However, in figure  b two cells have fused together 
with EN2 clearly visible close to or on the cell surface. This is an interesting 
observation as cell fusion events are rare and have been suggested as a 
mechanism of tumour initiation and progression (Lu & Kang 2009). Also, it is 
interesting to note that one of these cells (not expressing GFP-EN2) rounded first 
and then underwent fusion. 
! RT-qPCR was performed to detect MAP1B mRNA in WPMY-1 cells 48 hours 
after transfection. MAP1B protein has been reported to facilitate in cytoskeletal 
changes, vesicle formation, and membrane blebbing, and importantly it is under the 
transcriptional control of EN2 (Montesinos et al. 2001). 
Figure 6.3. MAP1B mRNA detection by RT-qPCR in PC3 and WPMY-1 cells transfected with 
GFP-EN2. Detection of Map1b mRNA after EN2 transfection in PC3 and WPMY-1 cells, WPMY-1 
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shows a marked increase in expression relative to media only control. Two technical repeats were 
performed for each sample and these were plotted as an average.                                           
! Figure 6.3 shows that MAP1B is up-regulated by approximately 4-fold in 
WPMY-1 cells expressing GFP-EN2 only and not in PC3 cells. Moreover, Chapter 5 
shows PC3 cells after transfection with GFP-EN2, that do not undergo apoptosis (no 
apoptotic blebs) but instead transfer EN2 by multiple mechanisms. 
6.4.3 Apoptosis evaluation after EN2 (untagged) transient transfection in         
WPMY-1
! In order to confirm that EN2 was causing apoptosis in WPMY-1 cells and not 
GFP toxicity, WPMY-1 cells were transfected with untagged EN2. A marker of 
apoptosis was used this time, which was Caspase 3/7. This live stain reagent 
stained Caspase-3/7 with green fluorescence that was then imaged. In addition, an 
MTS assay was performed to determine cell viability.
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Figure 6.4. WPMY-1 and PC3 were monitored for caspase 3/7 upregulation after EN2 
(untagged) transfection. The NucBlue® Live ReadyProbes® Reagent demarcated the nucleus. a) 
PC3 and WPMY-1 cells were transfected with EN2 (untagged) and additionally stained for 
caspase-3/7, images were taken at X20 magnification. b) An MTS assay was performed in triplicate 
on the transfected cells to test for viability. The controls were transfection (ViaFect™) reagent only 
and media only transfections.
! EN2 induced apoptosis (Figure 6.4a) in WPMY-1 cells and, to a lesser extent, 
PC3 cells as there was an increase in green Caspase-3/7 signal and cell 
aggregation (highlighted by the blue fluorescence of the nuclei). The induced cell 
aggregation is prominent, but it is unclear whether EN2 caused this directly or it was 
a consequence of apoptosis. 
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! In either case, WPMY-1 cells subsequently underwent extensive cell death, 
based on the MTS assay (Figure 6.4b) results that showed low percentage cell 
viability. However, PC3 cells did not undergo cell death and the percentage cell 
viability stayed consistently high under each transfection condition. 
!
Figure 6.5. Time-lapse confocal microscopy with Caspase 3/7 detection. Cells were transfected 
with untagged EN2 plasmid and a negative control (or media only), after which the CellEvent™ 
Caspase-3/7 Green ReadyProbes® Reagent (Molecular Probes™, Life Technologies, UK) was added 
and the resultant green fluorescence was measured over time (in seconds) a) WPMY-1 cells 
captured by X40 magnification, bright-field confocal microscopy overlapped with FITC fluorescence 
detection after EN2 transfection and plotted as a ratio of fluorescence: fluorescence at time zero over 
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time. b) PC3 captured by X40 magnification, bright-field confocal microscopy overlapped with FITC 
fluorescence detection after EN2 transfection and plotted as a ratio of fluorescence: fluorescence at 
time zero over time. 
! This experiment highlighted the immediate activation of apoptosis in WPMY-1 
by EN2 overexpression. It highlights the clear difference in EN2 regulation as PC3 
had a steady expression (a fluorescence detection ratio (F/F0) of 2) that was much 
lower than WPMY-1 expression, which instead had a fluorescence ratio of 6 at time 
0 which then reduced very quickly. Thus, reconfirming a previous finding that 
WPMY-1 is unable to down-regulate EN2 successfully, which leads toEN2 
expression becoming too high leading ultimately to cell death.
6.4.4 Exploring the cell autonomous role of EN2 in prostate cancer cell lines
! Time-lapse confocal microscopy was used to further elucidate the role of EN2 
by observing its behaviour between cells. 
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Figure 6.6. Time-lapse confocal microscopy of cells after transfection with GFP tagged EN2 
with cell fusion. a) PC3 cells transiently transfected with EN2-GFP seemingly show a large vesicle 
being internalised by a PC3 cell or a PC3 cell (with a more rounded morphology) has invaded 
another cell. b) PC3 cells transiently transfected with GFP-EN2 show a cell invading another and 
coming back out, which then becomes seemingly apoptotic. 
! After transiently transfecting PC3 cells with EN2-GFP, live cell imaging 
captured a large vesicle or cell that contained EN2-GFP that had invaded a non-
EN2-GFP expressing PC3 cell. Below, Figure 6.6b, is the same experiment carried 
out but with GFP-EN2. 
! When looking further at the cell that internalised EN2-GFP from the invading 
cell or internalised vesicle (Figure 6.6a), the cell adopted a more rounded 
a)
b)
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phenotype as a conseqeunce, which could be the cell seen in Figure 6.7. This was 
also seen by WPMY-1 that underwent cell fusion. Thus, this suggests that figure 
6.6a could be showing cell-in-cell action by a cancer cell (Y. Wang & X.-N. Wang 
2013). 
Figure 6.7. Time-lapse confocal microscopy of cells after transfection with GFP tagged EN2 
with cell invasion. A PC3 cell that was seemingly invaded by a PC3 EN2-GFP expressing cell 
evidently changed morphology to a more rounded shape. 
! Further live-cell imaging was carried out on PC3 cells after transient 
transfection with GFP-EN2 and images were captured over 24 hours. 
Figure 6.8. Time-lapse confocal microscopy of cells after transfection with GFP tagged EN2 
with unsuccessful cell-fusion. Two PC3 cells expressing EN2-GFP were imaged over time where 
they can be seen to attempt to fuse or invade one another, which seemingly leads to cell death. DOI: 
https://dx.doi.org/10.6084/m9.figshare.4057197.
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! The video shows that PC3 cells (Figure 6.8a) expressing GFP-EN2 
attempted to fuse together after cell-cell contact. Alternatively, both cells have tried 
to invade each other. Both of these cells have a distinct round shape, which signifies 
the switch to a more invasive phenotype (an increase in cell-cell adhesion markers 
at the cell surface). Thus, similar to Figure 6.6 perhaps the switch to cell-cell 
adhesion markers on the cell surface has caused both to pull one into the other 
instead of just one (where there is a clear imbalance), and the last image shows the 
cells lifting off and most likely undergoing cell death. 
! With this in mind, it was important to search for other evidence of increased 
cell-cell interaction (such as cell adhesion and cytoskeletal molecules) to provide 
further evidence that cell adhesion molecules at the cell surface had in fact 
increased due to increased EN2 expression. These candidate downstream effectors 
were selected from a microarray, where EN2 was over-expressed and knocked-
down, in ovarian cancer cell lines, carried out by Sophie McGrath in the Oncology 
department (McGrath 2015). The results showed a general increase of expression 
of mRNA that had a role associated with the cytoskeleton. Within this category the 
selected candidates were COL8A1, TMEM204 and INHBA as these had a role 
specific to cell surface interactions. To confirm this finding for prostate cancer cell 
lines, a RT-qPCR was performed with PC3 GFP-EN2 expressing cells (and GFP 
only and media only controls). 
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Figure 6.9. Investigating the cell autonomous role of EN2. a) RT-qPCR of potential downstream 
effectors INHBA, COL8A1 and TMEM204 after GFP-EN2 transfection (and GFP only, media only 
transfections). b) MTS time-course assay to shows the difference between viability of GFP-EN2, 
GFP and media only transfected PC3 cells, measured by OD492nm. Two technical repeats were 
performed for each sample and a student t-test.                                         
! Figure 6.3a shows that all three downstream effectors increased in 
expression with GFP-EN2 transfected PC3 cells only compared to non-transfected 
PC3 cells. COL8A1 showed the highest increase in fold expression relative to the 
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media only control and has been implicated in cell-adhesion (A. Chen et al. 2014). 
Figure 6.9b shows that the cells with EN2 overexpression were still viable (and 
presumably proliferating) even after 120 hours when the cells were seemingly 
confluent.  Together with the increase aggregation seen in Figures 6.6 and 6.8, it 
suggests that EN2 may be involved in the loss of cell contact inhibition - a property 
required at the early stages of tumorigenesis. However, when considering that there 
is likely an increase in cell-cell adhesion (as seen in Figure 6.9b), loss of cell 
contact inhibition would be a direct consequence of that - which one comes first 
would need further exploration (such as the detection of specific markers). Both of 
these (increase in cell-cell adhesion and loss of contact inhibition) would indirectly 
enhance cell survival. 
! These findings further suggest a role for EN2 is involved in cell-cell 
communication, although the exact mechanism remains unclear. 
6.4.5 Exploring the cell non-autonomous function of EN2 in prostate cell            
lines by co-culture assays
! A conditioned media transfer assay was first performed to assess whether 
conditioned media that contained secreted EN2 protein evoked a response to 
viability. From Section 6.4.1 it is evident that EN2 expressed endogenously causes 
WPMY-1 cells to undergo cell death. 
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Figure 6.10. MTS assay for WPMY-1 after conditioned media incubation over time. WPMY-1 
cells were incubated for 24, 48 and 72 hours with media that had been conditioned (no serum and 
concentrated with 10MWCO spin concentrator) and the viability was measure using an MTS assay. 
Two technical repeats were performed for each sample and a student t-test showed no significant 
difference.                                           
! No significant differences were found between the tested conditioned media 
with respect to cell survival (Figure 6.10) and the cells are still viable after 72 hours. 
However, the WPMY-1 cells incubated with media from stable GFP-EN2 expressing 
PC3 cell line are still increasingly proliferating at 72 hours compared to 24 hours and 
compared to the other cells incubated with different media sources. This is similar to 
the result from figure  where EN2 expressing cells were able to keep proliferating for 
longer. 
! This implies that EN2 in the microenvironment (and once internalised) may 
work similarly to endogenous expressed EN2. However, it is not possible to know if 
EN2 was present or effectively internalised with this experimental setup. The lack of 
cell-cell communication may have been an obstruction, especially considering the 
results from Figure 6.2. By simply transferring conditioned media the following 
limitations arise: EN2 is a ‘sticky’ protein and it is likely that much of it was lost after 
handling the media; Chapter 5 revealed EN2 secretion occurred through different 
mechanisms that seemingly required cell-cell contact, which could not be achieved 
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by this method and PC3 cells secreted EN2 within microvesicles that were most 
likely not efficiently transferred through media transfer.
! Therefore, a co-culture assay was used instead to show the transfer of EN2 
from PC3 cells to WPMY-1 cells and observe the influence of EN2 on WPMY-1 both 
in the environment and once it is internalised. The following fluorescent stable cell 
lines were used: PC3 expressing GFP-EN2 and GFP and WPMY-1 HaloTag® (with a 
red fluorescent ligand added in at a later stage). The co-cultures were monitored by 
time-lapse confocal microscopy. 
Figure 6.11. Investigating the cell non-autonomous role of EN2 by co-culture assay with PC3 
and WPMY-1 cell lines. PC3 GFP-EN2 and GFP stable cell lines co-cultured with WPMY-1 stable 
HaloTag® cell line (with red fluorescing ligand stain), imaged at X20 magnification with a 
fluorescence microscope. The dotted lines outline the aggregated cells. 
! After just 48 hours the GFP-EN2 stable PC3 cells (green) had seemingly 
caused WPMY-1 cells (red) to aggregate together (Figure 6.11) , mimicking the 
effect that endogenous EN2 overexpression had on WPMY-1 in Figure 6.4a. This 
was not the case with GFP only and media only control transfections. No EN2 
WPMY1	+	EN2GFP WPMY1	+	EN2GFP
WPMY1	+	GFP WPMY1
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transfer was observed and this is based on the observation of no yellow signal 
which would be generated as a result of the merged GFP fluorescence and red 
fluorescent ligand. Unfortunately, no antibody was sensitive enough to detect small 
amounts of internalised EN2. Interestingly, no EN2-containing microvesicles were 
produced and there was seemingly no EN2 transfer from PC3 cells to WPMY-1 
cells. 
6.4.6 Investigating the intercellular transfer of EN2 using co-culture assays
! To further investigate the intercellular transfer of EN2, a similar experimental 
design to Section 6.4.5 was used. The following stable cell lines were employed: 
PC3 GFP-EN2 (green fluorescence) and PC3 GFP and PC3 LifeAct (red 
fluorescence) and WPMY-1 LifeAct, as listed in Figure 6.12. These assays were 
carried out for longer than 48 hours due to the findings in Section 6.4.5 that 
seemingly showed no EN2 intercellular transfer at 48 hours.
220  
Figure 6.12. Cell co-culture assay to show GFP-EN2 transfer with prostate cell lines. The stably 
expressing LifeAct (actin) highlighted the cytoskeleton (red fluorescence). a) PC3 LifeAct and PC3 
GFP-EN2 stable cell lines. b) PC3 LifeAct and PC3 GFP stable cell lines. c) WPMY-1 LifeAct and 
PC3 GFP-EN2 stable cell lines. d) WPMY-1 LifeAct and PC3 GFP stable cell lines. All images were 
either taken at x20 and x40 as shown on the images using a fluorescent microscope. 
! These combinations were co-cultured for 72 hours. A combined fluorescent 
signal is only observed with the PC3 GFP-EN2 and PC3 LifeAct co-culture 
combination. This indicates that the effective transfer of EN2 only occurred between 
PC3 cells. 
! Figure 6.13 below highlights the images in Figure 6.12 (co-cultured PC3 
LifeAct and PC3 GFP-EN2 or GFP stable cell lines), which were enhanced by 
PC3	lifeact +	PC3	GFP
PC3	lifeact +	PC3	EN2GFP
WPMY1	lifeact +	PC3	EN2GFP
WPMY1	lifeact +	PC3	GFP
a)
b)
c)
d)
x40
x40
x20
x20
x20
x20 x20
x20
x20 x20
x20 x20
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increasing the gain of the red cytoskeletal fluorescence and zooming in to compare 
the difference in morphology. 
Figure 6.13. Enhanced images of cell co-culture assay to show GFP-EN2 transfer between 
PC3 cells. The stably expressing LifeAct (actin) highlighted the cytoskeleton red. a) PC3 LifeAct and 
PC3 GFP-EN2 stable cell lines. b) PC3 LifeAct and PC3 GFP stable cell lines. c) WPMY-1 LifeAct 
and PC3 GFP-EN2 stable cell lines. d) WPMY-1 LifeAct and PC3 GFP stable cell lines. Images were 
taken at x40 using a fluorescence microscope. 
! The polarity of the cells that have taken up GFP-EN2 apparently changes 
relative to PC3 GFP co-culture (right) in which the polarity and boundaries of the cell 
are clear. Furthermore, it is not obvious where the internalised EN2 is localising to 
once internalised by the recipient cancer cell. Therefore, the assay was then 
repeated but imaged over time and with a blue fluorescent nuclear stain to further 
determine EN2’s localisation after internalisation by the recipient cells.
PC#3%+%PC#3%GFP#EN2% PC#3%+%PC#3%GFP%
222  
Figure 6.14. Cell co-culture assay to show GFP-EN2 transfer between PC3 cells imaged at 72 
hours and 96 hours. The stably expressing LifeAct (actin) highlighted the cytoskeleton red and blue 
fluorescent highlighted the nucleus (recipient cell only). The PC3 GFP-EN2 and GFP stable cell lines 
were also the EN2 donor cell lines. The images were taken at X20 and X40 magnification (shown on 
the image) using a fluorescent microscope. 
! The resulting yellow signal (in the recipient cell) was seemingly located within 
discrete areas close to or on the membrane. Interestingly (and subjectively), no EN2 
in the recipient cell was detected in the nucleus.
! Overall, Figure 6.12 and 6.13 suggests that EN2 intercellular transfer is more 
efficient when cell-cell communication and contact is permitted. Furthermore, EN2 
localises within discrete areas close to and/or on the membrane even after 
intercellular transfer, consistent with previously reported findings that EN2 has been 
reported acts locally to affect protein synthesis (Brunet et al. 2005). This would 
suggest that EN2’s cell non-autonomous function is predominantly through protein-
protein interaction rather than protein-DNA interaction. 
72hrs&
x40&
PC3&LifeAct&+&PC3&GFP&control& PC3&LifeAct&+&PC3&EN2GFP&
96hrs&
x40&
PC3&LifeAct&+&PC3&GFP&control& PC3&LifeAct&+&PC3&EN2GFP&
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6.4.7 Evaluating intercellular transfer and mechanism of EN2 in prostate cell      
lines by Transwell® (ThinCert™) assay
! Thus far, EN2 intercellular transfer has been carried out by two methods:
a) co-culture assays with PC3 GFP-EN2 as the donor cell and efficient EN2 
intercellular transfer was observed between PC3 cells and not between 
PC3 and WPMY-1 cells. 
b) NanoLuc®EN2/ NanoGLO® experiment whereby EN2 in the media (LnCaP 
conditioned media) were internalised by WPMY-1 more than PC3 cells. 
! The obvious differences between these assays were the EN2 donor cells 
(PC3 versus LnCaP) and the cell-cell contact permitted only by the co-culture assay. 
Having PC3 as the donor cell meant that EN2 would be transferred in vesicles 
whereas LnCaP would cleave EN2. The following additional experiments were 
therefore performed in order to:
a) investigate whether cell-cell contact and microvesicle transfer was 
necessary for EN2 intercellular transfer between PC3 cancer cells and 
b) establish if free EN2 in a 2D experimental setup, rather than the 3D 
tumour microenvironment that is better represented by the co-culture 
assay, could have led to the misinterpretation of EN2 function and 
behaviour. 
! A Transwell® (Thincert™)  co-culture experiment was designed so that the two 
cells (donor and acceptor) were physically separated. To directly compare this to the 
co-culture experiment in Section 6.4.6: PC3 cells were transfected and seeded in 
the insert as the EN2 donor cells and PC3 or WPMY-1 cells were the acceptor cells 
seeded at the bottom of the 24 well plate and co-cultured for 72 hours.  
NanoLuc®EN2 was detected at two stages in order to determine the following, 
respectively:
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1) for media (in the control well) at the beginning of incubation, was the same 
amount of NanoLuc®EN2 available in the media?
2) for cells after 72 hours incubation, was NanoLuc®EN2 internalised, and if 
so was it selectively internalised?
Figure 6.15. Nano-GLO® bioluminescence detection assay for Transwell® (ThinCert™) 
NanoLuc®EN2 experiment. PC3 NanoLuc®EN2 transfected cells were donor cells and seeded in a 
ThinCert™ within a 24 well plate. secNluc® is a protein control that is constitutively secreted. Nano-
GLO® assay was performed at two stages: 1) media before the experiment began to and 2) cells 
after co-culture for 72 hours. a) Two biological repeats of PC3 as acceptor cells b) Two biological 
repeats of WPMY-1 as acceptor cells. For each assay a duplicate control was performed in which no 
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cells were seeded at the bottom to allow the accurate quantitation of the total amount of EN2 in the 
media available throughout the experiment. For each biological repeat there were three technical 
repeats for the Nano-Glo® assay, these results are displayed as an average. 
! The results show that the same amount of EN2 was in the media at the start 
of the experiment. secNanoLuc® (that is constitutively secreted) was used as both 
the secretory control and background internalisation reference to account for the 
difference in rate of internalisation between the cell lines, which allowed the direct 
comparison of selective internalisation of the NanoLuc®EN2 .
Figure 6.16. Nano-GLO® assay investigating the differential internalisation of Nluc-EN2 
between PC3 and WPMY-1 cell lines. a) Percentage internalisation and  Nano-GLO® assay was 
performed to detect the presence of NanoLuc®EN2 after 72 hours of Transwell® ThinCert™ co-
culture. A and B are biological repeats, three technical repeats were performed for each sample and 
the average has been plotted as a fold increase of the media only control (media Ct). b) Differential 
internalisation of NLuc®EN2 was calculated by normalised to the secNluc secretory control that was 
used as the background internalisation reference. Calculated as an average of the two technical 
repeats and two biological repeats. 
! The results now show that for WPMY-1 A repeat these cells selectively took 
up a lot more of the EN2 than any of the PC3 repeats, which were both markedly 
lower in comparison. The result for WPMY-1 A wasn’t repeated in WPMY-1 B and so 
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this would need extensively repeating to ensure that the experimental design is 
robust and accurate. 
! Furthermore, the cells were then seeded into a 96 well plate and allowed to 
grow for 48 hours before testing for viability using an MTS assay. 
Figure 6.17. Downstream analysis of NanoLuc®EN2 internalisation with MTS assay. The two 
biological repeats for each cell line were individually seeded into a 96 well plate and left for 48 hours 
before carrying out an MTS assay. a) The percentage cell viability was calculated for PC3 A and PC3 
B cancer cells after 72 hours co-culture in the Transwell® ThinCert™ with PC3 NanoLuc®EN2 
expressing cells. b) The percentage cell viability was calculated for WPMY-1 A and WPMY-1 B cells 
after 72 hours co-culture in the Transwell® ThinCert™ with PC3 NanoLuc®EN2 expressing cells. 
Each MTS assay consisted of three technical repeats.
! No significant differences were observed. However, WPMY-1 A that 
selectively internalised the the greatest amount of NanoLuc®EN2 showed a marked 
increase in cell proliferation compared to the other transfection controls. 
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! As the results in Figure 6.17 are not consistent with those in Figure 6.12 it 
indicates that: a) PC3 cells require cell-cell contact for efficient intercellular transfer 
of EN2 or EN2-containing microvesicles or b) the use of conditioned media to study 
EN2 dynamics is a misrepresentation to actual events because cell-cell 
communication has been shown here to play a vital role in EN2 intercellular transfer, 
for PC3 cells at least. 
! Consequently, 3D cell culture methods must be considered as an alternative 
in vitro/ ex vivo model, the setup is more representative of the tumour 
microenvironment that includes cell-cell contact and communication to further study 
the behaviour of EN2.
! This has also provided a novel method of tracking EN2 (in real-time) without 
the use of an antibody. 
6.4.8 Preliminary experiments to study the effects of EN2 forced expression      
both cell autonomously and non-autonomously 
! The main objective was to explore the phenotypic downstream effects of EN2 
particularly with cells that have taken up EN2 from the microenvironment. 
! Bose et al suggested that EN2 is able to regulate PAX2 (an activating 
transcription factor of EN2) by a feedback mechanism (Bose et al. 2008). Thus, EN2 
could regulate the expression of potential protein binding partners. PBX and EIF4E 
protein binding domains within EN2 have already been defined (Chapter 2, Figure 
2.13). Overexpression of EN2 could then affect the expression of PBX and EIF4E 
and to investigate this a RT-qPCR assay was performed using GFP-EN2 forced 
expression in prostate cell lines. 
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Figure 6.18. RT-qPCR of potential downstream effectors. The data for both graphs have been 
normalised to the GAPDH house keeping gene, the cDNA from cell lines are labeled at the bottom. a) 
EIF4E mRNA expression was displayed as a fold increase relative to WPMY-1, included cDNA from 
PC3 GFPEN2 stable and transient (trans) cells, PC3 GFP stable and transient control cells. A 5-fold 
increase in EIF4E expression was detected in the GFP-EN2 stable cell line only. b) PBX1-4 mRNA 
were detected and displayed as normalized to GAPDH only (x100000) to highlight that higher 
amounts are detected in the WPMY-1 normal cell line. c) Meis 1-3 and Prep 1-2 mRNA detection 
after GFPEN2 stable and transient (trans) transfection, Ct values are displayed relative to GAPDH 
(x1000).
! The RT-qPCR in Figure 6.18a reveals that EIF4E could be a potential 
downstream effector of EN2 as a 5-fold increase is calculated, interestingly this was 
only the case for the stable overexpression and not the transient overexpression of 
GFP-EN2 in PC3 cells. Figure 6.18b shows that PBX is not upregulated nor 
downregulated by EN2 and neither are PBX co-factors MEIS 1, MEIS2 and MEIS 3 
(Figure 6.18c) and this fits with the literature (J. L. Chen et al. 2012). 
! The increased activity of EIF4E is typically attributed with enhanced survival 
(Konicek et al. 2008). In order to test this the peptide HXR9 was employed. HXR9 
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prevents PBX binding to HOX, which in turn triggers apoptosis in malignant cells 
only. 
Figure 6.18. Cell viability of PC3 cell lines after HXR9 treatment with an MTS assay. HXR9 
peptide and the control CXR9 peptide were serially diluted from 120µM to 0µM and cells were treated 
for two hours before carrying out an MTS assay to calculate cell viability. A and B are biological 
repeats and three technical repeats were performed for each sample. 
! The calculated IC50s were not significant (data not shown) but the MTS did 
show a slight increase in percentage cell viability between PC3 GFP and PC3 
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GFPEN2 expressing stable cells (Figure 6.18). This is consistent with the literature 
(Bose et al. 2008) however, the mechanism by which EN2 enhances cell survival 
remains unclear.
6.5 Discussion
! There is a striking difference between PC3 and WPMY-1 expression of GFP-
EN2 and the resulting downstream effects. EN2 elicits cell death in WPMY-1 shortly 
after expression of EN2. Untagged EN2 produced a similar cell death response to 
GFP-EN2 in WPMY-1 cells and therefore GFP cytotoxicity could be eliminated as 
the cause. MAP1B was found to be elevated in WPMY-1 cells only and not PC3 
cells, after GFP-EN2 transfection. This is consistent with the observed vesicle 
formation and large amount of membrane blebbing - MAP1B has been linked to both 
of these physiological effects during autophagy (Harrison et al. 2008) . Autophagy is 
a lysosomal degradation process, also known as a non-apoptotic cell death 
mechanism, and has also been reported to both inhibit apoptosis and enhance 
survival (Codogno & Meijer 2005). The observed increase in caspase-3/7, which is 
part of the apoptotic pathway, would indicate that apoptosis is activated by EN2. 
However, more quantitative evidence is required to define whether both these 
mechanisms are turned on as a direct result of EN2 expression. 
! The MTS cell viability assay (Figure 6.4b) confirms that WPMY-1 cells 
definitively undergo cell death but PC3 cells do not. Thus, the mechanism of cell 
survival in cancer cells were further explored by examining EIF4E expression as this 
protein can bind to EN2 and prominent downstream effectors of EIF4E include the 
anti-apoptotic protein BCL-2 and MMP-9, which enhance cell survival and increase 
metastatic potential, respectively. It was found that only the stably expressing PC3 
GFP-EN2 cell line showed a marked increase level of EIF4E mRNA expression 
relative to WPMY-1 as opposed to transient expression and GFP expression. Thus, 
this provides rationale for further investigation of the role of EN2 in enhancing cell 
survival through its interaction with EIF4E (discussed further in Section 7.2.2). 
Interestingly MMP-9 was flagged as a candidate enzyme for the proteolysis of EN2 
in Section 4.4.10 and this will be further expanded upon in Section 7.2.2 also.  
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! Another experiment carried out to confirm this finding on enhanced cell 
survival was to challenge GFP-EN2 stably expressing PC3 cells with the HXR9 
peptide. Although EN2 has a PBX binding domain and could hinder the mechanism 
of action of HXR9 through competitive binding, this experiment was carried out 
because: co-localisation by ICC of the two proteins was not observed (data not 
shown); EN2 did not directly affect the mRNA expression of PBX (Figure 6.18b); 
PBX is generally downregulated in advanced prostate cancer cells (Figure 6.18b); 
there have been no reports of cell autonomous binding of EN2 and PBX (in cancer 
cells) in the cytoplasm. 
! The mechanism by which EN2 enhances cell survival has been largely 
unexplored. A MTS assay was performed on GFP-EN2, GFP stably expressing PC3 
cells after treatment with HXR9. This assay showed a slight increase in percentage 
cell viability between GFP-EN2 and GFP PC3 stable cell lines, for both repeats 
(Figure 6.18). Thus, EN2 did confer a survival advantage (as reported by Bose et al, 
(Bose et al. 2008)) but this may have involved EIF4E upregulation rather than direct 
competition with peptide binding. The other possibility was that EN2 causes loss of 
contact inhibition, as reported by Martin et al, where cells do not stop growing once 
they come in contact with each other (Martin et al. 2005). This could explain the 
increase in viability and proliferation with GFP-EN2 expressing cells, as reflected in 
the MTS assay results. However, it does not explain the increased resistance to 
HXR9. 
! It is possible that there was a link between the number of cell fusion events 
and enhanced cell survival and thus, the increased resistance to HXR9. Cell fusion 
has been reported to be involved in disease progression (particularly cancer) 
including an increased proliferation rate, a switch to a more invasive and metastatic 
behavior and an increased resistance towards drugs and apoptosis (Lu & Kang 
2009; Y. Wang & X.-N. Wang 2013). Live cell imaging showed that the cell fusion 
events were between GFP-EN2 expressing and non-expressing cells, for both PC3 
and WPMY-1; two GFP-EN2 expressing cells were not able to fuse (Figure 6.8). 
This points to the spreading or regulated dispersal of EN2 to perhaps allow the 
evasion of apoptosis and continued cell survival (Figure 6.2b), which have recently 
been reported in the literature (Noubissi et al. 2015; Noubissi & Ogle 2016). 
Membrane protrusions or nanotubes such as those made between WPMY-1 cells 
after GFP-EN2 transfection (Figure 6.2a) have also been implicated as a rescue 
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mechanism (Rustom 2016), and GFP-EN2 can be observed trafficking along these 
nanotubes. 
! A role for EN2 was also suggested by a general increase in all the candidate 
markers for cell-cell adhesion at the cell surface picked from the microarray (INHBA, 
COL8A1 and TMEM204). The elevated expression of these genes provides further 
evidence that EN2 is involved in cell-cell communication. However, the evidence in 
the literature and in this study suggests that EN2 is most likely to be affecting local 
protein synthesis due to its cytoplasmic localisation and perhaps, where the focused 
should be in future (Prochiantz & Joliot 2003; Brunet et al. 2005; McGrath, Michael, 
et al. 2013). Translational changes will affect the cell more quickly than 
transcriptional changes, and a role for EN2 in regulating translation is supported by 
the observations that: EN2 in highly metastatic cells resides on or close to the 
membrane (Chapter 5, Figure 5.3 and 5.4) and EN2 has the ability to bind to the 
translation initiation factor, EIF4E, with high affinity outside the nucleus (Nédélec et 
al. 2004). Furthermore, Figure 6.2b shows that EN2, even after intercellular 
transfer, remains close to the membrane. 
! This chapter has provided a protocol in which EN2 can be tracked in real-time 
using NanoLuc® tagging (just 17kDa) and the NanoGLO® detection assay. Its 
secretion and internalisation can be measured both in cells and in the media by 
simply detecting the luminescence. This assay doesn’t have to be an end-point 
assay when detecting extracellular EN2 only and so can be performed on live cells. 
This is a flexible platform to test varying conditions and to investigate, for example, 
the differential secretion and uptake of EN2 in vitro, especially when no reliable 
antibody is available. Investigation into the non-autonomous effects of EN2 on the 
recipient cells (Figure 6.17) showed disparities between conditioned media and co-
culture assays. This problem was predicted due to the findings in all three results 
chapters that showed cell contact to be a main mechanism of EN2 transport.
!  The NanoLuc®EN2 Transwell® (ThinCert™) system was used to investigate 
whether cell-cell contact was necessary for the intercellular transfer and paracrine 
activity of EN2, as it physically separated the cells. The results suggest that PC3 
cells require cell-cell communication in order to transfer EN2. From the co-culture 
assay it was evident that EN2 transfer occurred much more frequently between PC3 
GFP-EN2 and PC3 cells than PC3 GFP-EN2 and WPMY-1 cells, whilst this was not 
seen when the cells were physically separated. It was not possible to quantify the 
amount of intercellular transfer. One approach to quantification is to measure the 
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downstream effects to the EN2 recipient cells after co-culture with EN2 expressing 
cells. However, the non-autonomous effects of EN2 are yet to be defined. Despite 
this, the viability of the recipient cells were tested by an MTS assay because of the 
cell death caused by EN2 endogenous expression in WPMY-1 cells (Figure 6.4b).  
No significant difference was measured, which confirms that EN2 is not effective in 
this setup of no cell-cell communication and contact. Chapter 5, Figure 5.6 shows 
that EN2 was transferred to PC3 but it does not induce cell death, thus a viability 
assay would have been redundant. The results with WPMY-1 supports the notion 
that EN2 requires cell-cell contact in order to carry out its paracrine function. Other 
experimental approaches are explored in Chapter 7, Section 7.4.2.3.
! Furthermore, when we add together the effects seemingly caused by EN2 
when outside the nucleus (cell aggregation, cell-cell adhesion and cell-in-cell action) 
it supports the notion that EN2 switching from a predominant nuclear to non-nuclear 
localisation is critical to tumour progression.
!
6.6 Conclusion
! The findings of this chapter revealed different modes of EN2 expression, 
regulation and affects between PC3 and WPMY-1 cells. PC3 cells are able to 
survive forced EN2 expression, unlike WPMY-1 cells. WPMY-1 cells try to evade cell 
death by activating different rescue mechanisms such as intercellular trafficking of 
EN2 via membrane protrusions, and membrane blebbing, as reflected by MAP1B 
expression. PC3 cells (after forced EN2 expression) show a slight increase in 
caspase 3/7 protein expression - indicative of apoptosis -  but do not undergo cell 
death and do not show an increase in MAP1B expression. These cells can transfer 
EN2 through direct cell-cell contact, cell-in-cell action and in large vesicles. The 
increased EIF4E mRNA expression detected in these cells could also allow for their 
continued survival as it activates the expression of the anti-apoptotic protein BCL-2. 
Furthermore, EN2 is located at the periphery of these cells, even after intercellular 
transfer, unlike in WPMY-1 cells. 
! The increased amount of cell fusion events between the EN2 over-expressing 
cells and non-transfected cells also coincides with a general increase in cell-cell 
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adhesion markers. However, this is different from cell-in-cell action whereby cancer 
cells invade other cells. Thus, further studies are required to determine exactly 
which one of these mechanisms EN2 is inducing. 
! The mechanism of cell survival in cancer cells (as opposed to cell death in 
normal cells) through EN2 is unclear - this study presents two modes: 
a) an increase in EIF4E and 
b) cell fusion or cell-in-cell events that have been reported as a rescue 
mechanism to evade cell death (W.-J. Yang et al. 2012; Noubissi et al. 
2015).
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7. Final discussion
!
! Firstly, for refreshment, the thesis question is restated. The three results 
chapters will be collated together to address the hypotheses made at the beginning 
of the thesis in Section 1.5 and to ultimately answer the thesis question. 
Furthermore, the non-envisaged limitations of this work and the research novelty are 
highlighted. Future work for EN2 are recommended, the future of cancer biomarkers 
is discussed as well as the wider implications of this study to the field of cancer 
research. Finally, the thesis work is concluded. 
7.1 Thesis question 
‣ Is Engrailed-2 (EN2) a suitable prostate cancer target for an antibody 
drug-conjugate?
7.2 Thesis overview
7.2.1 EN2 as a cancer specific cell surface target
! At the beginning of the study, it was hypothesised that there would be a 
significant level of EN2 on the cell surface of prostate cancer cells relative to 
‘healthy’ cells (in vitro). Immunofluorescence experiments showed that all cells 
expressed EN2, even WPMY-1 cells that had no detectable EN2 mRNA. In most 
cases, mRNA expression correlated with protein expression, and so this finding was 
unusual. Furthermore, for all cell lines, EN2 expression was confirmed to be outside 
the nucleus however, the apparent size of EN2 protein was unexpectedly large. The 
bands were analysed by mass spectrometry, which is likely to confirm that this band 
was not EN2 - as of writing we are still awaiting the results. In hindsight, contacting 
the authors of the reports that did detect EN2 at the correct size would have been 
beneficial (to ask for the antibody that was used). The higher mass of EN2 could 
have been a result of post-translational modifications, but this modification was not 
investigated here (see Section 7.4.3.2). 
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! To carry on the study, EN2 was expressed de novo tagged to GFP, and live 
cell imaging showed that it could still be secreted (in vesicles). Moreover, confocal 
analysis revealed that the GFP-EN2 protein was close to or on the membrane only 
in cancer cells. For normal cells, GFP-EN2 resided mainly within the nucleus and 
caused cell death. Further analysis of the results suggest that in PC3 cells EN2 is 
downregulated and secreted by multiple mechanisms. PC3 cells represent highly 
metastatic tumours (high grade) in which EN2 has been previously reported to be 
packaged in secretory blebs at the periphery of the cell; only EN2 from the urine 
samples of low grade tumour patients positively correlated with tumour volume (R. 
Morgan et al. 2011). Taken together, the findings indicate that it is likely that only 
small amounts of endogenous EN2 protein remains in highly metastatic prostate 
cancer cells and therefore endogenous (and clinical) EN2 protein detection requires 
a more sensitive method (see Section 7.4.2.1).
! If an antibody-based diagnostic test is to make it to the clinic it is important 
that it targets the right antigen; if an antigen is concealed, cleaved or shed at the cell 
surface - all of which has been shown in this study - in a random manner, an 
antibody-based test or an ADC may not be appropriate at all. The panel of 
antibodies - that targeted short peptides along the EN2 protein - showed the C-
terminal detecting antibody Ab32 as producing the strongest cell surface signal. 
However, this antibody was seemingly not very well internalised. Previously 
published findings indicate that penetratin (the secretion and internalization motif of 
homeoproteins) internalisation is multi-mechanistic (Dinca et al. 2016) and the live 
cell imaging results in Chapters 4 and 5 reconfirm this as it shows that EN2 can, in 
addition to secretory vesicles, transfer directly between PC3 cells. As the antibody 
internalisation experiment (in Chapter 5) relied on endocytosis, it may not fully 
represent the extent of internalisation. These alternative mechanisms of 
internalisation and the possible ways that they can be measured are described in 
more detail in Section 7.4.2.3. The findings in Section 6.4.7 further suggest that 
EN2 intercellular transfer is not specific and/ or not exclusive to cancer cells as it is 
internalised by normal cells in the microenvironment. This means there is a high risk 
of toxicity when using an ADC against EN2 in the clinic (even if the antibodies are 
delivered directly to the tumour site), especially if largely acting at a short distance 
outside the cell as reported by Layalle et al. (Layalle et al. 2011).!
! The diagram below depicts a possible mechanism by which an equilibrium is 
established for the distribution of EN2 between the nucleus and cytoplasm that 
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could account for differences between the normal (embryonic), low and high grade 
prostate cancer cell lines:
!
Figure 7.1. Nucleo-cytoplasmic shuttling of EN2. The diagram depicts a theory to how EN2’s 
localisation could be disrupted (in cancer) so that EN2 is mostly located in the cytoplasm and cell 
surface. Under normal physiology, EN2 is exported in and out of the nucleus because it has both a 
nuclear localisation sequence and a nuclear export sequence. However, when this shuttling is 
(somehow) disrupted it favours one location over the other and this is mostly cytoplasmic in cancer, 
which allows more EN2 to reach the environment presumably via luminal vesicles as EN2 lacks a 
classical secretion sequence. 
EN2 contains both a nuclear localisation signal and a nuclear export signal, which 
means it can shuttle in and out of the nucleus, and the resulting nuclear-cytoplasmic 
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distribution may be disrupted in cancer cells. As a consequence, it could be that an 
increasing amount of EN2 protein localises to the cytoplasm, leading to a higher 
chance of EN2 trafficking into luminal vesicles and being secreted out of the cell. A 
possible modification - that could also be the cause of disruption in cancer - is 
SUMOylation, which is a post-translational modification that essentially adds sugar 
groups to the protein and has been reported to affect the nucleo-cytoplasmic 
shuttling of proteins (this will be discussed further in Section 7.2.2). !
7.2.1.1 Summary
! En2 mRNA expression was successfully shown to be higher in cancer cells 
compared to normal cells. For the use of ADC in cancer cells, in which EN2 is 
packaged into secretory blebs reported here and by Morgan et al. (R. Morgan et al. 
2011), there would only be a narrow window of opportunity for the ADC to bind to 
EN2 on the cell surface. This study advocates that if ADC treatment was to be 
pursued, to restrict its use to tumours with a low metastatic potential that are unlikely  
to secrete EN2 in vesicles. However, further study is needed of the translational and 
post-translational regulation of EN2; EN2 protein expression is complex and 
generally, the area of translation regulation is often overlooked in cancer research.  
7.2.2 Understanding the role and behaviour of EN2 in cancer
! Before proceeding with the study, it was hypothesised that EN2 localisation to 
the cytoplasm is promoted as prostate tumour grade increases due to its potential 
translational role at the cell surface. To investigate EN2’s role in cancer more 
closely, an attempt was made to characterise the secretory vesicles containing EN2 
- a protocol was successfully developed for isolating a mixed population from culture 
media. This population was then further separated by size-exclusion 
chromatography and the size of which was determined by NanoSight technology. 
Unfortunately, after separation, the presence of EN2 within the smaller exosomal 
population could not be confirmed without mass spectrometry. At the time of writing, 
these mass spectrometry results are still to be received. Regardless of whether EN2 
is present in exosomes (or other microvesicles), the other constituents could be 
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used as biomarkers; these could be obtained from serum and urine that are easily 
accessible biofluids and far less invasive than a biopsy, which unfortunately is still 
the next step after PSA measurement. Exosomes house a rich source of 
microRNAs, which have been shown to be transferred between cells and facilitate 
metastasis (J. Zhang et al. 2015). Thus, this could be a promising avenue to 
uncover novel prostate cancer biomarkers. 
! For EN2 packaged into these larger (and yet to be defined) vesicles, an 
understanding about the destination and regulation of these vesicles as well as their 
function within the tumour microenvironment would be useful in determining the best 
approach to therapy. This is especially true if EN2 is still to be targeted with a 
monoclonal antibody, which requires high accessibility to an antigen on the cell 
surface of the cancer cell or an antigen destined to be taken up by a cancer cell. 
These vesicles were seemingly regulated because, on multiple occasions, the live 
cell imaging revealed EN2 secretion and furthermore, large amounts of secretion 
were detected at a specific time-point during the experiment. Unfortunately, whether 
the vesicles were destined to be taken up by other cancer cells, normal cells, or any 
cell type was not clear from the results of the live cell imaging; as opposed to 
secretion, internalisation was seemingly unregulated or unspecific. 
! MMP-9 was shown to be a candidate proteolytic enzyme for EN2 (in Chapter 
4), producing a fragment size corresponding to that detected by western blot 
analysis - this requires further confirmation by mass spectrometry. In keeping with 
this, the results of Chapter 6 revealed that EIF4E (translation initiation factor) is a 
potential candidate downstream effector of EN2 in cancer and that it may (indirectly) 
increase the translation of MMP-9 protein (Hamdy et al. 1994). It has been 
previously reported that the knockdown of EN2 results in the down-regulation of 
MMP-9 protein (Li et al. 2015). Taken together, this study suggests the potential 
pathway outlined in Figure 7.2.
! ! !
Figure 7.2. A diagram to show the theory of EN2’s indirect regulation of MMP-9 translation.  
The increased localisation of EN2 in the cytoplasm rapidly phosphorylates EIF4E, which then 
EN2 (non-nuclear) EIF4E (non-nuclear) MMP-9 protein
protein-protein interaction upregulation
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increases local protein synthesis of MMP-9. MMP-9 is involved in cancer invasion and metastasis.
MMP-9 breaks down the extracellular matrix, driving invasion and metastasis in 
cancer (Plowright et al. 2009; Stewart et al. 2004). EIF4E can promote translation 
both directly and indirectly by selectively increasing mRNA trafficking to the 
cytoplasm (Topisirovic et al. 2005). The co-culture assays confirmed the presence of 
EN2 on or close to the membrane of the recipient cells that had internalised it; its 
absence from the nucleus would imply that its paracrine function is not 
transcriptional either. A previous study reported an autocrine function for EN2 during 
axon development. This provides further rationale that EN2 largely affects 
translation and local protein synthesis in cancer cells due to its predominant 
localisation outside the nucleus. 
! A closer examination of the live cell imaging videos revealed that GFP-EN2 
expressing cells fuse with or invade non-GFP-EN2 expressing cells (Figure 6.6), but 
cannot do so with other GFP-EN2 expressing cells (Figure 6.8). This invasion by a 
cancer cell has been reported previously and is known as cell-in-cell action (Y. Wang 
& X.-N. Wang 2013). This process may allow the switching from a cell-substrate 
phenotype to a cell-cell phenotype (such as an increase in cell-cell adhesion 
markers at the cell surface). This in turn pulls cells towards each other and indeed 
into each other. This invasion requires cell-cell contact and so in order to further 
study this a 3D setup is required (please see Section 7.4.1 for more details). When 
considering whether EN2 is instrumental to orchestrating this switch in phenotype 
and promoting invasion or is itself a protein that participates in this process directly, 
when at the cell surface, the answer is unclear. There are three possible 
consequences of cancer cell invasion that has been reported thus far (and observed 
in this study), which are outlined in the Figure 7.3.
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Figure 7.3. Cell-in-cell action and three known consequences. Adapted from (Y. Wang & X.-N. 
Wang 2013). Cancer cells have been observed to acquire invasive properties and invade cells. 
Consequently, there are three known fates (A) the cell survives and goes on to divide within the 
invaded cell (B) the cell manages to escape and survive or, most usually, (C) the cell dies. 
When two cells express GFP-EN2 both cells try to invade the other, which triggers 
cell damage and death. This would mean that a tumour cell is more likely to invade 
the normal stroma (that still have the cell-substrate phenotype) than another tumour 
cell in that microenvironment, suggesting a role in the tumour microenvironment. 
This is an important avenue to explore as it would provide further rationale to EN2’s 
oncogenic role, and blocking its function and secretion could slow tumour 
progression.  
! Ideally, the experiments described above need to be looked at more closely with 
more cell lines in order to: a) further understand this difference in EN2 localisation 
between a cancer cell and a healthy cell, b) confirm this switch in phenotype from 
cell-substrate to cell-cell interactions and c) observe the invasion of the normal 
stroma in the tumour microenvironment. Preferably, this would be done using 3D cell 
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culture and co-culture models and progress to using primary cell lines (for more 
details please see Section 7.4.1 and Section 7.4.2.4). 
! On a another note, it was also important to reveal the function of EN2 because 
biomarkers can be useful in a number of ways, including as screening, diagnostic, 
and prognostic tools (outlined in Section 2.2.2). It is not always obvious how 
biomarkers should best be used in the clinic; the more that is known of their basic 
etiology such as expression, regulation, localisation and function can help to guide 
their use. For example, the stage at which these biomarkers are highly expressed 
(early or late) is important in order to know whether it can be used as a screening or 
a predictive tool.
7.2.2.1 Summary
! The following can be concluded, but require further verification:
• EN2 acts through translation (outside the nucleus) and outside the 
cell to promote an invasive phenotype. 
• EN2 in the nucleus prevents tumour progression by transcriptional 
activation of aggregation, autophagy and cell death. 
• The equilibrium of EN2 movement in and out of the nucleus can 
change so that it becomes predominantly cytoplasmic. This, in turn, 
increases the amount of EN2 in luminal vesicles, at the cell surface 
and secreted into the microenvironment - where it then acts by 
translational regulation/ local protein synthesis (and in neighbouring 
cells that take them up). 
! This study has shown that EN2 can be secreted directly from one cell to 
another and within vesicles, and further study of this process will play an important 
part in deciding the best method of detection for diagnosis and therapy. These 
results strongly advocate the following: a) to look more closely at the local 
translational effect of EN2 at the cell surface and b) to use a more complex model 
such as 3D cell culture to continue deciphering the complex regulation and function 
of EN2. 
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7.3 Research novelty
	 The novelty findings of this research are that:
‣ the commercial goat antibody against EN2 does not specifically 
detect the EN2 protein and is unreliable. This research provides an 
alternative method to accurately track EN2 using HaloTag® and 
NanoLuc® technology (Promega, UK), and further advocates the use of a 
more specific detection method for native EN2 in clinical samples. 
Antibody-based detection methods should be avoided, unless the 
antibody can been validated. 
‣ EN2 is secreted and transferred within large microvesicles between 
PC3 cells. PC3 is a highly metastatic prostate cancer cell line, whilst 
cleaved EN2 is secreted from LnCaP cells. LnCaP cells have low 
metastatic potential and EN2 was not associated with vesicles. This 
suggests that PC3 cells are able to protect EN2 from proteolysis through 
its inclusion in large microvesicles, which are secreted. Isolating and 
purifying these vesicles could provide another means of using EN2 for 
clinical purposes. As this is a positive selection for the vesicles, EN2 
levels would be higher and mass spectrometry or other less sensitive 
detection methods would become suitable. EN2‘s intercellular transfer, 
protected within vesicles, infers a role during disease progression 
possibly in the tumour microenvironment.      
‣ once internalised, EN2 does not localise to the nucleus but within 
discrete areas close to or on the membrane. This was observed after 
the co-culture assay whereby EN2 remained within discreet areas close 
to the cell surface, after being internalised. Thus, EN2 could have a role 
in translation of local proteins at the cell surface. If EN2 was able to 
manipulate proteins at the cell surface it could play a role in cell 
morphology and migration; and manipulating the tumour 
microenvironment. 
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‣ microvesicles of a defined size can be isolated. The protocol 
developed in this study involves an initial precipitation step followed by 
size exclusion, that was successful with media, urine and serum samples 
and allowed the isolation of vesicles of a defined size using NanoSight 
analysis. This is a method (in progress) for isolating large microvesicles 
that are seemingly abundant in prostate cancer. 
‣ EN2 is probably not suitable for targeting by a monoclonal antibody-
drug conjugate, particularly in high grade tumours. EN2 is packaged 
within vesicles and is therefore less accessible to the antibody. Free EN2 
is susceptible to proteolysis. The discovery that EN2 expressing cells can 
invade non-expressing cells is a further complication. Taken together, 
these findings suggest that EN2 is not stable on the cell surface and that 
an ADC against EN2 is unlikely to be internalised or prove therapeutically 
effective. 
‣ EN2 may have a role in the tumour microenvironment. PC3 GFP-EN2 
expressing cells were found to be able invade non-GFP-EN2 expressing 
cells. This infers that prostate cancer cells that express EN2 are more 
likely to invade cells in their environment that do not express EN2, which 
are the surrounding normal stroma; and thus, promoting pro-tumour 
changes to the microenvironment. Both EN2 transference and invasion is 
also more likely to occur by the more metastatic cells, as this was only 
observed with PC3 cells and not LnCaP or Du145 cell lines.
! The new hypotheses created because of these findings are outlined in 
Section 7.4.3. The wider implications of these findings are further discussed in 
Section 7.5.
7.4 Future work and recommendations  
7.4.1 Practical limitations for future consideration 
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! Due to the unspecific nature of the commercially available polyclonal 
antibodies, including the ones used in this study against EN2, additional in-house 
validation is vital; for example, using CRISPR/Cas9 knock-out of the protein of 
interest, if available, for each sample type to be used in the study (further detailed in 
Section 7.4.2.1).
! The use of only in vitro experiments limits the interpretation of the study 
findings. The in vitro experiments were initially chosen because not many studies 
have been performed and so a more general, less expensive and easy to handle 
approach was necessary. However, 3D cell culture would be more suited in this 
case as EN2 is a dynamic protein, and to understand its behaviour requires a more 
complex 3D setting. It is clear now that the protein plays an important role 
extracellularly, most likely in the tumour microenvironment, including cell-cell 
communication that is also made more complex by temporal and spatial patterning 
(further confirmed with research into its function during development (Brunet et al. 
2005; Rampon et al. 2015). “ Most in vitro experimental systems use 2D cell culture 
and trans-well assays to study these interactions even though these paradigms 
poorly represent the tumor, in which direct cell-cell contacts in 3D spaces naturally 
occur.” (Majety et al. 2015). The advantages and potential of using such a model are 
further discussed in Sections 7.4.2.4 and 7.5.1. 
! In addition, it is estimated that only a small proportion of EN2 is actually 
secreted from cells (Joliot et al. 1997), and considering that GFP and HaloTag® are 
bulky proteins (approximately 30kDa) this could have altered the folding of the 
protein and hindered the movement of EN2 within the cells. The GFP especially may 
have been toxic to the cells and may well have contributed to EN2 degradation and 
cell death. 
! EN2 secretion is continuous and (for PC3 cells especially) a larger amount 
can be detected in culture media and within robust microvesicles, which may 
account for the difficulty in detecting EN2 within PC3 cells. In a number of 
experiments GFP-EN2 protein could not be detected in PC3 cell lysates by western 
blot even though it could clearly be seen by immunofluorescence, and was often 
cleaved. It is important, if EN2 continues to be explored as an ADC target, to 
establish whether the conformation of GFP-EN2 prevented the antibody from 
binding to its antigen or whether it was inaccessible to the antibody as a result of 
being encapsulated in vesicles. 
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! !
7.4.2 Future experiments 
! The overarching aims continue to be: a) validate and explore EN2 as a cancer 
specific cell surface protein target and b) increase our understanding of the role and 
behaviour of EN2 in cancer. Furthermore, with reflection and critical analysis of this 
present study it has been proven to be fundamental to continue unveiling the 
intercellular transfer of EN2 in order to guide the therapy developed against it. 
These experiments listed below are the logical next steps that will need to be carried 
out before investigating the new hypotheses listed in Section 7.4.3.  
7.4.2.1 Antibody target validation by EN2 knockout 
! This study did not achieve 100% knock down of En2 using siRNA in order to 
confirm the specificity of the antibodies used in this study. Another molecular tool is 
zinc finger nucleases (ZFN) that have two functional domains: a DNA-binding 
domain and a DNA cleaving domain (Gaj et al. 2012). When two ZFN’s are paired 
they act like genomic scissors excising the unique target sequence. A new 
technology that is becoming widely adopted is CRISPR/Cas9 technology (Gaj et al. 
2013). This technique has high precision and uses a lentiviral vector to deliver the 
machinery into cells and colonies are then selected for and thus, the methodology is 
simple and accessible (X. Liu et al. 2017). After knocking down EN2 completely and 
permanently, we would hope to see a much larger effect at the protein level via ICC 
and WB analysis with an EN2 antibody. This approach would validate the EN2 
antibodies and enable them to be used with confidence for further functional assays, 
without the need to tag the protein to a fluorophore. 
7.4.2.2 Mass spectrometry for protein size determination, protein isoform and 
post-translational modification verification
! In order to verify that EN2 is cleaved in LnCaP cells the protein bands need to 
be analysed by mass spectrometry. Mass spectrometry can be used for protein 
identification in two ways: a) searching for a known peptide mass (EN2) or b) de 
novo sequencing that would assign amino acids depending on the mass of the 
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peptide fragments. Whether these peptides are isoforms is difficult to determine 
using mass spectrometry alone as they have very similar sizes. RNA sequencing 
could help address this. EN2 protein may undergo SUMOylation that in turn would 
help regulate nuclear import and export. The addition of a SUMO protein has a 
similar effect to ubiquitination, although it may also be involved in other cellular 
processes. EN2’s protein sequence was run through a predictive software, 
SUMOplot™, and the results are outlined in Figure 7.4 below. The results suggest 
there is a very high probability that EN2 is SUMOylated within the homeodomain. 
! Figure 7.4. SUMOplot™ analysis for detecting SUMOylation sites. The analysis highlights 
! the areas within the protein that are highly susceptible to SUMOylation, and predicts and 
! scores sumoylation sites within the EN2 protein. High probability motifs are highlighted in red. 
! The commercially available kits to detect SUMOylation are unlikely to be 
sufficiently sensitive to detect a very small proportion of SUMOylated EN2, and 
additional techniques including ELISA and immunoprecipitation (using a antibody 
against the SUMO protein) may also be necessary. 
7.4.2.3 Exploring EN2 protein-protein interactions and intercellular transfer 
using the NanoBRET assay. 
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! An alternative approach to measuring the efficiency of EN2 intercellular 
transfer would be to use EN2 protein-protein interactions to detect internalised EN2 
in a recipient cell, using NanoBRET. Antibodies are generally not sensitive enough 
to detect trace amounts of protein. NanoBRET® detects resonance energy transfer 
between two proteins denoted as the donator and acceptor, as shown below (Figure 
7.5). 
Figure 7.5. NanoBRET® mechanism of action. The donor cell line that expresses the donor protein 
with the NanoLuc® tag and the acceptor cell line expresses an acceptor protein tagged with 
HaloTag® with a ligand attached. When the substrate is added to the culture the NanoLuc® will 
luminescence and if the acceptor protein has interacted with the donor protein it will close enough for 
the ligand to accept the energy from the luminescence and fluoresce. 
! If a protein-protein interaction is identified cell non-autonomously, such as 
EN2 and EIF4E, the NanoBRET® assay could also be used to establish whether 
this interaction is more or less efficient in a co-culture assay compared to separated 
cells (Transwell®), outlined in Figure 7.6, and in a quantitative manner. 
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Figure 7.6. Measuring EN2 intercellular transfer using a Transwell® assay and NanoBRET® 
system. The donor cell line (NanoLuc®-EN2 expressing cells) is seeded at the top inside the 
ThinCert™ and the acceptor cell line (HaloTag®-POI expressing cells) at the bottom of the Transwell 
plate. Once settled the ThinCert™ is transferred to the Transwell containing acceptor cells and 
incubated. The negative controls are no acceptor cells and/or acceptor cells that have not been 
transfected with the HaloTag-POI.  
In this study, EIF4E has been shown to be a primary candidate for this assay, 
though more evidence is required to show co-localisation before proceeding with the 
experiment (such as the confocal line profile carried out in Section 5.4.3). 
! Another experiment that could be setup is, for example, to determine whether 
EN2 dimerizes or not. In this instance, EN2 would be both the donor and acceptor 
and if a fluorescent signal is produced it shows that they have come together. It is a 
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flexible system, especially when little is known about EN2’s protein function and 
binding partners. Furthermore, EN2’s ability to induce rapid phosphorylation of 
translation initiation proteins could be investigated with this method, ideally within a 
3D cell culture model as discussed below in Figure 7.4.2.4.
!
7.4.2.4 Investigating EN2’s part during cell-in-cell action and in the tumour 
microenvironment using a 3D setup 
! The dynamic behavior and possible signaling function of EN2 (between cells) 
makes 3D cell culture particularly useful. In addition, Chapter 6 further implicated 
EN2 in the loss of cell polarity and the detachment from the natural basement 
membrane (adopting a more rounded shape, as shown in Figure 6.7), both of which 
are early events in carcinogenesis. If EN2 has a distinct role in cell-cell 
communication and interaction it could have been previously overlooked when 
studied with a 2D approach. In order to look at cell-in-cell action or cell fusion more 
closely and determine which one of these events is taking place and EN2’s role 
within it, the 3D cell culture would more accurately mimic the tumour 
microenvironment than previous studies (Nyga et al. 2011). 
Figure 7.7. Schematic diagram of 2D and 3D cell culture models. The diagram highlights the 
difference between 2D cell culture where cells are relatively flat and detached on a hard plastic 
surface (a), 3D cell culture in which multiple cell types are embedded within a porous scaffold, as a 
spheroid, that could be multicellular (b) that then closely resembles cell-cell and cell-matrix 
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interactions in vivo such as (c) that is also grown supported by stromal cells (taken from (Nyga et al. 
2011)).
! 3D model systems allow cells to delineate and mimic the tumour 
microenvironment. It allows cells to grow in all directions and retains the complex 
interplay between the cancer cells and the microenvironment that includes multiple 
cell types (such as immune cells and epithelial cells). For more details about 3D cell 
culture as a prerequisite to ex vivo and in vivo studies, and prostate cancer and the 
tumour microenvironment see Section 7.5.1.
 
7.4.2.5 Isolation and characterisation of EN2-containing vesicles and
further investigation into EN2’s intercellular transfer
! To continue investigating the best therapeutic approach, it would be useful to 
further characterise EN2’s secretory and internalisation mechanisms, particularly the 
EN2-containing vesicles seen in Figures 4.9, 5.6a and 5.12. Section 7.4.2.4 
describes 3D cell culture, which would be an ideal experimental setup to study the 
downstream effects of EN2 intercellular transfer and paracrine activities, between 
cancer cells, neighbouring cancer cells and the normal stromal epithelial cells. The 
seemingly regulated secretion and internalisation of EN2-containing vesicles require 
cell-cell contact and communication, which have been shown in this study to be 
fundamental to the process.  
! Due to the large size of the microvesicle they could be prostasomes. These 
have been investigated in a similar manner to this study by Ronquist et al where 
they sought to confirm whether there is differential uptake between prostasomes 
and PC3 exosomes by PC3 cells (K. G. Ronquist et al. 2016). The Norgen and SEC 
protocol worked well in this study for the isolation of microvesicles of a specific size-
range, as shown in Figure 5.14 (Chapter 5). After isolation and purification, mass 
spectrometry would still be required to confirm EN2’s presence. Furthermore, these 
vesicles could also be a source for other potential cancer biomarkers (Lance et al. 
2011). For more details see Section 7.5.1 below.
! !
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7.4.3 New hypotheses 
! The following hypotheses are suggestions for the continued exploration of 
EN2 as a clinical tool in prostate cancer, based on the discoveries and information 
acquired in this study. 
• EN2 promotes cell-in-cell action. 
• The function of EN2 changes during tumour progression from transcription to 
translation; EN2 close to the cell membrane can alter local protein synthesis. 
• Genetically modified T cells against EN2 could be more effective therapy.
7.5 Wider implications of this study 
7.5.1 Outlook: cancer biomarkers 
! From a clinical persepctive, the field of cancer biomarkers is moving toward 
measuring molecules that require much less invasive testing such as EN2 - an 
extracellular protein in urine (Thomas et al. 2010; Minciacchi et al. 2017). These 
tests are usually less painful, costly and risky. In some cases, the biomarkers are 
able to be detected much earlier in the process (even when tumours are not yet 
visible and the patient is relatively healthy) than a tissue biopsy and act as a 
screening tool - this is known as a liquid biopsy (Karachaliou et al. 2015; Kaisaki et 
al. 2016). Examples of other non-invasive biomarkers include microvesicles such as 
exosomes, circulating tumour DNA (ctDNA), circulating tumour cells (CTCs) and 
prostasomes - commonly found in prostate cancer, see below for more details. For 
microvesicles, defining and isolating the right size population has been particularly 
difficult; the methodology to do so is still being developed, using techniques such as 
ultracentrifugation and size exclusion chromatography (Lobb et al. 2015). 
Subsequently, there is also difficulty in standardising the collection, storage and 
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analysis due to the variation between laboratories. However, ctDNAs and CTCs are 
able to be quickly identified, in blood, due to the development of next-generation 
sequencing (or high throughput sequencing) (Kaisaki et al. 2016). 
! The interplay between cancer cells and their local environment (known as the 
tumour microenvironment or TME) is a vital component of metastasis and resistance 
to therapy. Strong interactions between the tumor-stroma will help promote 
metastasis (Balkwill et al. 2012); a change in receptors on the surface of cancer 
cells can manipulate the microenvironment to strongly favour regulatory T cells and 
promote immunosuppression (Facciabene et al. 2012). These are just two examples 
of how the TME is a barrier to therapy, the mechanisms of which can vary widely 
depending of the stage and location of the disease. The non-malignant cells found 
within the TME, which are often harder to delineate, are another source of tumour-
promoting signaling (Balkwill et al. 2012). Recently, there has been a focus on 
proteomic profiling of the heterogenous population of extracellular vesicles - 
particularly in prostate cancer - in order to find novel biomarkers and determine the 
role of microvesicle transfer between cancer cells and neighbouring non-malignant 
cells (Cesi et al. 2016; Minciacchi et al. 2017). 
! The search for biomarkers in the TME is vital as there is still a huge deficit in 
the number of biomarkers that make it to the clinic - such as those that can indicate 
the level of tumour aggressiveness and at early stages. Biomarkers that provide 
more information to the clinician can prevent unnecessary or inadequate treatment 
(due to poor stratification) and improve a patient’s quality of life. Those biomarkers 
that perhaps have failed as a standalone test could be part of a ‘panel of 
biomarkers’ that collectively are more informative. However, there is a more 
immediate issue of getting biomarkers into clinical trials in the first place, this is 
further discussed in Section 7.5.2 below.
7.5.2 Perspective: cancer research 
! It must become standard practice to validate all commercially bought 
products. A huge setback in this study was the over-reliance on a commercial 
antibody - one that had been used widely ‘in-house’ - against a protein that 
undergoes large changes in cell shape, folding and behaviour depending on its 
environment, such as cell type and cell culture media. Consequently, the levels of 
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detection observed and/or quantified becomes highly inaccurate. When a 
commercial product such as an antibody is validated by the company, it is important 
to check the method of validation and repeat it. Ideally, validation should be carried 
out in the environment that further in vitro experimentation are to be done. The 
actual validation methods usually consists of knocking down the protein of interest 
with a subsequent western blot analysis - this is semi-quantitative and can give an 
approximate size of the protein detected. There are several methods of knocking 
down a protein, the best approach (if possible) is to completely knock it out using 
new technologies such as CRISPR/ Cas9 (Section 7.4.2.1). If relatively little is 
known about the protein, such as EN2, it is pertinent to go on to immunoprecipitate 
the protein for further analysis by mass spectrometry (Persson et al. 2017). Mass 
spectrometry (MS) can identify and carry out high-throughput proteomic quantitation 
without prior knowledge of the protein of interest beforehand (unlike antibodies that 
are raised specifically against an antigen). Furthermore, the method/s and practices 
of antibody validation should be under continuous evaluation as techniques and 
technologies improve.
! Mass spectrometry (MS) has been mentioned many times here, and as 
another means of protein detection it often goes head-to-head with antibody-based 
detection methods (Hale 2013). However, depending on the target and specimen to 
be analysed it may not be appropriate. MS is not as sensitive as antibody detection; 
for example, MS cannot replace the antibody detection of EN2 because EN2 is not 
found at high enough concentrations relative to the other proteins that are also 
present in the urine - urine typically has as high noise-to-signal ratio. The latter 
should not stop MS from being used in the laboratory as a standard practice for 
validating antibodies (Persson et al. 2017). However, mass spectrometry is yet to be 
made simple and cost-effective and improvements to it’s sensitivity are required 
before it becomes more widely adopted (Wasinger et al. 2013). 
! I have previously mentioned (in Section 2.6.1) that there is a bottleneck 
between biomarkers going from the lab to the clinic - despite the huge surge in 
information (also known as ‘big data’) such as metabolomics, genomics and 
proteomics. The biomarkers that do make it through often fail at clinical trials. This 
study further advocates the need for a more translational approach and rigorous 
selection process during preclinical evaluation. 2D in vitro cell culture loosely mimics 
the environment in which these biomarkers act and thus allows only very general 
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questions to be asked - the analysis can therefore only guide the next set of 
questions. This is especially true here and for many studies that look at secreted 
proteins where the environment hugely influences the way the protein behaves, 
making it very difficult to interpret the data. The questions asked at early stages 
could be more vigorous if the following becomes widely adopted: a) 3D in vitro 
models sit in between 2D in vitro cell culture and in vivo mouse models and b) there 
is a shift from 2D to 3D earlier along the pipeline. 3D in vitro tumour models would 
improve accuracy (as mentioned already in Section 7.4.2.4); for example, 3D 
spheroids enable the cells to adopt a normal physiology instead of being stretched 
out unnaturally on a flat surface - this majorly affects the expression and the spatial 
organisation of surface receptors. In addition, due to advances in tissue engineering, 
these 3D models can include multiple cell types and thus, will develop to better 
imitate the tumour microenvironment and enable further advances to be made in 
studies that look at metastasis in particular (Nyga et al. 2011) - see Section 7.5.1 for 
more information. However, wide adoption of 3D in vitro models can only happen 
when it becomes easy-to-use and cost-effective; the continued development of 
these models by 3D bioprinting will play a vital role here (Albritton & Miller 2017). 
! In cases where sparse research has been conducted - such as EN2 and 
prostate cancer - standardised methods and existing data to work from are not 
available. Thus, it is important that the information (such as that in this thesis) 
becomes openly available to those also working on similar areas. Knowing what had 
been tried before and the methods used to do so - not necessarily those that had 
been published - would have saved time and resources. Furthermore, a platform to 
share the novel data, such as the time-lapse videos that were fairly subjective, could 
have helped to provide a wider and inter-disciplinary perspective when designing the 
next set of experiments. 
!
7.6 Thesis conclusions  
! This study has explored the potential of EN2 as a target for a monoclonal 
antibody drug-conjugate (ADC). The complex regulatory mechanism controlling EN2 
expression means that mRNA expression and protein expression do not strongly 
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correlate with one another and that the protein expression needs further 
confirmation using alternative methodology.
! The findings of this study indicate that there is regulated secretion of EN2 
within vesicles (in high grade cell lines), which would restrict the use of the ADC to 
early stage prostate tumours. Furthermore, the unconventional and complex 
secretion and internalisation mechanisms of EN2 make it difficult to accurately 
quantify the total amount of antibody internalisation with a single assay and thus 
establish the most effective therapy using EN2. 
! ! An alternative therapeutic strategy are engineered T cells that do not rely on 
the native protein localising to and on the membrane, but instead recognise peptide 
fragments displayed in a complex with MHC. This study indicates that the EN2-MHC 
complex will be present on the cell surface of cancer cells at elevated levels. 
Furthermore, there is no drug attached to the antibody and hence toxicity is less 
likely to be a problem. Alternatively, small blocking peptides targeting the largely 
protected domain (at the N-terminus) of EN2 may prevent its secretion and 
subsequent paracrine function. Doing so would allow the significance of these 
events to be further elucidated. 
! ! In conclusion, Engrailed-2 (EN2) protein remains a potential therapeutic 
target and diagnostic marker in cancer. A more robust understanding is needed of its 
secretion and internalisation mechanism, not only because it could help us better 
understand alternative mechanisms used by other proteins - perhaps for cell-cell 
communication during tumorigenesis - but also to help tailor a detection assay and 
future therapy against it.  
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